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Abstract
In this thesis, we use Bayesian methodology and Markov chain Monte Carlo tech-
niques to construct logistic-type latent variable statistical models for estimating the
consistency of hypoglycaemic symptoms experienced by individual diabetic patients.
Consistency in reporting experienced symptoms of hypoglycaemia is related to early
detection of symptoms and is therefore important for fast corrective action. Based
on a model developed by Zammit et al. (2011) we classify symptoms into different
groups and consider between-groups variability. Our work also explores a number of
possible symptom-experiencing thresholds that can be used in the consistency model.
To evaluate the performance of each consistency model, we develop ideas based on
Bayesian latent residuals (Streftaris and Gibson, 2012) to check on the models’ fit and
utilise posterior predictive checking methodology (Gelman et al., 1996 and Streftaris
et al., 2013) to assess relevant performance. The impact of using data from hypo-
glycaemic episodes occurring within 24 hours from an earlier episode is also explored
using various approaches, as previous work claims that such episodes might lead to di-
minished intensity of the episodes. Using generalised linear-type model methodology,
we investigate how various factors such as age, gender, type and duration of diabetes,
body mass index, retinopathy and others, or their interaction, can affect patients’
consistency. Additionally, we develop a hierarchical model that is able to estimate
consistency and identify factors affecting it in a single setting. Finally, we work on
determining the best sets of variables for a predictive model. For this purpose, we
use Gibbs variable selection and a stepwise regression procedure. Due to model un-
certainty, we apply Bayesian model averaging to a number of selected models given
by Gibbs variable selection.
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Diabetes is a health condition caused when glucose level in blood is high. Beta cells
in the pancreas produce insulin hormone which helps unlock cells for glucose to en-
ter. When the blood glucose level gets high, insulin is secreted and aids glucose to
enter cells, thus lowering the glucose level back to normal. Without insulin glucose
will accumulate in the bloodstream, raising the blood glucose level. Glucose needs to
enter cells before it can be used as energy source for our body to do daily activities.
In short, glucose acts as fuel to our body to live life.
The two most common types of diabetes are Type 1 and diabetes Type 2 (National
Diabetes Data Group, 1979). Type 1 diabetes is a condition caused when the body’s
immune system mistakenly destroys beta cells as if they are a harmful pathogen
(Atkinson and Maclaren, 1994). As a result, insulin cannot be produced and glucose
cannot enter cells from bloodstream. Type 1 diabetes is also known as ’Juvenile Dia-
betes’ because it is usually diagnosed in young people. Nonetheless, it is not rare for
adults to develop Type 1 diabetes nowadays. This type of diabetes is called insulin
dependent diabetes because patients need to rely on injected or pumped insulin to
help maintain their blood glucose level. Diabetes Type 2 is a condition when either
not enough insulin produced due to damaged beta cells, or insulin is there but not
functioning properly in helping cells take in glucose (Reaven et al., 1976 and Olefsky
et al., 1982). Type 2 diabetes has higher prevalence than other types. 90% of diabetic
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cases worldwide are Type 2 diabetes. Some of the factors that may increase the risk
of developing this type of diabetes are being overweight (Kolterman et al., 1980 and
Bogardus et al., 1985), lack of exercise, unhealthy diet, smoking and history of first
degree relatives with Type 2 diabetes.
Hypoglycaemia is a problem of glucose deprivation in the brain that is the result
of the blood glucose level in the body becoming abnormally low, usually bellow
4mmol/L. This condition is referred to as insulin reaction because it is caused by
insulin-treatment in diabetic patients. Glucose is the body main source of energy.
When carbohydrate is broken down into glucose, it is directly absorbed into the
bloodstream. However, glucose cannot enter a cell without insulin; a hormone se-
creted by pancreas that acts as a key to allow glucose to enter cells. For instance,
without insulin a cell will be starved of energy.
Diabetic patients, either have malfunction of insulin (Type 2), or no insulin at all
(Type 1), and rely on insulin treatment to help maintain their blood glucose levels.
However, too much insulin will drop the glucose level in bloodstream and trigger
hypoglycaemia. There are three possible conditions that can cause excess insulin in
body;
• Too much insulin released in bloodstream (e.g. increased insulin dosage, Banarer
and Cryer, 2004).
• Body’s sugar is used up too quickly (e.g. intense exercise, Banarer and Cryer,
2004).
• Glucose is released into the bloodstream slowly (e.g. eat later than usual or eat
smaller portion than usual).
In the second and third situations, even a normal dose of insulin can be too much
because the insulin required by the body at that moment is lower than usual. Not
having meals at the usual time or irregular meals are the most common factor that
lead to hypoglycaemia (Nattrass and Lauritzen, 2000 and Sotiropoulos et al., 2005).
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An event of hypoglycaemia occurrence is referred to as an ’episode’ throughout this
thesis. Hypoglycaemia episodes can range from mild, which the patients can treat
themselves, to severe which require other people’s aid (American Diabetes Associa-
tion, 2005 and Canadian Diabetes Association, 2003). They may result in a med-
ical emergency when a person becomes unconscious during a severe hypoglycaemia
episode. A doctor or a family member needs to inject glucagon hormone in an attempt
to bring the glucose level back to normal. This hormone helps to simulate liver to
release stored glucose when glucose level is too low.
It is very important for patients to be able to detect the onset of hypoglycaemia
so that they can take necessary action to bring their declining glucose level back to
normal. Failure to detect this will prevent immediate corrective action resulting in
a severe hypoglycaemia episode, where patient needs other people’s help to recover.
Untreated hypoglycaemia may impact on brain power (because brain needs glucose
to function), cause cognitive decline or dead-in-bed syndrome. Longer duration of
diabetes and insulin treatment increase the risk of hypoglycaemia (Henderson, 2003).
A symptom is defined as any subjective indication of disease that is apparent to the
patient. All symptoms of hypoglycaemia are common symptoms that can sometimes
be caused by another health problem or illness, rather than being exclusive to lack
of glucose. Therefore the only way to confirm an episode is by measuring the blood
glucose level using a glucose meter. There is a wide range of symptoms of hypogly-
caemia. By analysing insulin-treated diabetic patients using factor analysis, Hepburn
et al. (1993) concluded a list of 11 key hypoglycaemic symptoms; sweating, pound-
ing heart, shivering, hunger, confusion, drowsiness, difficulty speaking, unsteadiness,
nausea, headache and odd behaviour. These 11 symptoms were identified as the Ed-
inburgh Hypoglycaemia Scale. These symptoms vary between individuals (McAulay
et al., 2001, Zammit et al., 2011) and are idiosyncratic (McAulay et al., 2001). There
is variability of symptoms experienced between people (Cox et al., 1993).
A recent study by Zammit et al. (2011) revealed that symptoms of hypoglycaemia
of an adult patient also vary across episodes. Variability both within and between
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individual patients makes it difficult for patients to precisely detect the onset of hypo-
glycaemia episodes, with between-variability hindering the precise identification of a
condition-specific set of symptoms. Thus, it is crucial for them to be able to identify
a sufficient number of symptoms that are typical for themselves and understand that
they may experience different sets of symptoms in different episodes. Patients with
four or more reliable symptoms manage to detect their low glucose levels correctly in
75% of the hypoglycaemic episodes, while patients who have fewer than four reliable
symptoms, only manage to correctly recognise their low sugar levels half of the occa-
sions (Cox et al., 1993).
1.1.1 Earlier classification of symptoms
Symptoms of hypoglycaemia can be classified into groups based on their cause. Symp-
toms that develop from lack of glucose in the brain are classified as neuroglycopenic
symptoms whereas symptoms that happen unconsciously resulting from the nervous
system’s response to hypoglycaemia are categorised as autonomic symptoms. Hepburn
et al. (1991) assessed the classification of symptoms using factor analysis and man-
aged to separate the symptoms into two distinct groups. They allocated symptoms
dizziness, confusion, tiredness difficulty speaking, headache and inability to concen-
trate into the neuroglycopenic group, and symptoms sweating, trembling, warmness,
anxiety and nausea into the autonomic group. Analysis from the same researchers
(Hepburn et al., 1992) on a larger sample of insulin-treated patients derived five differ-
ent groups of hypoglycaemic symptoms; neuroglycopenic, autonomic, general malaise,
neurological dysfunction (motor) and neurological dysfunction (sensory).
Deary et al. (1993) came up with three groups that best partitioned the symptoms.
They suggested that confusion, drowsiness, odd behaviour, difficulty speaking, un-
steady and headache belong to the neuroglycopenic group. The second group is the
autonomic group, which includes symptoms sweating, shaking, hunger and pounding
heart. Symptoms nausea and headache were classified under a third group charac-
terised as the “ general malaise” group.
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Two of the commonly identified hypoglycaemia symptoms are debatable as to which
category they belong to. Although the “feeling warm” symptom appeared as an au-
tonomic symptom in Hepburn et al. (1991), it was not prevented by drugs that block
the autonomic nervous system in physiological studies (Towler, 1993). The same goes
for the “irritability” symptom. Nervousness and anxiety are autonomic but altered
behaviour is neuroglycopenic. So they can be autonomic, neuroglycopenic or both
depending on the interpretation of the patient filling in the questionnaire.
1.2 Aim of the thesis
In this thesis, our ultimate aim is to develop, fit and assess statistical models for the
consistency of symptoms experienced by individual patients during hypoglycaemia
using Bayesian methodology and Markov Chain Monte Carlo (MCMC) techniques
for estimation. We calibrate a consistency estimation model developed by Zammitt
et al. (2011) to consider between-group variability when symptoms of hypoglycaemia
are classified into groups and also develop a hierarchical model that can estimate
patients’ consistency and identify factors affecting it in one single setting. We also
extend previous work to investigate the impact of interactions among patient-specific
factors on symptom consistency and then determine a relevant predictive model. We
employ Gibbs Variable Selection with different prior distribution settings (Dellaportas
et al., 2002, Ntzoufras, 2002, 2011, and Ntzoufras et al., 2003) and stepwise regression
in order to choose the best set of covariates for our predictive model. One of the main
concerns when trying to obtain the best predictive model is model uncertainty. We
tackle this problem by using Bayesian Model Averaging. With several consistency
models developed, our challenge is to evaluate the performance of each model before
making decisions on which model can give better consistency estimates. Therefore,
we develop ideas based on Bayesian latent residuals (Streftaris and Gibson, 2012) to
check on the models’ fit and we also perform assessment based on posterior predictive
checking methodology (Gelman et al., 1996 and Streftaris et al., 2013).
The data used in our analysis were provided by the UK Hypoglycaemia Study Group
and will be discussed further in Chapter 2. We initially received data on hypogly-
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caemia episodes from 59 patients who experienced at least 19 episodes in a period of
9-12 months. At a later stage we received additional data concerning seven patients
with fewer than 19 episodes to include in our work. Some of the episodes occurred
within 24 hours from their preceding episode. Thus, we also explore whether there is
any significant difference or association between the intensity of these episodes and
other episodes.
All simulations to obtain parameter estimations in this thesis are mainly carried out
in WinBUGS (Spiegelhalter et al., 2003). Other computational work is done with the
help of the R software (R Core Team, 2013). This is a software suite that can be used
for Bayesian analysis employing MCMC methodology (see for example, Raab, 2001).
1.3 Thesis outline
The data used in this thesis are described in detail in Chapter 2 with brief explana-
tions on some related medical aspects. Chapter 2 also provides a review of the basic
symptom consistency model, which is the core model leading to further extensions
and analysis in the thesis. An overview of the methodology utilised in this thesis is
also given in this chapter.
We start to model individual patients’ consistency using Bayesian methodology and
MCMC techniques in Chapter 3. The earlier part of this chapter focuses on explor-
ing different possible thresholds that can be used in the consistency model and then
comparing their model fit using Deviance Information Criterion (DIC). Chapter 3
also discusses the expansion of the core model from Chapter 2, by adding symptoms’
grouping. The final sections of this chapter explain the model assessment and model
verification involving all discussed models. The methods used here involve stochastic
latent residuals and posterior predictive checking.
Chapter 4 analyses the effect of adding hypoglycaemic episodes that have occurred
within 24 hours from a preceding episode. This is done by analysing the correlations,
relative means and coefficient of variation of the episodes’ intensity. In the last section
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we provide results and posterior consistency estimates when we take into account all
episodes.
A study of potential factors affecting consistency is presented in Chapter 5. Gen-
eralised linear model methodology is used to model the effect of ten covariates and
their interactions on symptom reporting of an individual patient. We also propose a
hierarchical model which can be used to estimate consistency and investigate what
covariates affect it.
We perform model selection in Chapter 6 to determine the most suitable predictive
model for consistency prediction. Two methods used are the stepwise selection and
Gibbs variable selection with three prior settings. Due to model uncertainty, we also
use Bayesian model averaging.
In Chapter 7, we present our conclusions, discussions and ideas for further research.
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Chapter 2
Data and Core Model
This chapter discusses in more detail the data and modelling used in this thesis. We
first explain how the data was collected and then provide information on several med-
ical terms and conditions related to the collected data on the date. We also present
the basic model and framework for estimating individual patients’ consistency, which
is later expanded for other consistency models in subsequent chapters. This chapter
also provides a brief review of Bayesian inference and Markov chain Monte Carlo
techniques which are the core methodologies that will be used throughout this thesis.
2.1 Data
To achieve our aim of modelling the consistency of symptoms experienced by individ-
ual patients, we use symptoms reported by diabetic patients during hypoglycaemia
episodes. This data was collected by the UK Hypoglycaemia Study Group in 2002-
2004. The UK Hypoglycaemia Study Group initially recruited 436 subjects but 35
of them were not eligible for the study. 383 of them completed phase 1 of the study
and 84% of the subjects successfully completed phase 2 of the study. Every subject
that participated in this survey was given a form (see Appendix A) to record each of
their hypoglycaemia episode, and was asked to return the forms on a monthly basis
for 12 months. They would receive a follow-up call if they failed to do so. Note that
the available data was not collected so that it was representative of the population
of diabetic patients. Hence, we do not claim that the results and findings from the
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analyses in the current thesis can necessarily be generalised to an entire population of
diabetic patients with hypoglycaemic episodes. While our analyses do not form part
of a properly randomised study, they are valid for patients with the general charac-
teristics of the groups studied here, and we anticipate that our results can guide and
inform relevant conclusions.
Besides blood glucose level, the forms collected data of date, time and duration of
the hypoglycaemic episodes, treatments received during the episodes, and symptoms
experienced. Some of the symptoms are impaired concentration, where the patients
cannot concentrate or are unable to maintain focus on what they are doing, and dou-
ble vision or medically known as diplopia. This is a condition where the patients
see two images of everything. Another typical symptom of hypoglycaemia is anxiety,
which is a feeling of fear, worry and being tense for no apparent reason. Patients
may also experience pounding heart, which means rapid and irregular heartbeats, or
sometimes feel anger and be easily upset, i.e. irritability during their episodes. Table
2.1 gives the standard list of symptoms included in the work for this thesis. Cate-
gory “none” was used in the analysis to account for cases where patients recorded
an episode of hypoglycaemia as a result of self-checking of their blood glucose, even
if no other apparent warning symptom was experienced. This is different from the
“nonspecific awareness” category, where patients were allowed to add free text.
The form also required the respondents to report if they needed assistance or lost
consciousness during the hypoglycaemia episodes, as any episode that involves either
one of these is considered as a severe episode.
Subjects were asked to monitor their blood glucose using a Medisense G glucose meter
(Abbott Laboratories, Abbott Park, IL). Episodes with capillary glucose reading <
3.0 mmol/L ( < 54 mg/dL) or when there was no blood glucose measurement avail-
able and the symptoms resolved on taking carbohydrate are considered valid, while
episodes with capillary glucose > 4.0 mmol/L are not considered as valid hypogly-
caemic episodes (Zammitt et al., 2011).
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Symptom Description Category % of episodes
1 Confusion Neuroglycopenic 15.76
2 Sweating Autonomic 24.18
3 Drowsiness Neuroglycopenic 5.77
4 Weakness Neuroglycopenic 27.52
5 Dizziness Neuroglycopenic 10.18
6 Feeling warm Autonomic/Neuroglycopenic 16.23
7 Difficulty speaking Neuroglycopenic 3.91
8 Pounding heart Autonomic 8.74
9 Impaired concentration Neuroglycopenic 26.84
10 Shivering Autonomic 2.22
11 Unsteady Neuroglycopenic 14.19
12 Nonspecific awareness Other 4.80
13 Double vision Neuroglycopenic 0.64
14 Blurred vision Neuroglycopenic 12.47
15 Hunger Autonomic 20.85
16 Thirst Autonomic 3.83
17 Nausea General malaise 4.94
18 Anxiety Autonomic 13.54
19 Tiredness Neuroglycopenic 15.87
20 Tingling Autonomic 14.12
21 Trembling Autonomic 20.06
22 Headache General malaise 8.24
23 Malaise General malaise 0.57
24 Irritability Autonomic/Neuroglycopenic 0.93
25 Other Other 1.47
26 None No symptom 10.64
Table 2.1: List of symptoms on patients’ report forms.
The initial part of the analysis in this thesis excludes data arising from successive
episodes occurring within a period of 24 hours, to avoid issues with potential di-
minished intensity for episodes occurring in close time proximity, as some anecdotal
medical experience may suggest. We also initially restrict our analysis to patients
with 19 or more episodes following earlier work. Hence, we end up with 59 subjects
who reported a total of 3,474 episodes of hypoglycaemia. These subjects consist of
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cases of Type 1 (77%) and Type 2 diabetes, with age ranging from 22 to 74 years old.
There is a good representation of males and females, with 65% of them being male.
Data on seven additional subjects were provided during the course of this work and
were subsequently included in the analysis. Each of these subjects had reported <
19 hypoglycaemic episodes. All seven patients had Type 2 diabetes. This data was
included in our analysis from Chapter 3 onwards.
The study aimed to recruit 120 Type 2 diabetic respondents and 60 Type 1 respon-
dents. Instead of selecting patients of Type 1 diabetes with shorter period, before
the start of the study a pragmatic decision was made to select patients with Type 1
diabetes for < 5 years because of the need to recruit sufficient number of respondents.
A summary of the data for all subjects according to their group is given in Table 2.3.
We will make use of part of the information in this categorisation later, in selecting
covariates that will be used to predict the subjects’ symptoms reporting consistency.
However, we do not take into account the type of treatment received.
Category Description No. of cases
1 Type 2 diabetes treated with a sufonyl-urea (tablet) 4
2 Type 2 diabetes treated with insulin for < 2 years 8
3 Type 2 diabetes treated with insulin for > 5 years 9
4 Type 1 diabetes of < 5 years in duration 21
5 Type 1 diabetes of > 15 years in duration 24
Table 2.2: Groups of patients.
For each of the participant, we were also provided with certain characteristics such as
follows:
i. Gender: male, female (coded as 0 and 1, respectively)
ii. Duration of diagnosed diabetes: in months
iii. Body mass index (BMI)
iv. Age: in months
v. Type of diabetes: Type 1, Type 2 (coded as 0 and 1, respectively)
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vi. Awareness of hypoglycaemia: score from 1 to 7 with higher score corresponding
to diminishing awareness of hypoglycaemia
vii. Type of retinopathy: no retinopathy, background retinopathy, proliferative
retinopathy (coded as 0, 1 and 2, respectively)
viii. Levels of C-peptide: in nmol/L
ix. Percentage of haemoglobin A1c
x. Levels of serum angiotensin converting enzyme: in IU/L.
This information acts as useful variables and is used in this work to investigate which
of these characteristics affect the individual’s consistency of symptom reporting in
Chapter 5 and to determine the best predictive model in Chapter 6. In what follows
we provide some information on the characteristics that may not be standard, and
their association to diabetes. A list of characteristics of each patient is supplied in
Appendix B.
Retinopathy is a diabetic eye disease associated with poor control of blood sugar
level. In this study, we divided this condition into three categories; no retinopathy,
background retinopathy and proliferative retinopathy. Background retinopathy is the
mildest stage of retinopathy. At this stage, blood vessels in retina swell. Although
this will not cause any eye sight problem, it has to be monitored closely or it can
leads to a more severe stage. Proliferative retinopathy refers to a more serious stage
where there is blockage and bleeding in blood vessels in the retina thus forming new
abnormal blood vessels. This situation affects the eye-sight and has the potential to
cause blindness.
C-peptide is a protein released together with insulin by the pancreas. They are re-
leased with ratio 1:1, thus making it a perfect marker for insulin production. High
level of C-peptide means high insulin is produced and vice versa. Insulin helps to
regulate the glucose level in blood by allowing glucose to enter cells. Excessive insulin
released will results in low blood glucose level (hypoglycaemia). Therefore, C-peptide
test is useful in hypoglycaemia cases, when we want to measure if a patient’s body is
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producing too much insulin.
Serum angiotensin converting enzyme is a protein related to blood pressure control
and other functions. A person with diabetes has higher than normal level of this
protein.
Glucose in blood combines with haemoglobin making it ‘glycated’. This is termed
as haemoglobin A1c . We can know our blood glucose level by measuring the
haemoglobin A1c readings. The higher the concentration of glucose in blood, the
higher the haemoglobin A1c reading. Blood glucose levels reading obtained from
usual blood glucose test (i.e.: fasting glucose test), only provide indication of glucose
concentration in that particular time when we do the test. The haemoglobin A1c
readings on the other hand, give an average level of blood glucose in our body in a
period of 2-3 months.
Presence of retinopathy is detected by retinal screening. It is a procedure which allows
specialists to assessed any evidence or severity of retinopathy by taking photographs
of the retina. The damaged capillaries and spots of blood in retina are generally
visible as dots and blots in the photographs. Measurements of haemoglobin A1c and
serum angiotensin converting enzyme were done in a central laboratory.
The identity of each subject in the study is confidential. Therefore, a unique four-
digit code is assigned to each of them. There are missing values in the data set.
Subject 3065 has unspecified retinopathy record, whereas subjects 1028, 1039, 2021,
3050, 4023, and 6019 have no record of the haemoglobin A1c readings. The C-peptide
record for subject 4034 is also missing. The methodology for treating these missing
values is discussed further in Chapter 3.
From the detailed data included in the provided forms, our analysis uses the following
information:
• the reporting of symptoms in the occurrence of each episode used to model
individual consistency,
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• the date and time of the occurrence of each episode used to distinguish the
episodes occurring within 24 hours, and
• the patients’ characteristics; i.e. gender, duration of diabetes, BMI, age, type of
diabetes, awareness of hypogylcaemia, type of retinopathy, levels of C-peptide,
percentage of haemoglobin A1c, and levels of serum angiotensin converting en-













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































To assess consistent reporting across episodes for each subject, we present the symp-
toms and episodes of each patient in a matrix form with J×K dimension; J = number
of symptoms (=26 for all patients) and Ki = number of episodes for patient i, see for
example Figure 2.1 for Subject 6010 with K =19 episodes. In Figure 2.1(b) from the
top-left corner, symptoms and episodes are arranged in descending order, from more
frequent to less frequent symptom and from more intense to less intense episode. The
frequency of a symptom reported by a patient represents the symptom’s propensity
and the number of symptoms in one episode represents the intensity of that episode.
Figure 2.1: a) Example of a J ×K matrix of indicator variable (J=number of symp-
toms; K=number of episodes) for subject 6010 with symptoms 1-26 listed vertically
and hypoglycaemic episodes listed horizontally. Each reported symptom is marked
with a square. b) Rearrangement of the matrix rows and columns so that rows now
appear according to frequency with which symptoms are experienced and columns
according to the number of symptoms per episode (both following a descending order
from the top-left corner).
We assume that consistency of symptom reporting follows the principle that if a pa-
tient is consistent in reporting symptoms experienced throughout the hypoglycaemic
episodes, higher ranked symptoms must be reported first before reporting lower ranked
symptoms. For example, if a symptom ranked at number 7 (i.e. symptom 3 in 7th
row in Figure 2.1(b)) is reported at episode k then all symptoms in rows above and
columns to the left must also have been reported. When this principle is violated,
we will have embedded empty cells, meaning that there is at least one filled cell to
the right or below the empty cell, hence suggesting inconsistency. Thus we say that
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symptoms are experienced based on a hierarchical ordering determined by their latent
characteristics, i.e. propensity of symptoms and intensity of episodes.
2.3 Bayesian inference
This section gives a brief review of Bayesian estimation, and an introduction to MCMC
approaches (Metropolis-Hastings and Gibbs Sampling) will also be provided in the
following sections.
Bayesian methodology is employed to estimate the posterior distribution of model
parameters. The heart of Bayesian modelling is Bayes theorem. Suppose we have
observed data x = {x1, ..., xn} from a distribution involving an unknown parameter
vector θ, for which we wish to make inference. This parameter θ is assumed to be
random rather than fixed like in frequentist approach. We assume here that θ is a




where π(θ|x) is the posterior density of the parameter, given the observed data, x;
f(x|θ) is the likelihood of the data, which is the probability of observing different
data, x = {x1, ..., xn} given that θ is a true parameter; and p(θ) is the prior density
used to evaluate the probability of parameter θ. This prior incorporates our initial
belief and uncertainty regarding θ before data are observed. f(x) is the normalising




integration can be tedious to calculate and f(x) does not involve θ, we can often omit
this term in the MCMC techniques described later. Moreover, the posterior π(θ|x)
only needs to be known up to a constant proportionality for us to make estimation
from it. Therefore, the Bayes theorem is often quoted as π(θ|x) ∝ f(x|θ)p(θ).
We use Bayesian methodology to make inference for parameter θ. Among the useful
measures we can obtain from the sampled posterior distribution in making infer-
ences on θ, are the posterior mean E(θ|x), the posterior variance V ar(θ|x), and the
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Bayesian interval, {a(x), b(x)} for θ such that Pr{a(x) < θ < b(x)|x} = 0.95. A
95% Bayesian interval (or credible interval) can be interpreted as 95% chance that the
true value of the parameter of interest lays in this interval. There are different types
of credible intervals, with two of them being the highest posterior density (HPD)
which is the smallest interval enclosing (1−α)% of the posterior distribution, and the
equal-tailed interval which gives 2.5% and 97.5% quantile of the posterior distribution.
2.3.1 Choosing prior distributions
In Bayesian statistics, choosing a parameter prior distribution, p(θ), is an important
task. The prior distribution has to represent our uncertainty about the parameter.
With little knowledge of the parameter, either from expert or previous studies, we can
use non-informative or flat priors which cover all combinations of parameter values
with any support from the likelihood and the requirement is that the prior is rela-
tively flat within this range. For instance, we should assign equal probability to all
possible values. Vague prior distributions may cause problems such as large variation
in the posterior inference if the sample size is small. With large samples, the effect of
changes in prior distributions on results will be minimal.
Jeffreys’ prior (Jeffreys, 1961) is an example of non-informative prior which is con-







where log f(x|θ) is the usual log-likelihood function of the data x.




If a posterior distribution comes from the same family as the prior distribution, the
prior is termed as the conjugate prior for the likelihood. This type of prior approach
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was introduced by Schlaifer and Raiffa (1961).
2.4 Markov chain Monte Carlo
As it is often difficult, and in some cases almost impossible, to calculate integrals of a
complex posterior distribution, Markov Chain Monte Carlo (MCMC) sampling tech-
niques (Tierney, 1994) are widely used to obtain the posterior distribution iteratively
(e.g. Raab et al., 1998). The most well-known MCMC algorithms are Metropolis-
Hastings (M-H) and the Gibbs sampler.
2.4.1 Metropolis-Hastings
The Metropolis-Hastings algorithm was developed by Metropolis et al. (1953) and
later generalised by Hastings (1970). Let us say we are interested in making inference
for parameter θ, where θ can be a vector of parameters, but the posterior distribution
is non integrable. The M-H algorithm allows us to generate samples from the target
distribution π(θ|x) by utilising each parameter’s proposal distribution, q(θ, .).
The steps of the M-H algorithm are summarised as follows.
i. Initialise θ0 and set t = 1.
For iteration t = 1, 2, ... perform the followings:
ii. (a) Generate proposal value, θ∗ ∼ q(θ, .) and U ∼ U [0, 1].
(b) Calculate the acceptance probability,




(c) Accept the proposed value, θ∗ if U ≤ α. Set θt = θ∗.
Otherwise, reject the proposed value. Set θt = θt−1.
iii. Set t = t+ 1 and repeat step ii until convergence is achieved.
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If the proposal distribution used is a symmetric distribution, i.e. q(θt|θ∗) = q(θ∗|θt),
the acceptance probability can be simplified to




Note that in calculating the acceptance probability, the normalising constants f(x)
in (2.3.1) are cancelled out since (2.4.1) is a function involving the ratio of the poste-
rior distribution. Besides updating the parameter one by one, M-H algorithm is also
capable of updating a group of parameters at once.
2.4.2 Gibbs sampler
The Gibbs sampler was originally used to analyse the Gibbs distribution on a lattice
by Geman and Geman (1984). It was used in statistical physics much earlier, before
Gelfand and Smith (1990) and Gelfand et al. (1990) brought MCMC into mainstream.
This is a special case of the single-parameter Metropolis-Hastings algorithm. Suppose
we have a posterior distribution, π(θ|x) where θ = (θ1, ..., θp)′. Our full conditional
distribution, π(θj|θ\j,x), j = 1, ..., p is the conditional distribution of θj given all
other variables where θ\j = (θ1, ..., θj−1, θj+1, ...θp). With the Gibbs sampler, it is
compulsory for the full conditional posterior distribution to be known allowing a
random variate to be easily simulated from it. Therefore, we do not need a proposal
distribution implying that, since we sample from the posterior distribution to update
the jth component of θ, the acceptance probability is always equal to 1. Since the
posterior distribution acts as the proposal distribution, we have
q(θj|θ\j,x) = π(θ1|θ\j,x). (2.4.3)
Thus, substituting (2.4.3) into the acceptance probability in (2.4.1), will make it equal
to 1. Therefore, the chain will always move to new values.
The steps of Gibbs sampler algorithm are described as follows.
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iii. Repeat step 2 until the chain converges.
2.4.3 Convergence diagnostics
To ensure samples come from our distribution of interest, a Markov Chain must run
long enough until it converges, i.e. until it reaches the equilibrium or stationary state.
However, a common issue with MCMC applications is to determine how many itera-
tions the chain needs before it converges to our target distribution. Although we will
never know the exact number of iterations needed, there are several ways to prelimi-
narily assess convergence. Some of them are discussed below.
Examples of quick and simple ways to diagnose convergence are given by calculating
the Monte Carlo (MC) error and by monitoring the autocorrelation function of the
run (Ntzoufras, 2011). The MC error estimates the difference between the mean of
the sampled values and the targeted posterior mean. For instance, a small MC error
value implies that the chain has calculated the quantity of interest with precision.
Therefore as a rule of thumb, a chain is said to reach its stationary state when the
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MC error for each parameter is less than 5% of their standard deviation. As for the
autocorrelation, low values indicate fast convergence and vice versa.
We can also monitor the parameters’ trace plot, which is a plot of sampled values ver-
sus the iterations (Ntzoufras, 2011). If the chain has stabilised around a value without
or with little fluctuation, we say that the chain may have reached convergence. The-
oretically, we should monitor trace plots for all parameters including parameters that
are not of interest. This is because it is possible for some parameters to already
mix well while others have bad mixing. Making inference from these sampled values
might be inaccurate. However, it is not practical to observe all trace plots for a large
parameter set. In this case it is sufficient to randomly check 5 - 10 parameters from
a large parameter vector.
A more advanced diagnostic test is to run multiple chains with different starting points
(Ntzoufras, 2011). When the lines of these chains cross in the trace plot, the chains
are assumed to already have achieved convergence.
In this thesis, we estimate the parameters using MCMC methodology with the aid of
WinBUGS (Spiegelhalter et al., 2003). This software has been developed to facilitate
the implementation of MCMC methods and now is widely used especially for MCMC
simulations from complex statistical models. R software (R Development Core Team,
2009) is also used for other computations and to produce graphical outputs.
2.5 Basic model for individual patients consistency
Based on Zammit et al. (2011), we model the intra-individual consistency using a
logistic-type latent variable model. A latent variable is used when a given variable
cannot be observed directly and needs to be estimated from a number of related vari-
ables. In this case, consistency is non-observable, and also we cannot observe the
propensity of symptoms and the intensity of episodes directly. Therefore we need to
estimate them through observation of symptoms and episodes of hypoglycaemia.
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We define the indicator random variable such that
Yijk =
 1 if subject i reports symptom j at episode k0 otherwise.
We assume
Yijk ∼ Bernoulli(pijk) (2.5.1)
for individual i = 1, ..., I, symptom j = 1, ..., J and episode k = 1, ..., Ki, where pijk
is the probability of patient i reporting symptom j at episode k.
Individual i reports symptom j at episode k when h(αij, βik) exceeds a random thresh-
old associated with each patient, where αij represents the propensity of symptom j
for individual i, βik represents the intensity of episode k for individual i and h(·)
is an appropriate functional form. The propensity of a symptom refers to the ten-
dency for a patient to experience that particular symptom, whereas intensity of an
episode corresponds to how intense the episode is, with more symptoms experienced
in an episode implying higher intensity. The random threshold for each symptom
j = 1, ..., J experienced at episode k = 1, ..., Ki by individual i = 1, ..., I, denoted by
τijk, is assumed to follow a log-normal distribution:
τijk ∼ LN(0, σ2i ). (2.5.2)
This analysis is robust to the choice of the threshold distribution. Zammitt et al.
(2011) fit the model with thresholds following a Weibull distribution such that,
τijk ∼ Weibull(vi, λi) where vi and λi are the mean and scale parameter respec-
tively and found that the posterior estimates of consistency from the two models are
in close agreement.
There is no loss of generality when we set the mean of the log-normal distribution to 0
for all subjects i, because here the mean of the logarithm of the threshold E{log(τijk)}
is not of interest and inestimable. Thus, the probability of patient i reporting symp-
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tom j at episode k, is given by







where Φ(·) is the cumulative distribution function of a standard normal variable. In
earlier work (Zammit et al., 2011) a multiplicative threshold form h(αij, βik) = αijβik
was assumed, with individual i experiencing symptom j at episode k when τijk ≤
h(αij, βik) = αijβik. In this thesis we also explore different forms of h(·) as described
in Section 3.2.
Parameter σi measures the symptom-reporting consistency of a patient. A rescaled
consistency parameter, ci =
100
(1 + σ2i )
, is used for easier interpretation where ci ∈
(0, 100]. A large ci value indicates high consistency. For large ci (i.e. small σi)
the thresholds get highly concentrated around constant reporting of symptoms as-
sociated with latent symptom propensity αij and episode intensity βik such that
h(αij, βik) > τ
∗
i , with τ
∗
i approaching a constant value as σi tends to zero (or ci
tends to ∞). Therefore, consistent reporting is associated with high concentration of
the threshold distribution, corresponding to increased values of the consistency pa-
rameter ci.
Under a Bayesian framework (Berger JO, 1985), we specify appropriate prior dis-
tributions for the model parameters αij, βik and σi. In this analysis, we assume
independent priors for the latent variables with
αij ∼ Gamma(aα, bα),
βik ∼ Gamma(aβ, bβ), (2.5.4)
for individual i = 1, ..., I, symptom j = 1, ..., J , and episode k = 1, ..., Ki. We assign
an inverse-gamma prior distribution to the variance parameter, σ2i , given as
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σ2i ∼ Inv −Gamma(γσ, δσ) (2.5.5)
for i = 1, 2, ..., I.
The likelihood function of this model can be written as



















The joint posterior distribution of the parameters can be expressed as
π(αij, βik, σi|yijk) ∝ f(yijk|αij, βik, σi)p(αij)p(βik)p(σi), (2.5.7)
where p(αij), p(βik) and p(σi) are the prior densities given in (2.5.4) and (2.5.5).
Therefore, from (2.5.7), we can get the full conditional distributions for each param-
eter:













× αaα−1ij exp(−bααij) for i = 1, ..., I, j = 1, ..., J. (2.5.8)













× βaβ−1ik exp(−bββik) for i = 1, ..., I, k = 1, ..., Ki. (2.5.9)
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× σ2(−λσ−1)i exp(−δσ/σ2i ) for i = 1, ..., I. (2.5.10)
To estimate ci, we need to estimate the latent variables αij and βik first. Estima-
tion of αij and βik is informed by the frequency with which a symptom is reported
throughout all episodes and the number of symptoms per particular episode. We use
a Bayesian approach to estimate the posterior distribution of the unobserved latent
factors and the variability of the thresholds. Posterior distributions of the latent vari-
ables are obtained using Markov chain Monte Carlo simulation techniques (Arminger
and Muthen, 1998). The results, together with relevant discussion and extensions,





In this chapter, we model individual patients’ consistency mainly using Bayesian
methodology and Markov chain Monte Carlo techniques. To begin with, based on the
core model discussed in Chapter 2, we explore different functional forms, h(·), for the
threshold according to which individual i reports symptom j at episode k. Then, we
compare the models’ fit using Deviance Information Criterion (DIC) before selecting
a threshold to use throughout this thesis. Next, we expand the core model by adding
variability to symptoms’ reporting. Consequently, we perform comparisons on the
outcome from each model. Analysis in this chapter will include the data collected
from 66 patients including those from seven additional patients that we received later
in this study.
3.1 Consistency model for all patients
Referring to the core model in Chapter 2, i.e. (2.5.1) - (2.5.5), Zammit et al. (2011)
in earlier work assumed a multiplicative threshold form, h(αij, βik) = αijβik in (2.5.3)
with individual i experiencing symptom j at episode k when τi ≤ h(αij, βik) = αijβik.
Under Bayesian framework, we specify appropriate prior distributions for the model
parameters αij, βik and σi.
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We assign the following non-informative prior distributions
αij ∼ Gamma(1, 0.1), i = 1, ..., 66 and j = 1, ..., 26
βik ∼ Gamma(1, 0.1), i = 1, ..., 66 and k = 1, ..., Ki
σ2i ∼ Inv −Gamma(1, 0.1), i = 1, ..., 66. (3.1.1)
These parameters are estimated by using MCMC methodology implemented in Win-
BUGS. Posterior estimates for the parameters of interest are computed from 10,000
MCMC iterations after discarding the first 1000 iterations as the burn-in period. Fig-
ure 3.1 shows the trace plots displaying the mixing of the chain for the precision
parameter, σi, for four of the patients: Subjects 1009, 1025, 1028 and 2013. Notice
that these chains quickly converge from their initial values (left plots) and are mixing
well, reaching their stationary states (right plots). Recall that the consistency pa-
rameter ci is a function of σi. Note also that the MC error for each patient (Table
3.1) after 10 000 iterations is less than (or about) 5% of the corresponding parameter
standard deviation implying that the number of iterations is appropriate.
The distribution of the posterior mean estimates of the consistency parameter for
all 66 patients is shown in Figure 3.2, where estimates of both c̃i and log(σ
−2
i ) are
presented (left and right respectively). The distribution of the converted consistency,
c̃i = E(c̃i|y) is presented in a histogram (Figure 3.2 (left)). On the left graph, the
red lines refer to the highest and lowest estimated consistency, c̃i and the dotted lines
refer to their 95% Bayesian intervals (using equal-tailed intervals). Subject 1028, who
had Type 1 diabetes for more than 15 years, has the highest estimated consistency
(96.69; 95% Bayesian interval (92.95, 98.66)). This patient recorded 45 episodes of
hypoglycaemia. The lowest consistency score was estimated for subject 2013 (17.77;
95% Bayesian interval (13.23, 23.02)). This patient had reported the highest number
of episodes (138) and had Type 1 diabetes for more than 15 years. The average of c̃i
is 51.86 with standard deviation 17.19. The main sample quartiles of c̃i are q0=17.77,
q0.25= 38.46, q0.5=51.81, q0.75= 63.92 and q1= 96.67. A list of c̃i estimates for all
patients is provided in Table 3.1.
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Figure 3.1: Trace plots of parameter σi for subjects 1009, 1025, 1028 and 2013 for





































Figure 3.2: Histogram of estimated consistency parameter, c̃i and the log estimated
precision parameter, σ−2i .
3.2 Sensitivity to the prior
This section investigates how sensitive are the posterior estimates to variations in the
choice of the prior distributions (3.1.1) used in the model. To check this prior sensitiv-
ity, we study the posterior estimates of the consistency parameter for all 66 patients
using a variety of priors for parameters αij, βik, and σ
2
i , which belong to the same
family of distributions as those in (3.1.1), but have different prior hyper-parameters,
guided mainly by the location and spread of αij, βik and σ
2
i . We note here that
prior knowledge on likely values of these parameters is not available and therefore our
choices here are purely driven by exploratory and comparison purposes. Table 3.2
lists the different prior distributions introduced to evaluate this sensitivity, whereas
Table 3.3 gives the combinations of the prior settings used to fit the consistency model.
We obtain estimates of the posterior mean of individual consistency, c̃i, using each
new prior setting and compare them with the results obtained using the original model
with prior given in (3.1.1). For our prior sensitivity investigation, we are not inter-
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ested in absolute values of consistency, but instead we will examine relative values
among patients and focus on the ranking of the individuals’ consistency. Therefore,
we rank the consistency in descending order and compare the ranking.
Figure 3.3 shows five graphs representing these comparisons. The graphs demonstrate
that, in general the consistency ranking of the 66 patients is similar regardless of which
prior is used. Correlations in the ranking from each comparison are provided in Table
3.3 and also confirm that the choice of prior does not affect considerably the ranking.
We note that the ranking is most affected when prior setting (f) is used, with αij,
βik ∼ Gamma(1,1) and σ2i ∼ Inv-Gamma(1,0.1), resulting in the lowest correlation
(0.93). Although this still indicates strong agreement, it is perhaps expected as the
Gamma(1,1) prior on αij and βik imposes a rather strong assumption of precise prior
knowledge (relatively small prior variance).
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Subject No of episodes c̃i SD 95% interval MC error
1008 95 29.84 4.133 (22.46, 38.26) 0.2239
1009 74 52.21 5.653 (41.40, 63.73) 0.3122
1015 27 36.70 7.275 (23.30, 52.12) 0.3524
1021 43 47.95 6.809 (34.96, 61.66) 0.3322
1025 25 63.28 8.230 (46.96, 78.89) 0.4295
1028 42 96.68 1.522 (92.95, 98.66) 0.0301
1036 24 52.06 8.267 (36.37, 68.82) 0.4073
1039 43 31.03 5.998 (20.63, 43.90) 0.2619
1055 27 74.16 7.270 (58.24, 86.55) 0.3059
1057 11 73.17 8.018 (55.49, 86.73) 0.2468
1086 67 39.95 5.485 (29.43, 50.73) 0.2913
2009 86 30.11 4.207 (22.65, 38.97) 0.2515
2010 89 33.05 4.454 (24.82, 42.26) 0.2413
2012 37 29.59 6.093 (19.06, 42.74) 0.2883
2013 138 17.7 2.507 (13.23, 23.02) 0.1556
2015 32 43.71 6.929 (30.57, 57.41) 0.3219
2021 24 57.32 8.859 (39.92, 73.77) 0.3666
2022 36 44.39 7.482 (30.95, 59.67) 0.3826
2027 22 69.40 7.874 (52.89, 83.71) 0.2953
3001 31 57.54 7.883 (41.76, 72.58) 0.3667
3015 19 48.40 8.852 (31.93, 66.88) 0.3377
3016 22 72.61 7.271 (57.13, 85.41) 0.2926
3022 20 65.86 8.577 (47.66, 80.96) 0.3685
3024 27 50.78 8.147 (35.06, 66.94) 0.4595
3029 69 64.82 6.061 (52.46, 76.06) 0.2324
3043 17 49.06 8.694 (32.27, 66.45) 0.3043
3046 25 69.37 7.780 (52.39, 82.89) 0.3453
3048 31 66.94 7.740 (51.34, 81.66) 0.3162
3050 44 48.96 7.186 (35.57, 63.44) 0.2896
3052 105 49.93 5.298 (39.93, 60.36) 0.2313
3057 51 40.06 6.245 (28.49, 52.95) 0.3188
3065 26 55.14 8.683 (38.10, 71.45) 0.3568
3067 26 42.26 7.906 (27.92, 58.42) 0.3592
4003 23 75.69 6.773 (61.10, 87.31) 0.3045
4008 59 31.17 4.556 (23.21, 40.98) 0.2475
4013 39 74.45 7.192 (59.29, 86.94) 0.3359
4023 134 22.25 3.086 (16.71, 28.57) 0.1643
4028 12 62.02 8.886 (43.93, 78.55) 0.2222
4032 10 84.15 6.954 (68.05, 94.49) 0.1606
4034 55 60.01 6.723 (46.90, 72.76) 0.3282
4043 35 38.67 6.648 (26.61, 52.46) 0.3160
4045 38 48.22 7.483 (33.65, 63.32) 0.3686
4049 22 60.42 8.070 (44.14, 75.82) 0.3563
4061 12 63.55 9.032 (45.25, 80.02) 0.2802
4063 42 34.50 5.926 (23.47, 46.91) 0.2832
4072 39 57.68 7.089 (44.34, 71.78) 0.3651
4076 29 52.73 7.610 (38.08, 67.65) 0.4447
5004 26 59.22 8.468 (42.49, 75.38) 0.3641
5009 36 26.18 5.081 (17.58, 37.52) 0.2674
5023 20 72.88 7.750 (56.47, 86.41) 0.3645
5026 24 74.44 7.341 (58.49, 87.07) 0.3055
5029 45 62.37 6.780 (49.03, 75.35) 0.2959
5044 70 37.62 4.739 (28.70, 47.22) 0.2302
5045 68 47.19 5.708 (36.29, 58.70) 0.2595
5088 87 23.98 3.527 (17.70, 31.43) 0.1964
6002 34 40.89 6.630 (29.09, 54.72) 0.3843
6010 19 64.27 8.196 (47.84, 79.65) 0.4192
6018 39 29.63 5.642 (20.03, 42.03) 0.3078
6019 64 38.30 5.716 (27.97, 50.08) 0.2313
6023 59 32.35 4.774 (23.68, 42.19) 0.2312
6038 79 28.63 4.051 (21.36, 37.29) 0.2227
6062 13 59.60 9.485 (40.82, 77.35) 0.3914
6064 17 85.07 5.532 (72.48, 93.77) 0.3147
6065 39 57.41 6.479 (44.58, 69.58) 0.2890
6056 28 49.88 7.411 (35.97, 64.51) 0.1541
6058 20 75.02 6.943 (60.59, 87.41) 0.3049
Table 3.1: Posterior estimates of consistency (Mean, standard deviation, 95%
Bayesian interval and Monte-Carlo error) for all subjects using threshold h(αij, βik) =
αijβik.
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αij, βik priors E(α) V ar(α) E(β) V ar(β)
αij, βik ∼ Ga(1, 0.1) 10 100 10 100
αij, βik ∼ Ga(1, 0.01) 100 104 100 104






V ar(σ2) = β
2
(α−1)2(α−2)
σ2i ∼ Inv −Ga(1, 0.1) ∞ 0.05 ∞
σ2i ∼ Inv −Ga(2.1, 10) 9.1 3.23 826.4
σ2i ∼ Inv −Ga(2.1, 1) 0.9 0.32 8.26
σ2i ∼ Inv −Ga(1.1, 10) 100 4.76 ∞
Table 3.2: Alternative priors explored.
Prior Correlation
(a) αij, βik ∼ Ga(1, 0.1) and σ2i ∼ Inv −Ga(1, 0.1) -
(b) αij, βik ∼ Ga(1, 0.1) and σ2i ∼ Inv −Ga(2.1, 10) 0.96
(c) αij, βik ∼ Ga(1, 0.1) and σ2i ∼ Inv −Ga(2.1, 1) 0.99
(d) αij, βik ∼ Ga(1, 0.1) and σ2i ∼ Inv −Ga(1.1, 10) 0.96
(e) αij, βik ∼ Ga(1, 0.01) and σ2i ∼ Inv −Ga(1, 0.1) 0.98
(f) αij, βik ∼ Ga(1, 1) and σ2i ∼ Inv −Ga(1, 0.1) 0.93
Table 3.3: New prior settings compared to original prior (a) and the correlations of
the ranking of consistency estimates, c̃i between them.
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Figure 3.3: Ranking of consistency estimates, c̃i, of 66 patients when using different
prior settings - see Table 3.3.
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3.3 Exploration of different thresholds
In this section, we also explore two other different thresholds to fit to this model.
These are:
i. h(αij, βik) = αij + βik + αijβik, and
ii. h(αij, βik) = αij + βik .
For each new threshold, the probability of patient i reporting symptom j at episode k
is obtained by substituting the thresholds into (2.5.3). Figures 3.4-3.5 show the trace
plots of parameter σi for subjects 1009, 1025, 1028 and 2013 when using thresholds
h(αij, βik) = αij + βik + αijβik and h(αij, βik) = αij + βik respectively, for 10,000
iterations. The first 1000 iterations (left figures) are the burn-in period. However,
we can see that the chains quickly converge to some specific values within the first
200 iterations. The estimates of consistency for each patient for these two models are
summarised in Tables 3.4 and 3.5. The distributions of the estimated consistency c̃i
and the logarithm of estimated precision parameter σ−2i for both models are given in
Figure 3.6.
Using threshold h(αij, βik) = αij + βik + αijβik, the majority of the subjects have
high consistency with estimated mean of converted consistency parameter c̃i = 86.25
and standard deviation of 5.4369. Posterior estimates of c̃i and its credible intervals
for each subject are displayed in Table 3.4. Subject 1028 has the highest consistency
score, c̃i = 98.20 with 95% Bayesian interval (96.76, 99.08). Although subject 2013
still gives the lowest estimated c̃i, the value now gets drastically higher compared to
the values estimated from our previous model in Section 3.1 (73.26; 95% Bayesian in-
terval (67.93, 78.44)). Subject 3029 had the second highest consistency score (94.97;
95% Bayesian interval (92.57, 96.76)). However, this patient was previously ranked
at 13th largest consistency estimate. The patient had diabetes Type 1 for less than
five years and reported 69 episodes of hypoglycaemia.
Dropping the interaction term αijβik, we now have h(αij, βik) = αij + βik. Again,
the majority of the subjects have high consistency with estimated mean of converted
consistency parameter c̃i = 89.47 and standard deviation of 4.1310. The summary
35






































































Figure 3.4: Trace plots of parameter σi for subjects 1009, 1025, 1028 and 2013 using
threshold h(αij, βik) = αij + βik + αijβik.
statistics of the posterior consistency estimates, c̃i, for each patient are given in Table
3.5. Similar to the result from the previous thresholds, subject 1028 still has the
highest consistency, with c̃i = 98.36 and 95% Bayesian interval (97.08, 99.13). The
subject with the lowest consistency is 2013 with c̃i = 78.69 and 95% Bayesian interval
(73.77, 82.96).
Estimating individual patients’ consistency, c̃i, using the model with threshold
h(α, β) = αijβik clearly yielded a much wider range of c̃i compared to the patients’
consistency estimated from the other two thresholds (Figure 3.7). Although the scale
and spread of c̃i has changed, generally consistency ranking of the patients is mostly
similar except for a few patients who have quite big differences (Figures 3.8-3.9).
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Figure 3.5: Trace plots of parameter σi for subjects 1009, 1025, 1028 and 2013 using
threshold h(αij, βik) = αij+βik.
Note that these patients have a small number of episodes. We are not interested in
the absolute values of this estimate as we cannot define a cut-off to determine which
subject is consistent and which is not. Therefore, what is more important here is how
consistent a particular patient is, compared to other patients.
3.3.1 Model selection: DIC criterion
To compare models with different thresholds, we first use the Deviance Information
Criterion. DIC was proposed as a Bayesian measure of model fit by Spiegelhalter et
al. (2002), following the principle that it is a normal way to compare models using


































































(b) Model with threshold h(αij , βik) = αij + βik.
Figure 3.6: Histograms of estimated consistency parameter, c̃i, and the log of esti-
mated precision parameter, σ−2i , for model with different thresholds.
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Figure 3.7: Boxplots of estimated consistency parameter, c̃i in model with different
thresholds.













































Figure 3.8: Ranking of consistency estimates, c̃i, of 66 patients for model with thresh-
old h(αij, βik) = αijβik, versus model with threshold h(αij, βik) = αij + βik + αijβik.
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Figure 3.9: Ranking of consistency estimates, c̃i, of 66 patients for model with thresh-
old h(αij, βik) = αijβik, versus model with threshold h(αij, βik) = αij + βik.
corresponding complexity of the model. Thus, DIC is given by
DIC = “goodness-of-fit” + complexity.
Goodness-of-fit is measured by deviance, D(θ), which is a measure of overall fit for a
likelihood, L(θ; y). Following Gelman et al. (2004) the deviance is defined as
D(θ) = −2logL(θ; y).
Complexity is measured by the effective numbers of the parameters and is defined as
de = D̃(θ)−D(θ̃) (3.3.1)
where D̃(θ) is the posterior mean of D(θ) with respect to the posterior distribution
of θ. D(θ̃) is D(θ) evaluated at the posterior mean of θ. Therefore DIC is given by
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DIC = 2D̃(θ)−D(θ̃)
= D(θ̃) + 2de.
Larger deviance indicates poor fit. Hence, a model with smaller DIC value provides
better fit of the data. In general, if a model’s DIC value exceeds another model’s
DIC value by 5 or more, we can rule out that model, but if the difference of DIC
reported by the models is less than 5 and both models yield very different inferences,
it is not reliable to make conclusion based only on the DIC (Spiegelhalter et al., 2002).
We start our comparison by examining the DIC values of the three thresholds used
in the model on eight subjects individually. The following subjects were randomly
chosen from all 66 subjects: 1009, 1036, 3016, 3046, 3052, 3057, 3065 and 5009.
Smaller DIC values indicate a better model. From the results summarised in Table
3.6, it is worth noticing that subjects with small number of episodes favour thresh-
old h(αij, βik) = αij, βik whereas subjects who experienced larger number of episodes
favour a model with h(αij, βik) = αij + βik. The differences between the DIC values
from different thresholds for Subject 3016 are less than five, suggesting that all three
models fit the data reasonably well and it is not sufficient to distinguish the better
model based solely on the DIC values. We further our study by comparing DIC values
for the models with all subjects and summarise the results in the same table. The
model with threshold h(αij, βik) = αijβik produced the lowest DIC value suggesting
that this gives the best fit to the data. Therefore, all further analysis in this thesis
will be using this threshold. This is also supported by an analysis based on a different
comparison approach, presented in Section 3.5.
Table 3.6 elaborates more on the DIC results of these models by showing the values
of the deviance and the effective number of parameters together with the DIC val-
ues corresponding to each model. Note that the number of parameters of the model
with all patients is also given in Table 3.6. The results in Table 3.6 show that the
value of effective number of parameters differs considerably between models for cer-
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tain patients, which may not be expected here. For example, the effective number
of parameters for patients 3046 and 3065 seems uncharacteristically low under the
model with threshold αijβik. This highlights the problems with DIC methodology, as
discussed in Spiegelhalter et al. (2002) and Spiegelhalter et al. (2014). Therefore, in
order to confirm these model selection findings, we also present in the next section
results based on maximum likelihood estimation.
3.3.2 Model selection: Maximum likelihood estimation
We fit the models with the three different thresholds h(αij, βik) = αijβik; αij+βik; αij+
βik + αijβik using maximum likelihood estimation. For convenience we consider the
log-likelihood function, and using the likelihood in (2.5.6), our log-likelihood function
for the model with all patients when using threshold h(αij), βik = αijβik becomes




















For comparison purposes we also present in this section log-likelihood results for the
same individual patients presented in Table 3.6 when the DIC method was used.
We maximise the log-likelihood function above in R using the ‘nlminb’ command
which minimises the negative log-likelihood function. Here, in this classical analysis,
the form of the likelihood gives identifiability issues, with parameters αij, βik and σi
not all being identifiable in the estimation. So we need to use certain constraints, and
we choose to apply the following constraints to the parameters: αi1 = 1 and σi = 1.
We note here that the constraint on σi means that the present model can not be
used in the classical approach for the purposes of this work, which is to estimate the
patients’ consistency based on σi. However, under the Bayesian approach used in this
thesis, identifiability is not an issue as the prior distributions serve as constraints on
the parameters by ‘pulling’ them towards certain values and providing proper poste-
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rior distributions for all parameters (Xie and Carlin, 2006). This is the case when the
simple independent priors in (3.1.1) are used in the model, but also when common
priors are used for groups of symptoms later in the thesis (in Section 3.4).
Table 3.7 summarises the results of the log-likelihood function, evaluated at maxi-
mum likelihood estimates of the model parameters, for the three threshold models.
Larger values of the log-likelihood function indicate a better model. From the ta-
ble, we can see that data from the eight patients favour the model with threshold
h(αij, βik) = αijβik, which is also favoured when the analysis with all patients is con-
sidered. Note that our results in the previous section, when we compare models using
DIC values, indicate that the lowest DIC values for patients 1009, 3057, and 3052
are when using threshold h(αij, βik) = αij + βik. However, the overall results are
consistent in identifying αijβik as the most suitable model.
We then look further at the results from fitting the models using the Bayesian method
and maximum likelihood. Figure 3.10 compares the estimates of parameter α5009,j for
patient 5009 for model with threshold h(αij, βik) = αijβik. Although the absolute
values of the estimates are different, their rankings are the same except for those
symptoms with propensity estimates very close to zero. This observation is also true
for parameter βik for patient 5009 (Figure 3.11). The ranking of episodes with higher
intensity are the same regardless of the method used. Figures 3.12 and 3.13 compare
the estimates of parameters (αij and βik respectively for patient 1036 when using max-
imum likelihood (left) and the posterior estimates from the Bayesian method (right)).
We also compare the ranking of the αij estimates for patient 1009 and 3057 (Figures
3.14 - 3.15). Again, the ranking of the estimated values with maximum likelihood and
the posterior estimates under Bayesian estimation are the same for non-negligible es-
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Figure 3.10: Estimates of α5009,j obtained with the maximum likelihood approach
(left) and posterior estimates of α5009,j obtained from Bayesian approach (right).
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Group, Subject No of episodes c̃i SD 95% interval
1008 95 83.22 2.289 (78.40, 87.30)
1009 74 91.87 1.477 (88.68, 94.39)
1015 27 81.33 4.031 (72.50, 88.29)
1021 43 86.98 2.709 (81.07, 91.60)
1025 25 88.59 3.150 (81.46, 93.79)
1028 42 98.20 0.605 (96.76, 99.08)
1036 24 91.39 2.314 (86.14, 95.17)
1039 43 77.85 3.917 (68.67, 83.89)
1055 27 92.23 2.317 (86.96, 95.92)
1057 11 88.37 4.884 (76.51, 95.28)
1086 67 85.02 2.461 (79.90, 89.43)
2009 86 81.51 2.501 (76.37, 86.20)
2010 89 82.92 2.273 (78.15, 87.06)
2012 37 77.04 4.151 (68.50, 84.51)
2013 138 73.26 2.652 (67.93, 78.44)
2015 32 84.55 3.354 (77.45, 90.50)
2021 24 88.17 3.300 (80.60, 93.55)
2022 36 82.47 3.544 (74.94, 88.79)
2027 22 90.46 2.886 (83.92, 95.06)
3001 31 87.55 3.063 (80.97, 92.70)
3015 19 86.81 3.968 (78.04, 93.40)
3016 22 91.75 2.632 (85.65, 95.96)
3022 20 90.62 2.870 (84.13, 95.19)
3024 27 87.16 3.242 (79.95, 92.48)
3029 69 94.97 1.077 (92.57, 96.76)
3043 17 75.32 6.363 (61.20, 86.30)
3046 25 90.81 2.562 (85.12, 95.10)
3048 31 90.20 2.659 (84.23, 94.57)
3050 44 88.60 2.414 (83.44, 92.80)
3052 105 92.43 1.179 (89.88, 94.54)
3057 51 83.38 2.870 (77.40, 88.49)
3065 26 85.70 3.542 (78.09, 91.82)
3067 26 84.96 3.687 (76.62, 90.98)
4003 23 92.43 2.149 (87.34, 95.84)
4008 59 81.86 2.777 (75.90, 86.84)
4013 39 85.38 3.084 (78.78, 90.77)
4023 134 82.89 1.827 (79.05, 86.22)
4028 12 81.15 6.295 (66.83, 91.37)
4032 10 95.20 2.077 (90.00, 98.01)
4034 55 92.53 1.611 (88.98, 95.24)
4043 35 81.27 3.693 (73.21, 87.65)
4045 38 85.01 3.187 (78.11, 90.61)
4049 22 89.02 3.107 (82.10, 94.18)
4061 12 84.75 6.170 (69.54, 93.52)
4063 42 78.00 3.860 (70.10, 85.10)
4072 39 88.20 2.671 (82.22, 92.69)
4076 29 84.45 3.663 (76.69, 90.77)
5004 26 87.73 3.319 (80.27, 93.23)
5009 36 75.00 4.624 (65.19, 83.11)
5023 20 90.60 2.861 (84.08, 95.21)
5026 24 92.83 2.222 (87.64, 96.34)
5029 45 90.74 2.116 (86.10, 94.38)
5044 70 83.89 2.514 (78.48, 88.37)
5045 68 88.83 1.898 (84.79, 92.18)
5088 87 77.78 2.781 (72.00, 82.96)
6002 34 84.42 3.454 (76.87, 90.26)
6010 19 88.51 3.409 (80.86, 94.18)
6018 39 79.33 3.961 (70.64, 86.07)
6019 64 85.20 2.293 (80.36, 89.26)
6023 59 80.45 3.014 (74.94, 86.73)
6038 79 79.70 2.947 (73.52, 85.03)
6056 28 90.11 2.831 (83.68, 94.75)
6058 20 92.70 2.269 (87.43, 96.24)
6062 13 83.09 5.376 (71.50, 91.74)
6064 17 94.26 2.212 (88.85, 97.46)
6065 39 89.68 2.257 (84.74, 93.46)
Table 3.4: Posterior estimates of consistency (Mean, standard deviation, and 95%
Bayesian Interval) for all subjects using threshold h(αij, βik) = αij + βik + αijβik.
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Group, Subject No of episodes c̃i SD 95% interval
1008 95 87.83 1.780 (84.25,90.87)
1009 74 93.94 1.194 (91.28,95.93)
1015 27 85.98 3.473 (78.08,91.63)
1021 43 90.81 2.057 (86.10,93.98)
1025 25 91.51 2.409 (86.44,95.49)
1028 42 98.43 0.544 (97.18,99.25)
1036 24 94.10 1.796 (89.51,96.74)
1039 43 82.91 3.473 (74.77,88.72)
1055 27 94.19 1.715 (90.01,96.83)
1057 11 90.94 4.238 (80.34,96.43)
1086 67 89.08 1.996 (84.59,92.98)
2009 86 86.52 2.059 (82.65,90.70)
2010 89 87.12 1.778 (83.33,90.16)
2012 37 81.94 3.580 (74.45,88.10)
2013 138 78.94 2.538 (73.98,84.07)
2015 32 87.34 3.005 (81.15,91.90)
2021 24 91.13 2.532 (85.19,95.29)
2022 36 87.45 2.705 (82.03,92.42)
2027 22 93.12 2.094 (88.52,96.53)
3001 31 91.03 2.186 (85.98,94.85)
3015 19 87.45 3.616 (78.91,93.12)
3016 22 93.55 2.177 (88.43,96.83)
3022 20 93.16 2.093 (88.40,96.32)
3024 27 91.07 2.455 (85.44,94.81)
3029 69 96.61 0.715 (95.18,97.91)
3043 17 81.35 5.524 (68.90,90.40)
3046 25 93.38 1.548 (90.25,96.21)
3048 31 93.02 1.970 (88.62,96.33)
3050 44 92.22 1.820 (88.18,95.22)
3052 105 95.04 0.858 (93.15,96.61)
3057 51 88.14 2.268 (83.44,91.94)
3065 26 89.84 2.562 (84.38,93.83)
3067 26 89.13 3.289 (81.60,93.89)
4003 23 94.50 1.656 (90.77,97.05)
4008 59 87.50 2.345 (82.66,91.54)
4013 39 94.73 1.896 (90.59,97.54)
4023 134 87.80 1.480 (84.77,90.16)
4028 12 84.93 5.471 (72.16,93.10)
4032 10 95.88 1.721 (91.73,98.24)
4034 55 95.07 1.201 (92.29,97.01)
4043 35 85.75 3.189 (78.59,91.21)
4045 38 89.11 2.656 (82.85,93.43)
4049 22 91.91 2.574 (86.46,96.00)
4061 12 88.13 5.292 (75.22,95.29)
4063 42 83.48 3.061 (77.30,88.57)
4072 39 91.60 1.940 (87.42,94.80)
4076 29 87.52 3.045 (80.97,93.11)
5004 26 90.39 2.895 (83.86,94.91)
5009 36 82.27 3.725 (73.86,88.79)
5023 20 92.48 2.369 (87.12,96.18)
5026 24 94.53 1.846 (90.23,97.26)
5029 45 93.54 1.487 (90.01,96.14)
5044 70 87.75 2.201 (82.83,91.67)
5045 68 92.44 1.491 (88.81,94.80)
5088 87 82.56 2.478 (77.05,86.55)
6002 34 88.05 3.104 (80.20,93.04)
6010 19 91.79 2.640 (86.34,96.20)
6018 39 84.89 3.489 (77.12,90.66)
6019 64 89.41 1.699 (85.97,92.90)
6023 59 86.22 2.455 (81.01,90.81)
6038 79 84.98 2.640 (78.78,88.97)
6056 28 88.65 2.558 (83.17,93.02)
6058 20 94.71 1.668 (90.86,97.48)
6062 13 86.49 4.655 (75.31,93.90)
6064 17 95.55 1.689 (91.47,97.94)
6065 39 93.07 1.704 (89.38,95.61)
Table 3.5: Posterior estimates of consistency (Mean, standard deviation, and 95%
Bayesian interval) for all subjects using threshold h(αij, βik) = αij + βik.
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Patient No. of episodes No. of parameters D(θ̃) de DIC
αijβik
5009 36 63 592.3 28.3 620.6***
1036 24 51 308.8 17.3 326.1***
3016 22 49 154.4 14.4 168.8***
3046 25 52 184.4 7.7 192.0***
3065 26 53 301.6 2.7 304.4***
1009 74 101 313.5 58.6 372.1
3057 51 77 571.0 50.8 621.8
3052 105 131 354.8 67.7 422.5
all 2791 4573 24360.3 2948.1 30256.5***
αij + βik + αijβik
5009 36 63 586.4 44.8 631.2
1036 24 51 313.2 38.4 351.5
3016 22 49 148.9 24.8 173.7
3046 25 52 174.4 31.2 205.6
3065 26 53 296.8 36.8 333.5
1009 74 101 298.1 61.0 359.1
3057 51 77 562.0 55.1 617.1
3052 105 131 346.7 78.8 425.5
all 2791 4573 24411.3 3087.1 30585.6
αij + βik
5009 36 63 591.4 44.3 635.6
1036 24 51 315.7 37.9 353.6
3016 22 49 146.4 25.0 171.4
3046 25 52 172.1 29.4 201.5
3065 26 53 295.5 35.7 331.2
1009 74 101 288.5 57.0 345.5***
3057 51 77 557.7 52.7 610.4***
3052 105 131 335.2 70.9 406.1***
all 2791 4573 25012.9 2725.4 30463.6
Table 3.6: Value of the deviance (D(θ̃)), effective number of parameter (de), and DIC
values (*** marks the lowest value) for models with different thresholds, h(αij, βik) =
αijβik; αij + βik; αij + βik + αijβik.
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No. of No. of Threshold, h(αij, βik)
Patient episodes parameters αijβik αij + βik + αijβik αij + βik
5009 36 61 −265.7626*** −299.6110 −298.6920
1036 24 49 −130.4921*** −169.5425 −174.3250
3016 22 47 −57.9646*** −78.7651 −78.5283
3046 25 50 −72.0928*** −92.9805 −93.0193
3065 26 51 −128.7100*** −152.4640 −152.3290
1009 74 99 −119.8340*** −512.7560 −171.5770
3057 51 75 −251.4230*** −254.5510 −254.9340
3052 105 129 −131.4360*** −402.5420 −162.8760
All 2791 4571 −11986.18307*** −14834.30723 −13937.02632
Table 3.7: Maximum likelihood estimates (*** marks the highest value) for individual
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Figure 3.11: Estimates of β5009,k obtained with the maximum likelihood approach
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Figure 3.12: Estimates of α1036,j obtained with the maximum likelihood approach
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Figure 3.13: Estimates of β1036,k obtained with the maximum likelihood approach
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Figure 3.14: Estimates of α1009,j obtained with the maximum likelihood approach
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Figure 3.15: Estimates of α3057,j obtained with the maximum likelihood approach
(left) and posterior estimates of α3057,j obtained from Bayesian approach (right).
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Group Symptoms
1. Autonomic sweating, pounding heart, shivering, hunger,
thirst, anxiety, tingling and trembling
2. Neuroglycopenic confusion, drowsiness, weakness, dizziness,
difficulty speaking, impaired concentration,
unsteady, double vision, tiredness and blurred
vision
3. Autonomic/Neuroglycopenic irritability and feeling warm
4. General malaise nausea, headache and malaise
5. Other non-specific awareness and other symptom
6. No symptom no specified symptom
Table 3.8: The group categorisation of symptoms.
3.4 Grouped symptoms model
The core model framework for the intra-individual consistency (Section 2.5) allows
us to expand this model by having an additional source of variation in the precision
parameter, σ−2i . This is achieved by categorising all the symptoms into six distinct
groups, four of which are discussed in Chapter 1 (autonomic, neuroglycopenic, gen-
eral malaise, and autonomic/neuroglycopenic). The additional two groups are “other
symptom” for symptoms that were not specified by patients in the report form; and
“no symptom” when patients reported hypoglycaemia without experiencing any par-
ticular symptom. This group categorisation (Table 3.8) provides us with an additional
source of variation that may arise from inherent differences between symptoms in dif-
ferent groups.
The model is previously defined in (2.5.1)-(2.5.5). To allow for group effects, the
change made to this model relates to the prior for αij (2.5.4) which corresponds to
propensity of symptom j for patient i. Now, with each symptom being assigned to
a specific group, we have αijl, where l = 1,...,6 indicates group and we assume the
following hierarchical prior:
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αijl ∼ Gamma(θ, θ/ul) , l = 1,...,6




, l = 1,...,6, (3.4.1)
with
θ ∼ Gamma(aθ, bθ),
ul ∼ Gamma(aul , bul). (3.4.2)
Given the likelihood function in (2.5.6), the joint posterior distribution can be written
as (2.5.7), where the priors for βik and σi have been described in (3.1.1).
The full conditional distributions for parameter αijl now become
















αijl) for i = 1, ..., I, j = 1, ..., J, l = 1, ..., 6.
Here, we set θ equal to 1 since the information in the data at this level of hierarchy
is limited, and also to facilitate the convergence of the MCMC algorithm. This effec-
tively corresponds to an exponential prior with mean ul for αijl. For similar reasons,
we also use aul = bul = 1. Therefore (3.4.1) and (3.4.2) become:
αijl ∼ Gamma(1, 1/ul) , l = 1,...,6
ul ∼ Gamma(1, 1) l = 1,...,6.
Using WinBUGS, we run MCMC for 16,000 iterations for estimating parameters in
the grouped symptoms model. The first 1000 iterations were discarded as the burn-in
period. The sample paths of the simulation and summary statistics of the posterior
54
estimates of the group parameter, ul are provided in Figure 3.16 and Table 3.9 respec-
tively. According to the plots we can see that the chains converge well for all groups.
Their densities’ plot (Figure 3.18) shows that the mean propensity for each group is
different. The mean of propensity for group Autonomic, u1, is the highest followed
by group Neuroglycopenic, u2. This is consistent with previous findings, where these
two groups are equally prominent in identifying the onset of hypoglycaemia (Deary et
al., 2001). The “No symptom” group, u6, shows the highest variability because this
group is less reported by patients in this study.
The average mean of symptoms reporting consistency, c̃i, when using this model is
47.29 with standard deviation of 16.645. The consistency estimates range from 7.20
(Subject 3043) to 95.54 (Subject 1028) respectively. A list of posterior consistency,
c̃i, with its 95% Bayesian interval for all subjects is provided in Table 3.10.
Figure 3.19 shows the ranking of patient’s consistency using the model with grouped
symptoms, versus their ranking using the model without grouped symptoms. Patients
are ranked in descending order based on their consistency estimates starting from the
highest estimates to the lowest. When comparing these estimates with the consistency
estimates of the 66 patients in the model without grouped symptoms (Section 3.1), a
few patients have remarkably lower or higher consistency estimates values, c̃i, in this
model.
The biggest changes in ranking is Subject 6065, where this patient’s consistency was
initially the 28th highest of all 66 patients but then the consistency decrease and be-
come the second lowest. Using the grouped symptoms model, Subjects 5009 and 6002
both increase in their consistency estimates. They were ranked at number 63 and 46
before, implying low consistency but climb to higher ranking, 34 and 16 respectively.
Another two patients showing big changes in their ranking are patients 4008 and 6018.
They were originally at the 56th and 60th rank when using the core model, showing
very low consistency but increase to rank number 28 and 41 respectively after we
group the symptoms.
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Figure 3.16: Trace plots of group parameter, ul for l = 1,...6 where u1 refers to
Autonomic, u2 to Neuroglycopenic, u3 to Autonomic/Neuroglycopenic, u4 to General





































Figure 3.17: Histograms of estimated consistency parameter, c̃i and the log estimated
precision parameter, σ−2i for model with grouped symptoms.
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Figure 3.18: Distributions of posterior group propensity, ul.





















































Figure 3.19: Ranking of consistency estimates, c̃i, of 66 patients for core model (with-
out grouped symptoms), versus model with grouped symptoms.
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Group Mean SD 2.5% CI 97.5% CI
Autonomic 0.04767 0.00293 0.04227 0.05376
Neuroglycopenic 0.04196 0.00223 0.03780 0.04652
Autonomic/Neuroglycopenic 0.03033 0.00352 0.02417 0.03789
General Malaise 0.01320 0.00123 0.01092 0.01570
Other 0.00979 0.00120 0.00769 0.01236
No Symptom 0.04071 0.00604 0.03033 0.05383
Table 3.9: Posterior estimates of group propensity, ul.
58
Group, Subject No of hypos c̃i SD 95% interval
1008 95 27.84 3.433 (21.60, 35.17)
1009 74 53.40 5.312 (42.94, 63.87)
1015 27 32.09 6.329 (20.79, 46.03)
1021 43 44.08 6.150 (32.64, 56.61)
1025 25 42.90 7.731 (28.64, 58.92)
1028 42 95.37 2.390 (89.23, 98.38)
1036 24 59.07 7.496 (44.11, 73.01)
1039 43 31.77 5.368 (22.02, 42.87)
1055 27 56.63 7.883 (41.02, 71.88)
1057 11 11.61 5.123 (4.93, 23.87)
1086 67 31.51 4.418 (23.34, 40.67)
2009 86 26.58 3.518 (20.15, 33.91)
2010 89 26.71 3.621 (20.14, 34.29)
2012 37 28.99 5.329 (19.59, 40.34)
2013 138 16.15 2.060 (12.43, 20.59)
2015 32 34.55 5.830 (24.24, 46.73)
2021 24 48.99 7.661 (34.06, 64.07)
2022 36 37.94 5.623 (27.40, 49.23)
2027 22 48.49 8.201 (32.97, 65.06)
3001 31 49.33 7.218 (35.39, 63.83)
3015 19 35.80 7.001 (23.19, 50.61)
3016 22 62.23 7.850 (46.39, 76.89)
3022 20 52.79 8.698 (35.85, 69.88)
3024 27 50.78 8.147 (35.06, 66.94)
3029 69 56.59 7.515 (41.20, 71.00)
3043 17 7.18 5.524 (4.11, 11.90)
3046 25 49.13 7.857 (34.01,64.45)
3048 31 59.95 7.101 (45.74, 73.28)
3050 44 55.88 5.889 (44.31, 67.14)
3052 105 51.24 4.748 (41.96, 60.58)
3057 51 34.64 5.182 (25.03, 45.47)
3065 26 36.83 6.696 (24.84, 51.01)
3067 26 47.66 7.271 (33.46, 61.88)
4003 23 63.59 7.277 (48.81, 77.27)
4008 59 50.57 5.233 (40.68, 61.13)
4013 39 74.45 7.192 (59.29, 86.94)
4023 134 26.06 3.109 (20.31, 32.48)
4028 12 10.84 3.430 (5.67, 19.08)
4032 10 32.47 9.572 (17.49, 54.43)
4034 55 65.75 5.245 (55.27, 75.63)
4043 35 35.45 5.781 (24.65, 47.28)
4045 38 35.68 6.048 (24.67, 47.93)
4049 22 56.17 7.687 (41.31, 71.26)
4061 12 7.612 3.938 (2.92, 18.16)
4063 42 29.07 5.000 (20.16, 39.37)
4072 39 42.85 6.432 (30.70, 55.95)
4076 29 40.75 6.662 (28.42, 54.16)
5004 26 44.53 7.422 (31.47, 58.51)
5009 36 48.98 6.411 (36.78, 61.65)
5023 20 52.03 8.594 (35.32, 69.26)
5026 24 65.06 7.550 (49.87, 79.12)
5029 45 61.13 6.021 (48.68, 72.37)
5044 70 32.23 4.290 (24.20, 41.11)
5045 68 42.31 5.261 (32.49, 53.20)
5088 87 19.77 2.929 (14.39, 25.75)
6002 34 56.91 6.438 (44.39, 69.60)
6010 19 54.81 8.210 (38.94, 70.69)
6018 39 42.43 5.854 (31.55, 54.30)
6019 64 32.08 4.462 (23.86, 41.32)
6023 59 28.16 4.390 (21.64, 37.15)
6038 79 28.32 3.850 (21.25, 36.30)
6056 28 64.62 6.959 (50.25, 77.16)
6058 20 68.63 7.418 (53.20, 82.14)
6062 13 9.94 3.061 (5.29, 17.31)
6064 17 92.34 3.378 (84.20, 96.97)
6065 39 17.43 4.516 (10.44, 27.98)
Table 3.10: Posterior estimates of consistency (Mean, standard deviation, and 95%
Bayesian interval) for all subjects with grouped symptoms model.
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3.5 Model Assessment
In Section 3.4, we introduce the grouped symptoms models as one of our consistency
estimation models. In this section, we would like to test if this model is adequate. To
do this, we utilise the concept of stochastic latent residuals, zijk, described below.
First, we test the grouped symptoms model with threshold h(αij, βik) = αijβik. There-
fore, patient i reports symptom j at episode k when τijk ≤ αijβik. Thus, the observed
variable, Yijk is equal to 1 when symptom j is reported at episode k by patient i.
Otherwise, Yijk takes value zero.
We now consider the stochastic latent residuals, zijk, that would give rise to the ob-
served data under the considered model. Following the concept of generalised residuals
(Cox and Snell, 1968), the data can be regarded as generated through a functional
model, g(·), (Dawid and Stone, 1982) depending on the vector of all model parameters
and latent variables, say θ, i.e.
y = gθ(z) (3.5.1)
where z ∼ U(0, 1) are generalised residuals. Then, in the general case, the function
in (3.5.1) can be inverted to give the stochastic latent residuals
z = g−1θ (y).
For the assumed discrete model we have
yijk = I{zijk ≤ pijk}
where zijk ∼ U(0, 1) and I{·} is the indicator function. This implies that, under the
assumed model, we can write
zijk = yijku1 + (1− yijk)u2
where u1 ∼ U(0, pijk) and u2 ∼ U(pijk, 1). Therefore, if the model is adequate
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zijk ∼ U(0, 1) and we can obtain a p-value for testing the hypothesis of this uni-
form distribution. To implement this method, we run 10,000 MCMC iterations for
this model and obtain the latent residual, zijk, for each subject such that
If
 Yijk = 1, z
(1)
ijk ∼ U(0, p̂ijk)
Yijk = 0, z
(0)
ijk ∼ U(p̂ijk, 1)
where p̂ijk is the estimated probability of patient i reporting symptom j at episode k





ijk) ∼ U(0, 1).
We run a Kolmogorov-Smirnov goodness-of-fit test on each posterior sample of residu-
als obtained in each MCMC iteration, and calculate a corresponding p-value, πγ, where
γ = 1, 2, 3, ..., 10, 000 iterations. This will give a posterior distribution f(π|Yijk) where
Yijk denotes the observation data. As preliminary checking, we observe the histogram
of the residuals z for each patient i. We only show here the histogram for one patient,
Subject 4028 in Figure 3.20. The distribution pattern suggests that the residuals do
follow a Uniform(0,1) distribution. To further confirm the distribution of z we also
check on the histogram of p-values for this patient, π(4028). This is given in Figure
3.21. From this histogram, we can say there is no evidence against the adequacy of


















Figure 3.20: Histogram of stochastic latent residuals for model with grouped symp-
toms using threshold h(αij, βik) = αijβik for patient 4028.
Since threshold h(αij, βik) = αij + βik + αijβik is never favoured in Section 3.3.1, we













Figure 3.21: Posterior distribution of p-values, π, for fit of model with grouped symp-
toms using threshold h(αij, βik) = αijβik for patient 4028.
and h(αij, βik) = αij+βik are shown in Figure 3.22. We present here the histograms of
p-values, πγ, for four patients when using the two thresholds. Observing the posterior
distributions of πγ for subjects 5088, 4008, 2013, and 4023, once again we can see that
there is no strong evidence against the models tested, although it appears that there is
more evidence against the model when the model with threshold h(αij, βik) = αij+βik
is fitted. This can be seen from the higher concentration of p-values close to zero in
two of these four patients.
As implied earlier, to have strong evidence against a tested model, i.e. to reject the
hypothesis that the model is adequate, the posterior p-values, πγ, should be very
small. Therefore as a measure of model goodness of fit, we calculate the proportion
of πγ less than 0.05, Pr(πγ <0.05), for each subject in the models discussed here. For
comparison purposes, we can say that cases with greater Pr(πγ <0.05) show stronger
evidence against the model fit.
Bar plots in Figure 3.23 display the Pr(πγ <0.05) obtained from the grouped
symptoms model when using different thresholds. For 67% of the 66 subjects
the proportions of πγ <0.05 suggest that better fit of the model with threshold
h(αij, βik) = αijβik. For these patients, their Pr(πγ <0.05) when using threshold
h(αij, βik) = αij + βik (yellow bars) are higher than when using h(αij, βik) = αijβik
which is indicated by the red bars.



































































































































(h) Patient 4023, αij + βik
Figure 3.22: Posterior distribution of p-values, π, for fit of model with different thresh-
olds for patients 5088, 4008, 2013 and 4023 in grouped symptoms model.
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symptoms. For both models the h(αij, βik) = αijβik threshold is used, and the propor-
tion Pr(πγ <0.05) are calculated and plotted in Figure 3.24. Only seven patients show
higher Pr(πγ <0.05) when the grouped symptoms model is used (indicated by yellow
bars), compared to the model without grouped symptoms (indicated by red bars).
These subjects are 1055, 2010, 2015, 4013, 4049, 4063, and 4064. Pr(πγ <0.05) calcu-
lated from the grouped symptoms model and the without grouped symptoms model
for patient 2010 are 0.227 and 0.082 respectively. Patient 2015 has Pr(πγ <0.05) =
0.096 when using the grouped symptoms model and Pr(πγ <0.05) = 0.052 when using
the without grouped symptoms model. This suggests that the model with grouped








































































































































































































































































































































3.6 Model verification and posterior predictive
checking
To examine our model’s predictive capability, we run a validation approach relying on
the posterior predictive distribution. This approach is commonly used for checking
the model’s suitability, and is based on work that was elaborated by Rubin (1984) and
later expanded by Gelman et al. (1996). The purpose of the analysis is to compare
the observed data with values predicted from our model. Also, one of the important
aims of this work is to develop a model which can be used to make prediction of
values of interest with quantified confidence. Later in this thesis (Chapter 6), given
information on some specific characteristics about a patient, we will aim to predict
how consistent the patient is in reporting hypoglycaemia. This can be used in order
to assist early detection of hypoglycaemia and give necessary advice to the patient.
Our observations, Yijk are binary data that take value 1 if patient i reported symptom
j in episode k value zero otherwise. We define Y
(p)
ijk as the predicted data, such that
these are the data that will be obtained if we use the same model to do prediction.
We start off by selecting randomly 10% of the total number of observations we have,
which are then used as the validation sample. Then, we fit the examined model to the
remaining data. The fitted model is subsequently used to do prediction on symptom
reporting for the sampled patients episodes, Y
(p)
ijk for i,j,k in the sample. Recall from
(2.5.1), Yijk is Bernoulli distributed with probability, pijk. We sample the posterior
probability, pijk, from the fitted model and use it to obtain the reporting prediction,
Y
(p)
ijk . Consequently, we compare the total number of predicted reportings, Np to the
total number of observed reportings, Nobs. Accordingly, we compare the distributions
of Yijk and Y
(p)
ijk .
Streftaris et al. (2013) also use another four measures to assess and describe the
usefulness of their model predictions. The measures are related to sensitivity, speci-
ficity and predictive values. Here, sensitivity is defined as the proportion of experi-
enced symptoms that are correctly predicted as being reported by the models whereas
specificity is the proportion of symptoms that have not been experienced which are
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correctly predicted as not reported by the model. Ideally, a good predictive model
should have high sensitivity and specificity. However these two measures are often
inversely proportional, meaning as sensitivity increases specificity decreases and vice
versa. To evaluate the probability of the model giving correct prediction we also
calculate the positive predictive value (PPV) and negative predictive value (NPV).
These four measures were calculated using Yijk and Y
(p)
ijk in the validation sample and










for i, j, k in the sample.
Therefore PPV is the proportion of symptoms with positive prediction that were
correctly classified as reported. PPV measures the probability of patient i truly
experiencing symptom j at episode k given that the model predicts the symptom










for i, j, k in the sample.
NPV is the proportion of symptoms with negative reporting prediction that were
correctly classified as absent. NPV measures the chance of patient i having symp-









for i, j, k in the sample.
True Positive Rate (TPR), also known as the sensitivity of our predictive model,










for i, j, k in the sample.
True Negative Rate (TNR), or also called specificity, represents the capacity of the
model to predict that symptom j is not reported at episode k when the symptom
is truly absent.
3.6.1 Results
We applied the posterior predictive checking approach to study the predictive ability
of the core model (without grouped symptoms) and the grouped symptoms model,
using threshold h(αij, βik) = αijβik. Graphical plots in Figure 3.25 show the posterior
distributions of the total predicted number of reporting symptoms, with blue (dotted)
lines marking the total number of predicted reportings, Np, whereas the red (solid)
lines refer to the total observed value, Nobs for subjects 5004, 6038, 4045, and 5009.
The symptom reportings i.e. the total observed value, Nobs, for subject 5004 is 9 and
the prediction from the non-grouped symptoms model is Np = 12.19 with 95% CI (7,
19), while the prediction made by the grouped symptoms model is much closer, Np
= 10.14 with 95% CI (5,16). Prediction for patient 6038 is good when using both
grouped and non-grouped symptoms model as we can see the red lines (Nobs = 21) lie
within the predicted number of reporting symptoms’ distributions from both models.
The reporting symptoms for patient 4045 is very well predicted by the grouped symp-
toms model as indicated by the blue and red lines that almost overlap. The prediction
made was 15.26 with 95% CI (9,22) and the observed value is 15. However, the non-
grouped symptoms model also made a good prediction, although it is slightly over
estimated (Np = 17.63). The posterior predictive checking for subject 5009 also shows
that the grouped symptoms model yield a slightly better prediction in comparison to
the non-grouped symptoms model. The predicted value from the non-grouped model,
Np = 31.45 lies at the lower tail of the estimated distribution (95% CI (24,39)) while
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the grouped-symptoms model gives Np = 27.18 and the 95% CI (20, 35) comfortably
contains Nobs = 24.
We also test the performance of different thresholds with the core model. Figure 3.26
gives the posterior distributions of the total predicted number of symptom reportings
for subjects 5009, 3057, 2015 and 6038. With each threshold, the predicted distribu-
tions comfortably contain the total number of observation, Nobs (represented by red
solid lines). This indicates that for these patients, we cannot distinguish between the
three threshold models in terms of their predictive ability.
Finally, we want to compare the performance of prediction for different models when
all patients are used in the analysis. We omit threshold h(αij, βik) = αij +βik +αijβik
here since this threshold did not perform very well using other criteria in earlier
analysis (see Section 3.3.1). Therefore, we test the models with and without grouped
symptoms using thresholds h(αij, βik) = αijβik and h(αij, βik) = αij +βik. The results
are provided in Table 3.11 and the posterior distributions of the predicted number
of symptoms reported are displayed in Figure 3.27. The plots show that among the
four models, the model with grouped symptoms with threshold h(αij, βik) = αijβik
gives the closest predicted value, Np, to the observed number of symptoms reported.
The total number of symptoms predicted to be reported, is 754.3, with a 95% credible
interval of (713,797), which contains the observed number of reported symptoms, 771.
The other three models considered here do not perform well in terms of this predic-
tion, with the corresponding posterior predictive distributions failing to contain the
true value.
Regarding the other four predictive measures presented in Table 3.11, we notice that
the models explored here do not display substantial differences. It is also obvious
that prediction referring to symptoms not being experienced (NPV, TNR) is much
more successful, as compared to prediction for reported symptoms (PPV, TPR). The
fact that the developed models perform better in predicting that symptoms will not
be reported, may be explained by the nature of the data, where the frequency of
reporting symptoms is relatively low (771/7033). The proportion of symptoms with
70




















































































































































Figure 3.25: Posterior density plots of number of reportings, Np, for patients 5004,
6038, 4045, and 5009 under non-grouped symptoms model (left) and grouped symp-
toms model (right) using threshold h(αij, βik) = αijβik. Blue dotted lines show the
number of predicted symptom reportings of each model, and red lines represent the
true number of reported symptoms, Nobs.
71





















































(c) Np= 27.99, Nobs=24


































































































































































Figure 3.26: Posterior density plots of number of reportings, Np, for patients 5009,
3057, 2015, and 6038 under non-grouped symptoms model using thresholds αijβik
(left), αij + βik + αijβik (middle) and αij + βik (right). Blue dotted lines show the
number of predicted symptom reportings of each model, and red lines represent the
true number of reported symptoms, Nobs.
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positive prediction that were correctly classified as reported is highest when using the
core model with threshold h(αij, βik) = αijβik, i.e. PPV = 0.413, whereas the chance
of a symptom not present in an episode given that the model predict it will not be
reported is also highest with this model (NPV = 0.933).

















(a) Non-grouped symptoms model, αijβik

















(b) Non-grouped symptoms model, αij + βik

















(c) Grouped symptoms model, αijβik

















(d) Grouped symptoms model, αij + βik
Figure 3.27: Posterior density plots of number of reportings, Np, for all patients under
different models. Blue dotted lines show the number of predicted symptom reportings
of each model, and red lines represent the true number of reported symptoms, Nobs.
From the analysis in Sections 3.4 and 3.5, we can conclude that among the three
thresholds explored, h(αij, βik) = αijβik fits the data best. Also the model with
grouped symptoms performs better than the model with non-grouped symptoms in
predicting symptom reporting.
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αijβik αij + βik
mean 95%CI mean 95%CI
PPV 0.413 (0.390, 0.436) 0.330 (0.310, 0.348)
NPV 0.933 (0.930, 0.936) 0.931 (0.928, 0.935)
TPR 0.464 (0.435, 0.489) 0.469 (0.437, 0.498)
TNR 0.919 (0.913, 0.925) 0.883 (0.876, 0.890)
Np 866.626 (820, 908) 1095.216 (1044, 1142)
(a) Non-grouped symptoms model
αijβik αij + βik
mean 95%CI mean 95%CI
PPV 0.408 (0.383, 0.432) 0.380 (0.359, 0.402)
NPV 0.926 (0.923, 0.930) 0.931 (0.928, 0.935)
TPR 0.399 (0.368, 0.429) 0.457 (0.431, 0.492)
TNR 0.929 (0.923, 0.934) 0.908 (0.902, 0.914)
Np 754.300 (713, 797) 928.084 (876, 969)
(b) Grouped symptoms model
Table 3.11: Model predictions for validation sample for all subjects (The number of
reported symptoms, Nobs = 771).
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3.7 Concluding remarks
This chapter develops and assesses statistical models for the consistency of hypo-
glycaemic symptom reporting by individual patients. Initially, we fit models with
three different thresholds to the core model. Comparing the deviance information
criterion values of the three models, we conclude that the core model with threshold
h(αij, βik) = αijβik fits the data better. These findings are also confirmed by using
ML estimation.
Next, we introduce an additional source of variation in the consistency model by
grouping the symptoms into different groups according to their cause. Thus, varia-
tion now comes from within each group and between groups. Output from this model
shows that the mean propensity of symptoms in each group is different. Section
3.4 discusses the assessment of models with different thresholds using the concept
of stochastic latent residuals. It was found that the grouped symptoms model with
threshold h(αij, βik) = αijβik fits the data better. Finally, we perform model verifi-
cation and posterior predictive checking to verify which model is best in predicting
symptom reporting. The grouped symptoms model with threshold h(αij, βik) = αijβik




Within 24 Hours From Preceding
Episodes
In this chapter, we investigate the effect of adding data from episodes that occurred
within 24 hours from their preceding episode. We start by checking correlations be-
tween the two cases: excluding episodes within 24 hours and including those episodes.
We then compare the intensities of episodes between the two cases. We further our
analysis by measuring the relative mean difference in consistency for both situations
and also calculate the consistency’s coefficient of variation. The comparisons show
that adding these new episodes does not have a significant impact on the intensity of
episodes. Therefore, in the final section of this chapter we look at the similarity of
the posterior distributions of consistency when we include and exclude the episodes
within 24 hours.
4.1 Correlation and intensity of hypoglycaemic
episodes
In a previous study (Zammitt et al., 2011), any episode occurring within 24 hours
from a previous episode was excluded from further consideration because it was ar-
gued that it may reduce the intensity of subsequent hypoglycaemic episodes. Such
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episodes could potentially affect our model given that it is based on the patient’s
inherent propensity to report a given symptom and the intensity of that symptom in
a given episode.
In this chapter, we are interested to see what happens if these discarded episodes are
included in subsequent analyses, as in real life patients would want to know whether
their hypoglycaemic episodes occurring soon after a previous episode are more likely
to generate inconsistent symptoms. There are 775 episodes which occurred within
24 hours from their previous episode. Before we use them, we need to analyse these
episodes to explore if the claim that they have diminished intensity is true. If it is
shown that it is not true and symptoms are not blunted, then it is worth including
those episodes in our study.
First, we want to compare the correlation between the intensity of episodes occurring
within 24 hours, with the correlation of episodes after we take out episodes occurring
within 24 hours. Correlation A, rA, refers to the correlation between the intensity
of episodes not containing any episode that occurred within 24 hours of the previous
episode, while correlation B, rB, is the correlation for pairs of episodes reported within
24 hours from their previous episodes. With βik providing, as previously, the intensity










where i = 1,...,I refers to patients and k = 1,...,M to pairs of episodes. For correla-
tion A, rA, we calculate the correlation for pairs (βik, β
′
ik) such that β
′
ik is the episode
following βik given that β
′
ik is not reported within 24 hours of βik. To calculate corre-
lation B, rB, we pair the episodes (βik, β
′
ik) such that β
′
ik is an episode that occurred




denotes the mean of episodes’
intensity for patient i, over the relevant M pairs of episodes and similarly for β′ik. The
computation of r is based on posterior estimates of βik obtained from the MCMC es-
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timation, and therefore estimates of the entire posterior distribution of r are available.
This correlation measures how much two successive episodes are correlated and as
usual will give values between −1 and 1. Correlation equal to 1 implies the episodes
have perfect positive linear relationship while −1 indicates that the episodes have per-
fect negative linear relationship. Positive correlation between episodes means that if
the first episode has high intensity, the following episode will have high intensity too.
Having negative correlation means that if one episode has high intensity, the intensity
of the following episode will diminish. If there is a very weak or no correlation, r ≈ 0,
we say that the intensity of each episode does not affect the intensity of the following
episodes.
To compare the two sets of correlations, plots of their 95% credible intervals corre-
sponding to each patient were produced and split into two figures for presentation
purposes. Figure 4.1 summarises the correlations for 31 subjects and the remaining
subjects are presented in Figure 4.2. The presented intervals are equal tailed credible
intervals. Looking at these plots where credible intervals for correlation A, rA, and
correlation B, rB, are presented by black and red lines respectively, it is clear that
most correlations have intervals including 0 meaning that the correlation between
the episodes is generally weak. More importantly, there is no considerable differ-
ence between the posterior distributions of rA and rB, i.e. between the correlation
of episodes not occurring within 24 hours, and the correlation of episodes occurring
within 24 hours. We conclude that there is no significant difference between those
two cases in terms of the time gap between episodes. Only patient 2015 shows some
difference in correlation and this might be explained by the fact that this patient has
a small number of episodes occurring within 24 hours (seven episodes). We also note
here that cases where a red credible interval is not present in the graph, correspond
to patients not having episodes occurring within 24 hours.
Next, we want to see if there is any difference in the level of intensity between episodes
occurring within 24 hours and episodes not within 24 hours. Again, βik corresponds
to the intensity for episode k for each patient i. From our MCMC run, we obtain the
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posterior estimates of βik for all patients in each iteration. Let Case A be the case
where no episode is reported within 24 hours from previous episode and Case B is
when the episodes occurred within 24 hours from previous episodes. We are interested
in comparing the average posterior intensity between these two cases, i.e. the average
over all episodes under consideration for each patient.
Figures 4.3-4.4 show caterpillar plots of the 95% credible intervals of the average pos-
terior intensity for episodes in Case A (black bars) and episodes in Case B (red bars).
Again, we have to split the intervals into two figures to accommodate all 66 patients.
It is apparent from both plots that the intervals of the two cases overlap thus leading
us to conclude that there is no considerable difference in intensity either if episodes



































−1.0 −0.5 0.0 0.5 1.0
correlation
Figure 4.1: Caterpillar plot showing the 95% credible intervals of correlation between
the intensity of episodes not within 24 hours (black bars) and between the intensity
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Figure 4.2: Caterpillar plot showing the 95% credible intervals of correlation between
the intensity of episodes not within 24 hours (black bars) and between the intensity
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Figure 4.3: Caterpillar plot showing the 95% credible intervals of average posterior
intensity for episodes not within 24 hours (black) and episodes within 24 hours (red)
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Figure 4.4: Caterpillar plot showing the 95% credible intervals of average posterior
intensity for episodes not within 24 hours (black) and episodes within 24 hours (red)
for 33 patients, arranged in ascending order based on their posterior mean episode
intensity.
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4.2 Testing the association between possible episodes
In this section, we want to investigate whether episodes’ intensity exhibits change that
goes beyond random variation when episodes are in temporal proximity. If there is
association between cases where there are no episodes occurring within 24 hours and
cases when there are episodes occurring within 24 hours, it is possible that episodes
occurring soon after a previous episodes to generate inconsistent symptoms. As pre-
viously, βik is the latent variable that corresponds to the intensity of episode k for
patient i. The idea is that if we arrange the posterior estimates of all βik according to
the date and time of the occurrence of the corresponding episode, we should be able
to calculate a total ‘intensity distance’; from episode 1 to episode K. If we then ran-
domly permute the arrangement of the episodes and calculate the distance again, if
there exists association between the intensity of episodes within 24 hours and episodes
not within 24 hours, the total intensity distance will become longer. This is because
with association, episodes that occurred within 24 hours from a preceding episode
may be considered to have big impact on the intensity; either reducing or increasing
it.
To implement this idea, we make use of permutation testing. Permutation techniques
were introduced by Edgington, (1987) and Blair and Karniski, (1994). Earlier practice
of permutation test was given by Fisher in 1971. The study was about the difference
between two means of height of different plants (Fisher, 1971).
We are testing the null hypothesis that there is no temporal association in the magni-
tude of βik for k = 1, ..., Ki (i.e. the change in βik over successive episodes is random),
while the alternative is that there is such temporal association (i.e. that change in
βik is greater than random change). We run the consistency model with grouped
symptoms for 2000 MCMC iterations with the first 1000 iterations discarded as the
burn-in. Note that the MCMC convergence is already achieved after the burn-in pe-
riod. We denote the intensity distance calculated from the posterior βik estimates as
the observed distance, D(obs), whereas the distance calculated using the permuted βik
is referred to as the replicated distance, D(rep).
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Figure 4.5 illustrates how we calculate the intensity distance. This plot shows the
ordered episodes with their corresponding posterior intensity estimate, β̃ik for patient
4063. The episodes are plotted based on the time gap between them (in days). Black
dots and lines refer to β4063,k before any permutation (Figure 4.5(a)), while the green
colour refers to β4063,k after permutation (Figure 4.5(b)). Episodes occurring within
24 hours from a previous episode are plotted red. Consider the intensity distance,
dik, between two successive episodes, k − 1 and k, for patient i, with corresponding
intensities βi,k−1 and βi,k. If we also assume that the two episodes occur at times ti,k−1
and ti,k respectively, then the intensity distance between them is
dik =
√
(ti,k − ti,k−1)2 + (β̃i,k − β̃i,k−1)2. (4.2.1)




dik , where dik is (4.2.1).
The algorithm is summarised as follows.
For patient i, at each γ = 1,...,1000 iteration,
i. Compute the observed distance, D
(obs)
i,γ .




Step ii is repeated for n = 100 iterations, thus using the permutation of βik will
generate a distribution of the test statistic under the null hypothesis (Edgington,
1987 and Manly, 1997). From each sampling distribution, we obtain a p-value, πγ.














Therefore, after 1000 iterations we can produce a histogram of p-values, πγ, for every
patient and observe any evidence against the tested hypothesis. We present his-
tograms for six subjects selected at random (Figure 4.6). Observing the distribution
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Figure 4.5: This graph plots the posterior estimates of intensity versus the time gap
between episodes (in days) for patient 4063. Red points refer to the episodes occurring
within 24 hours from previous episode. Black plots and lines refer to β4063,k before
any permutation and the green colour refers to β4063,k after permutation.
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of πγ, patient intensities do not show any evidence against the tested hypothesis. The
null hypothesis will be rejected if we have very small πγ, for example smaller than 0.05.
Therefore, we are interested to see the proportion of πγ less than 0.05, Pr(πγ <0.05).
Figure 4.7 plots the Pr(πγ <0.05) versus the mean time between episodes for each
patient. Patients with many episodes occurring within 24 hours are likely to have
smaller mean time between their episodes. However, there is no specific pattern ob-
served from this plot. There are four subjects with high Pr(πγ <0.05); 1057, 1008,
4045, and 5045. Histograms of p-values for these four patients are shown in Figure 4.8.
Evidence against the null hypothesis here is stronger than in Figure 4.6, as the plots
exhibit higher proportion of Pr(πγ <0.05). Especially, patient 1057 has the highest
Pr(πγ <0.05) = 0.796. However, this subject has no episodes within 24 hours and
average mean time between episodes = 25.17. For patient 5045 the ratio of episodes
within 24 hours over all episodes is 0.13 and the average mean time between episodes
is 4.03 days. Pr(πγ <0.05) for this patient is 0.243. Subject 4045 has 1 episode occur-
ring within 24 hours from a total of 36 episodes. The mean time between episodes is
17.53 days with Pr(πγ <0.05) = 0.3180. Subject 1008 has mean time between episodes
of 3.23 days and Pr(πγ <0.05) = 0.408. Patient 1057 has the highest Pr(πγ <0.05):
0.7960. This subject has no episodes within 24 hours and average mean time between
episodes = 25.17.
As a conclusion, we can argue that the intensity of episodes that occur within 24
hours is not systematically different from the intensity of other episodes, and does
not exhibit higher correlation either. Therefore, it is reasonable to include those dis-






























































































Figure 4.6: Histograms of p-values, πγ, when testing the association between the
intensity of episodes for Subjects 2012, 2013, 2021, 3057, 5009, and 3043.
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Figure 4.8: Histograms of p-values, πγ, when testing the association between the
intensity of episodes for Subjects 1057, 1008, 4043 and 5045.
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4.3 Considering episodes within 24 hours in the
analysis
In previous sections, we investigated episodes reported within 24 hours from a previ-
ous episode and concluded that these episodes do not result in diminished intensity
of hypoglycaemia. Thus, there is no reason to exclude those episodes from further
analysis. Hence, episodes with missing date of occurrence can also be included in our
work as there is no need to determine the time gap between consecutive episodes.
This section will discuss how these episodes affect consistency when they are included
in our work.
Eleven subjects do not have any episode occurring within 24 hours or episode with
missing date. Therefore, this section will focus on the remaining 55 subjects. Table
4.1 summarises the number of episodes for each patient together with their number of
episodes that occurred within 24 hours and episodes with missing date. Three differ-
ent measures or estimates are used to show the effect of adding those episodes: relative
difference in consistency; the coefficient of variation of consistency; and consistency
estimates. All results and discussions are based on the model with grouped symptoms.
Relative difference in consistency
We use the relative difference in consistency estimates after episodes within 24 hours
and episodes with missing date are included in our work to assess possible changes.








all denotes the posterior estimate of consistency for patient i when all episodes
are included in the analysis, and c̃i is the corresponding estimate when episodes oc-
curring within 24 hours or episodes with missing date are excluded. Figure 4.9 plots
the relative difference of estimated consistency when those episodes are included in
the analysis versus the corresponding percentage of those episodes for each subject.
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Generally, the majority of the patients have relative mean difference in consistency
about zero, indicating little change in their consistency estimates. Only six subjects
have quite a distinct reduction in the consistency estimate. These are subjects 2013
(55% within 24 hours episodes), 2015 (32%), 5004 (14%), 5044 (21%), 6023 (22%) and
6038 (37%). Negative values in relative difference of consistency suggest that these
patients’ consistency was lower after adding the within 24 hours episodes. While other
patients also have high percentage of those episodes, only these six patients experience
big decrement in consistency.
Patient 2015 has relative difference in consistency of −1.1853. Since relative differ-
ence is usually expressed in percentage, we say that for this patient the consistency
estimated from using all episodes is 118% lower than the consistency estimated when
we exclude the within 24 hours episodes and episodes with missing date. Subject 2013
has relative difference in consistency of 107% while the relative difference for subjects
5004, 5044, 6023, and 6038 are 145%, 92%, 171%, and 127% respectively.
































Figure 4.9: Relative difference in consistency estimates versus the percentage of
episodes occurring within 24 hours and episodes with missing date.
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Coefficient of variation
We also consider the consistency’s coefficient of variation (CV) for each patient in both
situations; with and without the episodes occurring within 24 hours from previous





where c̃i is the posterior consistency estimate of patient i. Our interest is to see in
which case the consistency is more dispersed. This is measured by calculating the
difference between the CV in two cases;
CV alli − CVi,
where CV alli is the CV for patient i when all episodes are included and CVi is when
episodes within 24 hours or episodes with missing date are excluded. The difference
of these CVs for every patient is plotted against their percentage of episodes within 24
hours and episodes with missing date in Figure 4.10. Negative CV difference implies
that the calculated CV when including all episodes is smaller than CV without those
episodes. The majority of subjects we observed had negative CV difference implying
that the calculated CV when including those episodes is smaller than the CV without
those episodes (with the difference being rather small, i.e. ≤ 0.02). This could also
be interpreted as more reliable estimates (smaller CV) when the additional episodes
are included in the analysis.
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Figure 4.10: Difference in consistency’s coefficient of variation versus the percentage
of episodes occurring within 24 hours.
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Subject Total number Number of episodes Number of episodes % within 24 hours and
of all episodes within 24 hours with missing date missing date episodes
1008 123 25 8 26.83
1009 96 19 3 22.92
1015 35 8 0 22.86
1021 49 1 5 12.24
1025 26 0 5 19.23
1028 45 2 4 13.33
1036 42 5 13 42.86
1039 47 3 1 8.51
1055 27 2 0 7.41
1057 11 0 0 0
1086 91 24 3 29.67
2009 101 10 8 17.82
2010 102 13 1 13.73
2012 42 5 0 11.9
2013 296 140 22 54.73
2015 44 7 7 31.82
2021 33 6 5 33.33
2022 41 5 2 17.07
2027 26 3 1 15.38
3001 35 4 0 11.43
3015 19 0 0 0
3016 23 3 0 13.04
3022 23 2 1 13.04
3024 30 1 2 10
3029 78 7 2 11.54
3043 17 0 0 0
3046 25 2 0 8
3048 37 0 6 16.22
3050 54 8 3 20.37
3052 146 29 11 27.4
3057 91 21 19 43.96
3065 27 1 0 3.7
3067 32 6 0 18.75
4003 26 0 0 0
4008 67 5 8 19.4
4013 55 11 9 36.36
4023 210 64 12 36.19
4028 12 0 0 0
4032 10 0 0 0
4034 61 6 0 9.84
4043 36 1 0 2.78
4045 46 6 3 19.57
4049 23 1 0 4.35
4061 12 0 0 0
4063 48 2 4 12.5
4072 40 1 0 2.5
4076 32 3 0 9.38
5004 28 1 3 14.29
5009 40 1 3 10
5023 22 2 0 9.09
5026 26 0 0 0
5029 47 2 0 4.26
5044 87 14 4 20.69
5045 78 10 0 12.82
5088 100 11 2 13
6002 34 1 0 2.94
6010 19 0 0 0
6018 62 21 5 41.94
6019 93 27 2 31.18
6023 76 17 0 22.37
6038 122 40 4 36.89
6056 36 6 2 22.22
6058 20 0 0 0
6062 13 1 0 7.69
6064 17 0 0 0
6065 44 3 2 11.36
Table 4.1: Number of hypoglycaemic episodes for individual patients.
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Consistency estimates
To compare the distributions of c̃i between the two cases, we plot histograms of these
cases on the same plot in Figure 4.11. The overlapping histograms tell us that the
distribution of c̃i does not significantly change after we include the 24 hour episodes
and/or episodes with missing date. The mean of c̃i when we exclude the episodes
within 24 hours or episodes with missing date (yellow plot) is 43.39 with standard
deviation of 18.41 whereas the mean of c̃i when using all episodes (blue plot) is 45.26
with standard deviation of 18.74.
In addition, when comparing the boxplots of the two cases, we observe that the two
plots are very similar in shape and scale (Figure 4.12). The red boxplot represents the
estimated consistency when using all episodes and the quartiles of c̃i are q0 = 7.82,
q0.25 = 30.55, q0.5 = 43.82, q0.75 = 57.03 and q1 = 95.62. When excluding the episodes
occurring within 24 hours or episodes with missing date, the quartiles of c̃i obtained
are q0 = 7.20, q0.25 = 30.76, q0.5 = 43.30, q0.75 = 55.90 and q1 = 95.54 (yellow plot).
Table 4.2 provides the summary of posterior estimates of c̃i for each subject when
including all episodes. The summary of the corresponding estimates when we exclude
episodes within 24 hours and no date is already given in Table 3.7.
We then produce violin plots to compare the estimated posterior distributions of con-
sistency for each patient in both cases (with and without episodes occurring within 24
hours and episodes with missing date) in Figures 4.13-4.14. These plots are divided
into two plots such that Figures 4.13 contains the first 27 subjects listed in ascending
order of their unique code number, while the plots for the remaining subjects are given
in Figure 4.14. Red plots refer to the estimates obtained when we include the within
24 hours episodes and episodes with missing date in the model whereas yellow plots
refer to the estimates when those episodes were excluded. Examining these plots, we
observe that overall there is no significant difference in the distribution of consistency
between the two cases. The majority of the patients have very similar densities in
the two cases. However, there are six subjects with some difference in their poste-
rior distribution of consistency. These are the same patients as identified previously


























Figure 4.11: Histograms of posterior consistency. The grouped symptoms model is
used with all episodes (blue) and without the 24h episodes or episodes with missing











Figure 4.12: Boxplots of posterior consistency. The grouped symptoms model is used
with all episodes (red) and without the 24h episodes or episodes with missing data
(yellow).
5044, 6023, and 6038. The differences in their posterior estimate of c̃i are listed in
Table 4.3.
As given before, subject 2013 has 54.33% new episodes of the total number of episodes.
When using all available episodes, the posterior consistency density shifts to the left
and has narrower distribution, as compared to when excluding those new episodes
(Figures 4.13). As for subject 2015, from all 44 episodes 31.82% of them are newly
added. Again, the scales of the density when using all episodes is much narrower and
also moved to the left (Figure 4.13).
With subjects 5004, 5044, and 6023 we observe the same trend, where their consis-
tency densities are much narrower and shifted to the left when the new episodes are
considered (Figure 4.14). Another subject with similar result is subject 6038. This
patient has total number of episodes of 122 and 31.97% of them are new episodes.
Although the distributions in the two cases are different for these six subjects, the
densities overlap indicating that there is no significant difference in consistency be-
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tween these two cases.
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Subject c̃i SD 25% CI 95% CI
1008 26.19 3.244 19.99 32.77
1009 50.28 4.817 41.06 60.17
1015 32.99 5.682 22.60 45.00
1021 43.08 5.901 32.41 54.87
1025 43.52 7.703 29.64 59.66
1028 95.62 2.194 89.93 98.39
1036 51.32 6.408 38.95 63.87
1039 32.66 5.525 22.98 44.25
1055 56.91 7.811 41.55 72.44
1057 83.72 6.158 69.47 93.00
1086 27.97 3.745 21.18 36.01
2009 23.95 3.250 18.00 30.74
2010 25.76 3.511 19.36 33.17
2012 27.46 4.797 19.03 37.80
2013 7.78 0.890 6.13 9.63
2015 15.81 2.460 11.48 21.25
2021 42.80 6.651 30.47 56.24
2022 37.92 5.538 27.70 49.44
2027 49.22 7.855 34.56 64.89
3001 47.41 6.924 34.45 61.76
3015 15.93 3.052 10.77 22.59
3016 62.43 7.598 46.92 76.85
3022 50.60 7.959 35.66 66.65
3024 58.22 7.006 44.86 72.04
3029 74.79 4.692 64.67 83.29
3043 42.45 8.583 26.05 59.52
3046 50.77 7.640 36.48 66.04
3048 60.00 6.715 46.80 73.27
3050 53.30 5.540 42.78 64.40
3052 41.41 3.939 33.99 49.25
3057 29.55 3.920 22.39 37.61
3065 38.65 6.884 26.14 53.03
3067 45.88 6.498 33.51 58.89
4003 62.67 6.929 49.05 75.70
4008 49.20 4.849 39.76 58.67
4013 30.54 4.523 22.27 39.92
4023 20.74 2.247 16.56 25.41
4028 53.86 9.885 34.67 72.66
4032 75.70 9.474 54.65 90.85
4034 64.89 5.198 54.54 74.48
4043 30.11 5.048 20.91 40.83
4045 33.79 5.473 23.67 45.14
4049 57.55 7.579 42.61 72.02
4061 78.34 6.810 63.50 89.60
4063 27.55 4.516 19.54 37.09
4072 44.01 6.536 31.80 57.17
4076 39.94 6.563 28.12 53.64
5004 18.16 3.630 12.08 26.24
5009 48.81 6.168 37.25 61.08
5023 51.23 8.528 35.42 68.55
5026 64.78 7.179 50.26 78.40
5029 60.83 6.112 48.58 72.60
5044 16.80 2.170 12.94 21.65
5045 42.21 4.978 32.79 52.30
5088 18.74 2.769 13.72 24.74
6002 57.07 6.291 44.75 69.45
6010 55.33 8.347 38.87 71.27
6018 37.48 4.631 28.86 47.13
6019 30.10 3.952 22.74 38.33
6023 10.41 1.640 7.51 13.95
6038 12.47 1.740 9.33 16.06
6056 58.28 6.469 45.20 70.52
6058 69.58 7.362 54.09 82.86
6062 49.37 9.668 30.74 68.66
6064 88.90 4.156 79.24 95.22
6065 23.76 5.520 14.68 36.29
Table 4.2: Posterior estimates of consistency (Mean, standard deviation, and 95%
credible interval) for all subjects using grouped symptoms model when including all
episodes.
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without 24h & no date episodes all episodes
Subject mean SD 95% CI mean SD 95% CI
2013 16.15 2.06 (12.43, 20.59) 7.78 0.89 (6.13, 9.63)
2015 34.55 5.83 (24.24, 46.73) 15.81 2.46 (11.48, 21.25)
5004 44.53 7.42 (31.47, 58.51) 18.16 3.63 (12.08, 26.24)
5044 32.23 4.29 (24.20, 41.11) 16.80 2.17 (12.94, 21.65)
6023 28.16 4.39 (20.46, 37.56) 10.41 1.64 (7.51, 13.95)
6038 28.32 3.85 (21.64, 37.15) 12.47 1.74 (9.33, 16.06)
Table 4.3: Posterior estimates of c̃i when using the grouped symptoms model with
all episodes and without episodes occurring within 24 hours of preceding episode and
































































































































































































































































































Previous work had excluded episodes in temporal proximity from further analysis
because there is a possibility that these episodes may significantly affect the intensity
of other episodes. This chapter explores different ways to assess the effect of including
these episodes in our study. First by assessing the correlation of the intensity of
episodes and difference in posterior intensity of the episodes between the two cases;
including and excluding episodes within 24 hours does not support the claim that there
are any significant changes in intensity. Furthermore, the permutation test conducted
also concludes that the change in the posterior estimates of βik over successive episodes
is random, i.e. there is no significant difference in intensity between the two cases.
By using all episodes in the analysis, we also discussed the relative difference in
consistency, the coefficient of variation and the consistency estimates between the two
cases; with and without the within 24 hours episodes. Therefore, our analysis suggests
that episodes occurring within 24 hours from their previous episode are generally not
significantly affected by the intensity of preceding hypoglycaemic episodes, and in






In this chapter, we no longer exclude episodes within 24 hours from our analysis.
Based on the conclusion we made in previous chapters, episodes that occur soon after
other episodes do not affect considerably the intensity of the episodes of hypogly-
caemia. Thus, the analysis in this chapter uses the complete data set of reporting
regardless of the occurring time. This chapter discusses the investigation of what
factors affect the consistency of symptom reporting of individual patients. There are
ten factors in consideration and we also test the effect of interactions between them.
The association between the factors and consistency is modelled with a Bayesian
Generalised Linear Model (GLM), using the individuals’ posterior precision estimates
obtained from the model with grouped symptoms discussed in Section 4.3 as the re-
sponse variable. Also, in this chapter, we expand the consistency estimation model of
Section 3.4 to allow hierarchical modelling where we are able to do both estimations in
one model: estimate consistency and identify significant factors affecting consistency.
5.1 Modelling using estimates from grouped symp-
toms model
To help diabetic patients recognise their hypoglycaemic episodes efficiently, it is vital
to educate them about factors that may cause variation in their symptoms. Zammit
et al. (2011) previously investigated the effect of ten patient-specific covariates on
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consistency using GLM methodology. Here we expand this analysis by first including
episodes occurring within 24 hours from a previous episode and episodes with miss-
ing date. The covariates we use are gender, age, diabetes type (1 or 2), duration
of diabetes, retinopathy, hypoglycaemia awareness score (1 to 7, with higher scores
corresponding to weaker awareness of hypoglycaemia), body mass index (BMI), stim-
ulated C-peptide, haemoglobin A1c (Hba), and serum angiotensin converting enzyme
activity (ACE). A brief explanation on each covariate is already provided in Chapter
1 and details of the values of these covariates are summarised in Table 5.1.
Covariates Number of Levels Measurement units/
Additional Information
x1 Age Numerical Years
x2 Duration of diabetes Numerical Months
x3 BMI Numerical kg/m
2
x4 C-peptide Numerical nmol/L
x5 Hba Numerical Percent
x6 ACE Numerical IU/L
x7 Awareness of hypoglycaemia 7 1=aware , 7=not aware
x8 Gender 2 (M & F) M is the base category
x9 Type of diabetes 2 (T1 & T2) T1 is the base category
x10 Retinopathy 3 1. No retinopathy
2. Background retinopathy
3. Proliferative retinopathy
Table 5.1: Definitions of the covariates
All covariates have numerical values except for gender, awareness of hypoglycaemia,
type of diabetes and retinopathy which are considered as categorical factors in the
model. For the categorical factors gender and type of diabetes, each factor has one
coefficient in the model with male and Type 1 as the baseline (i.e. gender was coded
as male = 0 and female = 1, while Type 1 diabetes = 0 and Type 2 diabetes=
1). As for retinopathy, it has three coefficients and we use a sum-to-zero constraint
(i.e. b10,1RET1 + b10,2RET2 + b10,3RET3 = 0) for comparing effects to a mean level.
RET1 was also coded as binary, 0 when subjects have no retinopathy and 1 otherwise.
RET2 was coded as 0 when subjects have background retinopathy and 1 otherwise.
For RET3, proliferative retinopathy = 1 and otherwise = 0.
Without standardising, Figure 5.1 shows the box plots of the six covariates with nu-
merical values; age, BMI, duration, C-peptide, Hba, and ACE. The mean of age and
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BMI are 54.45 and 26.42 respectively. Data for duration are in months and have mean
of 205.64 with the minimum duration is six months. The mean for C-peptide is 0.50


















































Figure 5.1: Box plots of six covariates with numerical values.
We utilise the posterior precision estimates, σ̃−2i obtained from the grouped symptoms
model in Section 4.3. Based on our discussion in Chapter 4, we include data from all
episodes reported regardless of the time they occur. To link estimates of the posterior
estimate of the consistency parameter σ−2i with the covariates, a generalised linear
model with gamma errors is used, with linear predictor:
log{E(σ−2i )} = b0 +
7∑
l=1
blzil + b8GENi + b9TY PEi
+ b10,1RET1 + b10,2RET2 + b10,3RET3 (5.1.1)
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for i = 1, ..., 66, GEN represents gender, TYPE represents type of diabetes, and
RET represents covariate retinopathy. zil are the standardised observations of co-
variates x1, ..., x7 in Table 5.1 with xil being the original observation. Therefore,
zil = (xil − x̄l)/sd(xl). b0 is the standardised intercept term and coefficients b1, ..., b7
are the standardised coefficients for x1, ..., x7, whereas b8 and b9 correspond to co-
variate gender and type of diabetes respectively, and b10 represents different levels of
retinopathy factors.
To simplify notation, we use wi = σ
−2
i . The generalised linear model response variable





) for i=1, 2, ..., I, (5.1.2)




Parameter mi is the mean consistency response and linked to all patient-specific co-
variates through function
mi = exp(Z
∗b) where i = 1, 2, ..., I. (5.1.3)
b = (b0, b1, ..., b10,1, b10,2, b10,3)
T is a vector of coefficients corresponding to the vector
of covariates Z∗ = (1, z1, z2, z3, z4, z5, z6, z7, GEN, TY PE,RET1, RET2, RET3), as
shown in detail in Table 5.1.
All bl, l = 1, 2, ..., 12 are assumed to have Normal prior distributions and the prior for
λ is inverse-gamma:
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λ ∼ Inverse− gamma(γλ, δλ) where γλ = δλ = 10−3. (5.1.5)



























and the joint posterior density is
π(λ, b|yijk) ∝ f(w̃i|λ, b)p(λ)p(b), (5.1.7)
where p(b) and p(λ) are given in 5.1.4 and 5.1.5 respectively.
We note that there are other options when choosing the distribution for the type of
model fitted here. For example, a model with log-normal errors is commonly used.
However, fitting a log-normal model does not provide a better fit when compared to
the gamma error model (Zammitt et al., 2011).
There are missing values in the data where eight subjects have unspecified records for
covariates retinopathy, C-peptide and A1c haemoglobin. This is a common problem
in research and can be overcome using the Bayesian paradigm. MCMC techniques are
used to impute values for the missing covariates where the covariates are treated as
random variables, allowing their posterior distributions of the incomplete data given
the observed data to be estimated by the model (Ibrahim et al., 2002). Covariates
C-peptide and A1c haemoglobin are continuous measurements and can be denoted by
x4,mis and x5,mis respectively where xmis refers to the missing value. When treated
as random variable, a probability distribution must be specified to these covariates
which will give rise to the values of covariates. We assumed these covariates to be
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normally distributed
z4 ∼ Normal(µ4, τ 24 ),
z5 ∼ Normal(µ5, τ 25 ),
and the prior distributions assigned are
µ4, µ5 ∼ Normal(0, 103),
τ4, τ5 ∼ Inverse− gamma(1, 1).
The effect of each covariate is assessed using 95% equal-tailed Bayesian Intervals of
their corresponding b coefficients.
From (5.1.7), we get the estimates of the mean and standard deviation of each b co-
efficient corresponding to covariates. Table 5.2 lists these posterior estimates which
were obtained from 20,000 iterations after 5000 burn-in period. As can be noticed in
Figure 5.2, all chains converge very well for all bl parameters in the sampled itera-
tions. A caterpillar plot representing the posterior estimates with their 95% credible
intervals is given in Figure 5.3. Covariates gender and no retinopathy have significant
effects on consistency. This agrees with the findings in Zammit et al. (2011) where
it was found that gender and awareness are two factors affecting consistency. How-
ever, after removing patients with highest score of awareness from their analysis, only
gender was significant. The mean of the gender coefficient, b8, is −0.5417 implying
that female subjects are less consistent than male subjects in reporting their symp-
toms of hypoglycaemia. Although covariate awareness of hypoglycaemia now appears
to be not significant, this covariate is marginal with b7 = 0.0988 and 95% credible
interval (−0.0293, 0.2278). The posterior mean of coefficient b10,1, corresponding to
‘no retinopathy’ is 0.4728 with 95% credible interval (0.0194, 0.9077) meaning that
patients with no retinopathy are more consistent in reporting their hypoglycaemic
symptoms in contrast to those who have retinopathy.
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Parameter Mean SD 2.5% CI 97.5% CI
b1 −0.0062 0.1219 −0.2449 0.2320
b2 0.0994 0.1720 −0.2470 0.4349
b3 0.1207 0.1066 −0.0810 0.3423
b4 −0.1567 0.1199 −0.3963 0.0836
b5 −0.1512 0.1089 −0.3383 0.0919
b6 −0.1483 0.1126 −0.3608 0.0775
b7 0.0988 0.0640 −0.0293 0.2278
b8 −0.5417 0.2265 −0.9872 −0.0886
b9 0.5190 0.3203 −0.1099 1.1460
b10,1 0.4728 0.2226 0.0194 0.9077
b10,2 −0.2743 0.1553 −0.5808 0.0341
b10,3 −0.1985 0.2502 −0.6741 0.3073
Table 5.2: Posterior estimates of b coefficients corresponding to patient-specific co-
variates for model with grouped symptoms.
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Figure 5.3: Posterior means (bullets) and 95% equal-tailed Bayesian intervals (bars)
for standardised coefficients of patient-specific covariates for model with grouped
symptoms.
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5.1.1 Effect of interactions between covariates
We are also interested to investigate how the interactions between the patient covari-
ates affect the consistency. We would like to see whether the effect on consistency
of one factor is not the same at all levels of another factor. For example, unequal
levels of consistency between Type I and Type 2 patients might be much different
for males than for females. We will consider a number of interaction terms. Gender
is a significant factor affecting consistency, and therefore we want to explore possible
interactions with other covariates.
Based on unpublished expert information, there are indications that duration of di-
abetes is a factor that can potentially interact most with the other factors. Patients
with longer duration of diabetes will tend to have a higher prevalence of retinopathy.
Duration is also associated with diminishing awareness of hypoglycaemia symptoms.
Other than that, duration may also be associated with lower levels of C-peptide. C-
peptide is a C shaped protein that is cleaved off the proinsulin molecule to make active
insulin. It is a marker of endogenous insulin production and exists with insulin in a
1:1 molar ratio, that is one C-peptide molecule produced for every insulin molecule
produced. There is no C-peptide in insulin injections. Therefore, it is a good way of
telling how much insulin a person is making for themselves, even when they are on
insulin injections as a top up.
C-peptide can also possibly interact with type of diabetes. Patients with Type 1
diabetes lose insulin production completely within a few years of diagnosis whereas
those with Type 2 diabetes lose it much more gradually over the years.
Awareness of diabetes has the potential to interact with age as it is known that older
patients experience less intense symptoms of hypoglycaemia than younger patients.
Another possible interaction is between awareness and type of diabetes. Impaired
awareness of diabetes tends to be more common in Type 1 diabetes of long duration
than in diabetes of short duration. It can also develop in long-standing Type 2 di-
abetes but less frequently than in Type 1. Thus, awareness may also interact with
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duration of diabetes.
We therefore have a new linear predictor, replacing (5.1.1), given as
log{w̃i} = log{mi} = b0 +
7∑
l=1
blzil + b8GENi + b9TY PEi + b10,1RET1
+ b10,2RET2 + b10,3RET3 + bgen×type × (GEN.TY PE)i
+ bgen×dur × (GEN.DUR)i + bgen×awar × (GEN.AWAR)i
+ bgen×bmi × (GEN.BMI)i + bcpep×dur × (CPEP.DUR)i
+ bcpep×type × (CPEP.TY PE)i + bawar×age × (AWAR.AGE)i
+ bawar×dur × (AWAR.DUR)i + bawar×type × (AWAR.TY PE)i
+ bdur×ret1 × (DUR.RET1)i + bdur×ret2 × (DUR.RET2)i
+ bdur×ret3 × (DUR.RET3)i + bgen×ret1 × (GEN.RET1)i
+ bgen×ret2 × (GEN.RET2)i + bgen×ret3 × (GEN.RET3)i
i = 1, 2, ..., 66 (5.1.8)
As previously, we assign a normal prior distribution to bl coefficients where l = 1, ..., 27
such that:
bl ∼ Normal(0, 103).
We sample the posterior coefficient estimates after 15,000 MCMC iterations where the
first 5000 are the discarded burn-in iterations. The trace plots we monitored show
that convergence had been achieved after the burn-in period (refer Figures 5.4-5.5).
A full list of summary statistics of the covariates and their interactions is provided in
Table 5.3. Figure 5.6(a) plots the 95% credible intervals of the posterior estimates cor-
responding to the main covariates and Figure 5.6(b) gives a similar plot representing
the interactions between covariates. The mean for gender coefficient was positive, b8 =
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1.6250 (95% CI 0.6432, 2.7430). If we take into account the overall effect of gender,
the estimated consistency of female patients (mean = 48.51, 95% CI (23.27,78.70)) is
lower than that of male patients (mean = 72.39, 95% CI (50.84, 88.83)). The ratio
of male to female consistency is 1.63 (95% CI (0.9066, 2.9500)). It is interesting to
see that gender, which is highly significant in the previous analysis now shows not to
be significant. We suspect this is the effect of including gender in other interaction
terms thus pulling or stretching the effect that gender has.



















































































































Figure 5.4: Trace plots of b coefficients corresponding to the main covariates when
interaction between covariates are included.
The significant estimates for coefficient b10,1 show that lack of retinopathy also affects
the consistency measure. The estimate of b10,1 is 0.7806 (95% CI (0.1069, 1.4590))
which tells us that patients with no retinopathy recorded lower variability in their
symptoms than those with mean level of retinopathy.
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Figure 5.5: Trace plots of b coefficients corresponding to the interaction terms between
covariates.
This analysis suggests a number of significant interactions involving covariate gen-
der. These include interactions between gender with duration of diabetes, BMI, no
retinopathy, and proliferative retinopathy. bgenXdur is −1.404 with 95% credible inter-
val (−2.429, −0.366) indicating that for female patients, as the duration of diabetes
increases, their consistency of reporting symptoms decreases. Consistency of female
patients also reduced with higher BMI, bgenXbmi = −0.8185 and 95% credible interval
(−1.417, −0.1984).
Also, the results indicate that the interaction between covariate gender and ‘no
retinopathy’ is significant with bgenXret1 = −2.5590 and 95% credible interval (−4.161,
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Parameter Mean SD 2.5% CI 97.5% CI
b1 0.1309 0.3438 −0.6343 0.7852
b2 -0.04742 0.3772 −0.7921 0.7234
b3 0.2360 0.2554 −0.3002 0.7108
b4 -0.0627 0.2767 −0.5981 0.5105
b5 0.0400 0.1301 −0.2075 0.2949
b6 0.0585 0.1563 −0.2429 0.3600
b7 −0.0452 0.1753 −0.3712 0.3563
b8 1.6250 0.5260 0.6432 2.7430
b9 −0.5976 1.0800 −2.6730 1.9510
b10,1 0.7806 0.3489 0.1069 1.4590
b10,2 −0.3728 0.2999 −0.9566 0.1794
b10,3 −0.4077 0.4622 −1.2870 0.5355
bgenXtype 0.1694 0.8235 −1.3150 1.9320
bgenXdur −1.4040 0.5135 −2.4290 −0.3660
bgenXawar −0.3339 0.1881 −0.7049 0.0370
bgenXbmi −0.8185 0.3052 −1.4170 −0.1984
bdurXcpep −0.3536 0.1556 −0.6600 −0.0550
bcpepXtype 0.2467 0.3597 −0.4993 0.9115
bawarXage −0.0379 0.1593 −0.3379 0.3277
bawarXdur 0.0633 0.1418 −0.2290 0.3360
bawarXtype 0.2195 0.5508 −1.0290 1.2250
bdurXret1 1.1120 0.3088 0.5377 1.7450
bdurXret2 −0.5548 0.2882 −1.1420 0.0260
bdurXret3 −0.5568 0.3100 −1.1820 0.0855
bgenXret1 −2.5590 0.7748 −4.1610 −1.095
bgenXret2 0.3562 0.5373 −0.6855 1.4650
bgenXret3 2.2030 0.7168 0.6256 3.5280
Table 5.3: Posterior estimates of b coefficients for all covariates and their interactions.
−1.095). This means that female subjects with no retinopathy have lower consistency
compared to their male counterpart. However, female subjects with proliferative
retinopathy have higher consistency than male. This is given by the posterior esti-
mate, bgenXret3 = 2.2030 with 95% credible interval (0.6256, 3.5280). Note that with
different type of retinopathy, female patients have different effect on consistency than
male patients.
Another interaction found to be significant in affecting consistency is between covari-
ates duration and no retinopathy. Consistency of symptom reportings rises as duration
increases for patients with no retinopathy. The posterior estimate of the coefficient
corresponding to this interaction is bdurXret1 = 1.1120 with 95% credible interval
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(0.5377, 1.7450). Patients with longer duration of diagnosed diabetes have lower con-
sistency with the increment of C-peptide level. This is given by bdurXcpep = −0.3536
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(b) Interactions between factors
Figure 5.6: Posterior means (bullets) and 95% equal-tailed Bayesian intervals (bars)
for standardised coefficients of patient-specific covariates and their interactions.
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5.2 Hierarchical model
In Chapters 2 and 3 we explain the model for consistency estimation, whereas early
sections of this chapter discuss the GLM methodology for checking the association
between covariates and consistency. In this section, we propose a hierarchical model,
where, unlike in previous work where it was needed to obtain the precision parameter
first before using the posterior estimation in GLM to test the covariates effect on
consistency, this hierarchical model does both estimations in one setting.
Referring to the consistency model in Section 2.5, we have
yijk ∼Bernoulli(pijk),







where i = 1,...,66 patients, j = 1,...,26 symptoms and k = 1,...,Ki episodes. yijk is
the observation variable and pijk is the probability of a threshold being less than or
equal to latent variables αij and βik, with αij being the propensity of symptoms j for
patient i and βik the intensity of episode k for patient i.
As before,
τijk ∼ LN(0, σ2i ).
To allow for hierarchical estimation, the variance parameter, σ2i , follows a hierarchical
inverse gamma distribution:
σ2i ∼ Inv-gamma(δ, δ/mi)
where
δ ∼ Inv-gamma(aδ, bδ).
To facilitate the MCMC algorithm’s convergence, we set aδ = bδ = 1 as it reduces
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the variability of hyper-parameter δ. As defined earlier, parameter mi is the mean
consistency response and linked to each covariate through function mi = exp(Z
∗b)
where i = 1,2,...,I and b = (b0, b1, ..., bp)
T is a vector of coefficient corresponding to a
covariate vector Z∗ = (1, z1, z2, z3, z4, z5, z6, z7, GEN, TY PE,RET1, RET2, RET3).
For this hierarchical model, interactions between covariates are not included. There-
fore, p = 12. The b coefficients have the same prior as given in (5.1.4).
Since we are using the model with grouped symptoms, the prior for latent variable
αijl is as defined in (3.4.1), that is
αijl ∼Gamma(θ, θ/ul)
with θ ∼Gamma(aθ, bθ)
ul ∼Gamma(aul , bul).
The prior distribution given to latent variable βik is
βik ∼ Gamma(aβ, bβ).
We set θ equal to 1 and use aul = bul = aβ = 1 and bβ = 0.1.
We observe the trace plot of the model’s parameters to check their convergence (Fig-
ures 5.7- 5.9). Their posterior distributions were sampled after a 5000 burn-in period.
It is obvious from the plots that chains of parameter σ2i have achieved stationarity.
However, we only present trace plots for twelve subjects; 5009, 3057, 3065, 1055,
3048, 3052, 3067, 4076, 3016, 6002, 4072, and 6056 in Figure 5.7. Figure 5.8 shows
the sample paths of the simulation for parameter b. Again, the chains are strongly
converging without any problems. This is also true for the group’s propensity param-
eter, ul (Figure 5.9).
Consistency estimates for all patients obtained from this model are comparable with
what we obtained with the non-hierarchical consistency estimate model with grouped
symptoms in Section 3.4. Figure 5.10 (left) gives the distribution of the posterior
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mean estimates of the consistency parameter, c̃i, for all 66 patients in the hierarchical
model with grouped symptoms, whereas Figure 5.10 (right) shows the estimates of
log(σ−2i ). Subject 1028 was the most consistent patient among all 66 patients when
we estimated the consistency using the non-hierarchical model. However, when using
the hierarchical model, this subject has become the second most consistent patient,
with c̃i = 80.87. The least consistent patient among all is still subject 2013, c̃i = 11.53
(marked by red lines in Figure 5.10 (left)). Figure 5.11 gives the rank of consistency
estimates for this hierarchical model versus the non-hierarchical model. Patients are
ranked such that the patient with the highest consistency is ranked first and patient
with the lowest consistency is ranked last. This plot shows a decent correspondence
suggesting that the estimations obtained from the hierarchical and non-hierarchical
model are similar. Posterior estimates of c̃i for all patients are given in Table 5.4.
Table 5.5 provides posterior estimates of the mean propensity in each group, ul for
l = 1,...,6, and their distributions are shown in Figure 5.12. The distributions are
very similar to what we get when the non-hierarchical model is used, as can be ob-
served from the violin plot in Figure 5.13. Autonomic and neuroglycopenic groups
have the highest propensity suggesting their importance in detecting the onset of hy-
poglycaemia (u1 = 0.0420 and u2 = 0.0377 respectively).
We can also investigate the covariates’ effect using this hierarchical model. Figure
5.14 shows the caterpillar plots for coefficients b corresponding to each covariate, and
the summary statistics of posterior estimates of b are given in Table 5.6. Recall that
for the non-hierarchical model with grouped symptoms in Section 5, covariates gen-
der and no retinopathy significantly affected the consistency reporting (Figure 5.3).
However, the implementation of hierarchical modeling to grouped symptoms results
in no covariate appearing to be affecting significantly the consistency, as exhibited
by the 95% credible intervals of all b coefficients containing zero (See Figure 5.14).
The hierarchical setting allows for more variation about the consistency-related pa-
rameter (σ2i ) to enter the model (through the Inverse-gamma distribution), and this
can potentially account for differences in patient characteristics (covariates) not being
identified. Figure 5.15 displays the contrast between posterior densities of the coef-
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ficients for covariates gender and no retinopathy in non-hierarchical and hierarchical
model. Under the hierarchical model, the density of gender seems to have shifted to
the right whereas the density of no retinopathy has shifted to the left.
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Figure 5.7: Trace plots of σ2i coefficients in hierarchical model with grouped symptoms,
for selected patients i.
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Figure 5.8: Trace plots of b in hierarchical model with grouped symptoms.
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Figure 5.9: Trace plots of group parameter, ul for l = 1,...6 where u1 refers to Au-
tonomic, u2 to Neuroglycopenic, u3 to Autonomic/Neuroglycopenic, u4 to General


































Figure 5.10: Histogram of estimated consistency parameter, c̃i and the log estimated
precision parameter, σ−2i for hierarchical model with grouped symptoms.

















































Figure 5.11: Graph shows ascending order for ranking of consistency estimates, c̃i =
of 66 patients for hierarchical and non-hierarchical model for model with grouped
symptoms.
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Subject No. of episode c̃i SD 25% CI 95% CI
1008 123 26.20 3.220 20.33 32.83
1009 96 47.50 4.573 38.86 56.66
1015 34 32.82 5.803 22.39 44.98
1021 49 41.91 5.731 31.30 53.84
1025 26 39.73 6.809 27.36 53.63
1028 45 80.87 5.232 69.77 90.01
1036 42 49.83 6.162 38.07 62.01
1039 47 31.88 5.282 22.37 42.96
1055 27 53.31 7.104 39.53 67.25
1057 11 75.91 7.012 60.66 87.73
1086 91 27.36 3.771 20.38 35.24
2009 101 24.00 3.242 18.16 30.74
2010 102 25.29 3.210 19.39 32.06
2012 42 27.21 4.736 18.61 37.18
2013 300 11.53 1.331 9.09 14.36
2015 44 33.09 4.847 24.43 43.20
2021 32 39.96 6.133 28.57 52.11
2022 41 36.54 5.360 26.67 47.82
2027 26 44.92 6.950 31.61 58.89
3001 35 46.66 6.495 34.24 59.45
3015 19 15.35 2.908 10.46 21.80
3016 23 58.53 7.314 43.86 72.55
3022 23 46.42 7.489 32.39 61.85
3024 30 54.54 6.658 41.71 67.76
3029 78 69.87 4.913 59.55 78.91
3043 17 41.80 8.273 26.19 58.55
3046 25 45.60 6.944 32.64 59.84
3048 37 55.07 6.263 42.87 67.24
3050 54 51.89 5.171 41.67 61.93
3052 146 40.82 3.902 33.24 48.80
3057 91 29.45 3.839 22.38 37.51
3065 27 36.73 6.388 25.19 50.12
3067 32 44.22 6.331 32.08 56.97
4003 26 55.81 6.800 42.40 68.81
4008 69 48.51 4.635 39.56 57.85
4013 55 30.18 4.532 22.19 39.78
4023 211 20.69 2.241 16.50 25.41
4028 12 51.42 9.291 32.63 68.69
4032 10 65.42 9.546 45.53 82.37
4034 61 63.24 4.986 53.12 72.41
4043 36 30.43 5.217 21.01 41.25
4045 47 32.07 4.863 22.98 42.09
4049 23 54.10 7.046 40.05 67.79
4061 12 74.42 7.184 58.95 86.89
4063 48 27.37 4.429 19.37 36.59
4072 40 40.27 5.729 29.51 51.95
4076 36 38.45 5.935 27.52 50.44
5004 28 40.23 6.332 28.74 53.26
5009 40 48.14 5.808 36.89 59.63
5023 22 47.33 7.725 33.01 62.76
5026 26 57.55 6.886 44.03 70.93
5029 47 58.82 5.905 47.14 70.05
5044 87 29.56 3.744 22.67 37.35
5045 78 40.68 4.640 32.12 50.13
5088 100 18.73 2.657 14.03 24.39
6002 34 55.22 6.098 43.32 67.07
6010 19 51.84 7.786 36.47 66.81
6018 62 37.60 4.701 28.84 47.10
6019 93 30.14 3.777 23.03 37.96
6023 76 24.46 3.562 18.03 31.95
6038 122 24.28 3.056 18.91 30.73
6056 36 54.18 6.494 41.52 66.95
6058 20 62.27 6.973 48.21 75.09
6062 13 48.52 9.195 30.70 66.30
6064 17 82.79 5.010 71.62 91.20
6065 44 19.61 4.491 12.34 29.63
Table 5.4: Posterior estimates of consistency (Mean, standard deviation, and 95%
credible interval) for all subjects using hierarchical model with grouped symptoms.
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Group Mean SD 2.5% CI 97.5% CI
Autonomic 0.0420 0.0023 0.0376 0.0467
Neuroglycopenic 0.0377 0.0019 0.0341 0.0416
Autonomic/Neuroglycopenic 0.0280 0.0031 0.0225 0.0347
General Malaise 0.0106 0.0010 0.0088 0.0126
Other 0.0085 0.0011 0.0066 0.0108
No Symptom 0.0432 0.0068 0.0317 0.0582
Table 5.5: Posterior estimates of group propensity, ul when using hierarchical model.





















Figure 5.12: Posterior distributions of mean group propensity, ul in hierarchical model.
Parameter Mean SD 2.5% CI 97.5% CI
b1 −0.0155 0.1355 −0.2787 0.2500
b2 −0.0936 0.1732 −0.4438 0.2428
b3 −0.0121 0.1231 −0.2404 0.2440
b4 −0.1093 0.1390 −0.3778 0.1800
b5 0.0670 0.1154 −0.1554 0.3001
b6 −0.1607 0.1175 −0.3913 0.0646
b7 −0.0235 0.0738 −0.1721 0.1260
b8 0.0245 0.2363 −0.4232 0.5062
b9 0.3698 0.2429 −0.0775 0.8732
b10,1 0.0135 0.2243 −0.4220 0.4533
b10,2 0.1708 0.1673 −0.1809 0.4810
b10,3 −0.1843 0.2488 −0.6814 0.3125
Table 5.6: Posterior estimates of b coefficients corresponding to patient-specific co-










































Figure 5.13: Violin plots of posterior distributions of mean group propensity, ul for
l = 1, ..., 6 obtained with non-hierarchical model with grouped symptoms (M1) and
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Figure 5.14: Posterior means (bullets) and 95% equal-tailed Bayesian intervals (bars)
for standardised coefficients of patient-specific covariates in hierarchical model with
grouped symptoms.
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Figure 5.15: Posterior densities of b coefficient for covariate gender (GEN) and no
retinopathy (RET1) in hierarchical model and non-hierarchical model with grouped
symptoms. The hierarchical model is represented with red lines.
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5.3 Concluding remarks
As a conclusion, examining the effect of patient specific covariates on consistency
using estimates obtained with the non-hierarchical grouped symptoms model, shows
that gender and no retinopathy significantly affect the consistency of symptom re-
portings for individual patients. When interactions between the covariates are taken
into account, three interactions involving gender are significant, i.e. gender × du-
ration, gender × BMI, and gender × retinopathy 1 (no retinopathy). The effect on
consistency of covariate duration is also different as the level of C-peptide changes.
Another significant interaction is between duration of diabetes and lack of retinopathy.
We have also considered a hierarchical model which is able to estimate patients’ con-
sistency and determine which covariates affect it in a single model. The consistency
estimates for patients are similar to what we had obtained with the non-hierarchical
model in Section 4.3. However, with the hierarchical model, no covariate appears to




This chapter presents variable selection methodologies used to select the best pre-
dictive model for predicting patients’ consistency. We first implement a stepwise
regression procedure to identify important covariates that should be included in a
predictive model. We use this methodology for the model with grouped symptoms,
including when we consider interactions between the covariates, and the hierarchical
model introduced in Chapter 5. Next, we provide an overview of the second method
used, Gibbs variable selection, before discussing the results. In the final section, we
use Bayesian model averaging to overcome the model uncertainty issue shown from
the Gibbs variable selection.
6.1 Stepwise selection
In Chapter 5, we investigate the association between individuals’ consistency and
covariates. Using the GLM approach in that chapter, we developed a model for pre-
dicting the consistency of symptom reporting among patients. Our aim is to develop a
model that efficiently predicts a patient’s consistency using the available information
of that patient’s characteristics. Ideally, we would like to have a simplified model
that only consists the best subset of explanatory variables. We take the precision,
σ−2i , in (5.1.1) as the response, since the consistency parameter is ci =
100
(1 + σ2i )
, and
the variables listed in Table 5.1 as the predictors. To select the desired model from
a large set of plausible models, we use variable selection. One option is to fit all 2p
possible models where p is the number of potential explanatory variables which in
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our case is p = 10. Therefore we need to consider 210 = 1024 models and calculate
the marginal likelihood estimates for all of them. This is almost impossible and time
consuming to be done. Therefore, to avoid actually fitting all the models, we use a
stepwise selection procedure.
In general regression-type problems, a stepwise procedure is employed to simplify a
model containing a large number of possible covariates to a reduced model containing
a subset of ‘better’ covariates which provide important information about the response
variable, thus giving the model a good predictive ability (Miller, 2002). The stepwise
selection method adds in or removes one variable at each stage, given that the variable
meets a selection criterion for entry or removal, until there is no new predictor that
can be added or deleted. The selection criterion used in this analysis is the DIC (as
defined in Section 3.3.1). Every time a new variable is added or dropped from the
model, the significance of each of the variables already in the model is re-examined and
compared sequentially. To run the stepwise regression, we incorporate a binary vector
γ = (γ1, ..., γ10) to the linear predictor in (5.1.1). As defined previously, wi = σ
−2
i





) for i=1, 2, ..., I




where mi = E(σ
−2
i ) (Ntzoufras, 2009). We simplify the procedure as follows.
i. Specify the initial model with binary indicator γ(0), and set γ = γ(0).
ii. The currently selected model is



















γcq,k = γqI(q 6= k) + (1− γq)I(q = k),
bcq,k = bqI(q 6= k) + (1− bq)I(q = k)
with I() being the indicator function. If Xq is included in the model, γq = 1,
then it is removed from qth candidate model (γcq,q = 1 − γq = 0) but is included
in all other candidate models (γcq,k = γq = 1, for all k 6= q).
iii. From step ii, we fit p models and estimate their DIC values.
iv. Select the best model among all fitted models, i.e. the model with the lowest
DIC value.
v. If the selected model is the same as the one indicated by the previous steps,
terminate the procedure. Otherwise, repeat step ii.
Our data set contains missing data as was previously discussed in Chapter 5. For
variable selection, we substitute the missing values with their mean posterior estimates
(Celeux et al., 2006). Their estimates using the model with grouped symptoms are









Table 6.1: Posterior estimates of missing values for grouped symptoms model.
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We explore three different ways of starting the stepwise procedure which are: 1)
starting with the null model, i.e. the model containing only the intercept parameter
without any covariate; 2) starting with the full model, i.e. model containing all p
covariates. This starting point is suitable to use if (p + 2 < n), where n is the sam-
ple size; and 3) starting with model containing only significant covariates (Section 5.1).
Starting the procedure using the null model takes seven cycles before it is terminated,
thus 71 models were fit in total. The DIC value from each step is summarised in
Table 6.2. First, covariate retinopathy (x10) was added to the null model followed
by covariate BMI (x3). Gender (x8) and haemoglobin A1c (Hba) (x5) were added in
the third and fourth cycle respectively. Finally, covariate awareness of hypoglycaemia
also enters the final predictive model. The model with these covariates is found to
be the best model, indicated by its DIC value, 159.13. Therefore, the best predictive
model has linear predictor;
log{E(σ−2i )} =b0 + b3 ×BMIi + b5 ×HBAi + b7 × AWARi + b8 ×GENi
+ b9 × TY PEi + b10 ×RETi
i =1, 2, ..., 66
with the posterior standardised intercept term, b0 = −0.1552 with 95% CI (−0.6074,
0.3212) and the posterior estimates for coefficients corresponding to each covariates
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being
b3 = 0.2194 with 95% CI (−0.0049, 0.4680),
b5 = −0.1970 with 95% CI (−0.3816,−0.0112),
b7 = 0.1293 with 95% CI (0.0095, 0.2486),
b8 = −0.4086 with 95% CI (−0.8588, 0.0550),
b9 = 0.5010 with 95% CI (−0.0397, 1.0670),
b10,1 = 0.4438 with 95% CI (0.1306, 0.7531),
b10,2 = −0.2895 with 95% CI (−0.6255, 0.0745),
b10,3 = −0.1543 with 95% CI (−0.5535, 0.2876).
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Step (1) (2) (3) (4)
Previous model: γ − 0000000000 0000000001 0010000001
Action Initialise +x10 +x3 +x8
Current model DIC 183.87 174.56 168.43 162.65
γ 0000000000 0000000001 0010000001 0010000101
x1 185.78 174.86 168.92 163.83
x2 185.44 174.05 169.47 162.80
x3 177.86 168.16 (∗)174.66 (∗)169.03
x4 185.25 176.03 169.49 163.16
x5 176.90 171.28 165.02 160.67
x6 179.48 171.23 167.60 163.67
x7 180.00 170.78 166.10 161.73
x8 179.34 169.05 162.89 (∗)168.44
x9 183.81 175.42 170.02 164.67
x10 174.49 (∗)183.87 (∗)177.83 (∗)173.20
Step (5) (6) (7)
Previous model: γ 0010000101 0010100101 0010101101
Action +x5 +x7 +x9
Current model DIC 160.79 160.46 159.13
γ 0010100101 0010101101 0010101111
x1 161.70 160.68 160.62
x2 161.15 162.59 159.84
x3 (∗)167.46 (∗)166.86 (∗)160.96
x4 161.37 162.42 159.22
x5 (∗)162.36 (∗)161.65 (∗)161.84
x6 161.06 160.22 159.19
x7 160.51 (∗)160.79 (∗)161.88
x8 (∗)165.10 (∗)163.57 (∗)160.42
x9 162.05 159.15 (∗)160.35
x10 (∗)169.47 (∗)170.48 (∗)164.96
Key: (+) = add a covariate to the current model, (−) = remove a covariate from a
current model, and (∗) = covariate present in the current model.
Table 6.2: Tabulated summary of stepwise procedure for grouped symptoms model,
starting from null model. Bold values refer to the lowest DIC values in each step.
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Using the full model to initiate the stepwise procedure gives a slightly different predic-
tive model which was achieved after three cycles and fitting 31 models. The procedure
is summarised in Table 6.3 (a). Covariate age (x2) was eliminated in the first cycle.
Later in the following cycles, covariates duration of diabetes (x1) was removed before
we reach the final model which has the following linear predictor
log{E(σ−2i )} =b0 + b3 ×BMIi + b4 × CPEPi + b5 ×HBAi + b6 × ACEi
b7 × AWARi + b8 ×GENi + b9 × TY PEi + b10 ×RETi
i =1, 2, ..., 66
Notice that this model has two extra predictors in comparison to the predictive
model obtained when we start with constant model. This model has DIC value
of 158.95 and the posterior standardised intercept term, b0 = −0.1919 with 95% CI
(−0.6365,0.2899). The posterior estimates of each coefficient are as follows
b3 = 0.2031 with 95% CI (−0.0291, 0.4534),
b4 = −0.1851 with 95% CI (−0.4430, 0.0697),
b5 = −0.2065 with 95% CI (−0.3876,−0.0193),
b6 = −0.1592 with 95% CI (−0.3652, 0.0511)
b7 = 0.1112 with 95% CI (−0.0144, 0.2399),
b8 = −0.4606 with 95% CI (−0.9405, 0.0277),
b9 = 0.7212 with 95% CI (0.10501.3710),
b10,1 = 0.4133 with 95% CI (0.0995, 0.7200),
b10,1 = −0.2971 with 95% CI (−0.6352, 0.0496),
b10,1 = −0.1162 with 95% CI (−0.4973, 0.3261).
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Finally, if we start the procedure with the model containing the only covariate that
significantly affects individual consistency, i.e. gender (from Section 5.1), predictor
retinopathy (x10) was added in the first cycle. Then, BMI (x3) and Hba (x5) were
selected as prominent predictors according to their DIC values. During the fourth
and fifth cycle, we add awareness of hypoglycaemia (x7) and type of diabetes (x9)
to the model respectively. The procedure stopped in the sixth cycle giving the final
model exactly as what we obtain when using null model as starting points. Table 6.3
(b) gives the summary of this procedure.
Step (1) (2) (3)
Previous model: γ − 1111111111 1011111111
Action Initialise −x2 −x1
Current model DIC 163.05 160.64 158.95
γ 1111111111 1011111111 0011111111
x1 (∗)161.09 (∗)159.99 161.18
x2 (∗)160.89 161.93 160.36
x3 (∗)163.34 (∗)161.44 (∗)159.49
x4 (∗)163.43 (∗)162.65 (∗)159.40
x5 (∗)165.44 (∗)163.66 (∗)160.99
x6 (∗)162.49 (∗)161.42 (∗)160.42
x7 (∗)163.63 (∗)162.91 (∗)161.03
x8 (∗)164.33 (∗)162.80 (∗)160.67
x9 (∗)165.14 (∗)163.05 (∗)161.56
x10 (∗)167.23 (∗)166.92 (∗)165.00
(a) Initial model: full model
Step (1) (2) (3) (4) (5) (6)
Previous model: γ − 0000000100 0000000101 0010000101 0010100101 0010101101
Action Initialise +x10 +x3 +x5 +x7 +x9
Current model DIC 179.28 169.16 162.65 160.79 160.46 159.13
γ 0000000100 0000000101 0010000101 0010100101 0010101101 0010101111
x1 181.38 170.38 163.83 161.70 160.68 160.62
x2 180.79 167.80 162.80 161.15 162.59 159.84
x3 173.08 162.67 (∗)169.03 (∗)167.46 (∗)166.86 (∗)160.96
x4 180.66 169.87 163.16 161.37 162.42 159.22
x5 174.33 167.37 160.67 (∗)162.36 (∗)161.65 (∗)161.84
x6 177.14 168.39 163.67 161.06 160.22 159.19
x7 178.19 167.60 161.73 160.51 (∗)160.79 (∗)161.88
x8 (∗)183.79 (∗)174.58 (∗)168.44 (∗)165.10 (∗)163.57 (∗)160.42
x9 178.61 169.94 164.67 162.05 159.15 (∗)160.35
x10 168.92 (∗)179.22 (∗)173.20 (∗)169.47 (∗)170.48 (∗)164.96
(b) Initial model: model containing covariate gender
Key: (+) = add a covariate to the current model, (−) = remove a covariate from a
current model, and (∗) = covariate present in the current model.
Table 6.3: Tabulated summary of stepwise procedure for grouped symptoms model,
using different starting points. Bold values refer to the lowest DIC values in each
step.
With these three starting models, we obtain two different best predictive models (Ta-
ble 6.4). This might be because stepwise regression only adds or drops one variable
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at a time. Two or more variables might have joint significant effect on the model
although individually they do not, and the stepwise procedure cannot detect this.
Starting model Covariate in final model DIC value
Null BMI (x3), HBA (x5), AWAR (x7), GEN (x8), 159.13
TYPE (x9), RET (x10)
Full BMI (x3), CPEP (x4), HBA (x5),ACE (x6), AWAR (x7), 158.95
GEN (x8), TYPE (x9), RET (x10)
With GEN BMI (x3), HBA (x5), AWAR (x7), GEN (x8), 159.13
TYPE (x9), RET (x10)
Table 6.4: Summary of the selected models from stepwise selection with different start-
ing points for grouped symptoms model. Covariates in blue highlight the covariates
which are common in the three models.
6.1.1 Stepwise selection: model with interactions between
covariates
In Section 5.1.1, we discussed the effect of interaction between covariates on consis-
tency. To decide upon which interactions are important to include in a consistency
predictive model, we apply the stepwise procedure. The interactions considered for
the variable selection are as given in (5.1.8) and the estimated missing values when
we include those interactions are provided in Table 6.5. We initiate the procedure
using the null model as the starting point. The procedure fitted 91 models within nine
cycles before it was terminated. The final model contains four main predictors and
six interactions between the covariates with DIC value = 153.74. Covariates gender
(x8), retinopathy (x10), BMI (x3), and awareness of hypoglycaemia (x7) are selected
as prominent variables in predicting individuals’ consistency. Two interactions among
them are also selected as important predictors, i.e. interaction between gender with
awareness of hypoglycaemia, and BMI. The link function for the final model is as
143
follows:
log{E(σ−2i )} =b0 + b3 ×BMIi + b7 × AWARi + b8 ×GENi + b10 ×RETi
+ b2×4 × (DUR · CPEP )i + b2×10 × (DUR ·RET )i
+ b3×8 × (BMI ·GEN)i + b4×9 × (CPEP · TY PE)i
+ b7×8 × (AWAR ·GEN)i + b8×10 × (GEN ·RET )i
i =1, 2, ..., 66
and the corresponding posterior estimates for all coefficients are
b0 = −0.1043 with 95% CI (−0.6416, 0.4877),
b8 = 0.9632 with 95% CI (0.2316, 1.7690),
b3 = 0.3372 with 95% CI (−0.0405, 0.7217),
b7 = 0.2148 with 95% CI (0.0554, 0.3693),
b10,1 = 0.3185 with 95% CI (0.0021, 0.6106),
b10,2 = −0.1718 with 95% CI (−0.5013, 0.1770),
b10,3 = −0.1467 with 95% CI (−0.5522, 0.2947),
b7×8 = −0.6251 with 95% CI (−0.8737,−0.3740),
b3×8 = −0.5909 with 95% CI (−1.0370,−0.1250),
b2×4 = −0.3918 with 95% CI (−0.6571,−0.0838),
b2×10 = 0.1937 with 95% CI (−0.1061, 0.5122).
When starting from the full model, the procedure was terminated after 13 cycles,










Table 6.5: Posterior estimates of missing values when interactions between covariates
are included.
in the first two cycles. Then, in the following cycles interaction between age and
awareness (x2×7), duration of diabetes (x2), C-peptide (x4) and interaction between
C-peptide and type of diabetes (x4×9) were also dropped from the model. The final
model obtained here contains three main factors and four interactions terms, i.e.
log{E(σ−2i )} =b0 + b3 ×BMIi + b8 ×GENi + b10 ×RETi
+ b2×8 × (DUR ·GEN)i + b2×4 × (DUR · CPEP )i
+ b3×8 × (BMI ·GEN)i + b7×8 × (AWAR ·GEN)i
i =1, 2, ..., 66
with DIC value = 141.92. The posterior standardised intercept term, b0 = 0.1931
with 95% CI (−0.0578,0.4735) and the posterior estimates of bp:
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b8 = 1.5720 with 95% CI (0.7716, 2.4520),
b3 = 0.2652 with 95% CI (−0.0910, 0.5999),
b10,1 = 0.6124 with 95% CI (0.2580, 0.9594),
b10,2 = −0.4923 with 95% CI (−1.0000,−0.0176),
b10,3 = −0.1201 with 95% CI (−0.6582, 0.5418),
b2×8 = −1.0800 with 95% CI (−1.7240,−0.4918),
b7×8 = −0.3580 with 95% CI (−0.5817,−0.1192),
b3×8 = −0.8622 with 95% CI (−1.2860,−0.4172),
b2×4 = −0.3883 with 95% CI (−0.6194,−0.1486).
The summary tables of the stepwise procedure is not shown here but Table 6.6 sum-
marises the final models with their DIC values obtained when we include interaction
between covariates. Starting from full model gives a simpler predictor model as com-
pared to the model obtained when starting with null model. As indicated by the blue
covariates, the simpler model is almost like a subset from the other model except for
interaction between duration and gender.
Starting model Covariate in final model DIC value
Null BMI (x3), AWAR (x7), GEN (x8), RET (x10) 153.74
DUR·CPEP (x2×4), DUR·RET (x2×10),
CPEP·TYPE (x4×9), BMI·GEN (x3×8),
AWAR·GEN (x7×8), GEN·RET (x8×10)
Full BMI (x3), GEN (x8), RET (x10), 141.92
DUR·GEN (x2×8), DUR·CPEP (x2×4),
BMI·GEN (x3×8), AWAR·GEN (x7×8)
Table 6.6: Summary of the selected models from stepwise selection with different
starting points for grouped symptoms model with interaction between covariates.
Covariates in blue highlight the covariates which are common in the two models.
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6.1.2 Stepwise selection: hierarchical model
Previously, in Section 5.2, we constructed a hierarchical model where we can both
estimate individual consistency and effect of covariates. This section will present
the results from variable selection for this model using stepwise methodology. As
mentioned earlier, for variable selection we need to substitute the missing values with
their posterior estimates. For this model, the posterior estimates are given in Table
6.7. As before, we first started the procedure with a null model and then adding or
dropping a predictor with the lowest DIC value in each cycle which we run for 10,000
iterations. Table 6.8 (a) gives a summary of the procedure. The final model is selected
after six cycles with DIC value = 96.66. In the first cycle, we add variable type of
diabetes (x9), followed by retinopathy (x10) in the second cycle. Then, gender (x8)
and C-peptide (x4) are added and the final predictor to enter the model is the Ace
(x6). Therefore, the best predictive model given by stepwise regression is
log{E(σ−2i )} =b0 + b4 × CPEPi + b6 × ACEi + b8 ×GENi + b9 × TY PEi
+ b10 ×RETi
i =1, 2, ..., 66
where the posterior estimates of the coefficients are:
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b0 = 0.5016 with 95% CI (0.1194, 0.8752),
b4 = −0.1715 with 95% CI (−0.1715, 0.0064),
b6 = −0.1400 with 95% CI (−0.3021, 0.0339),
b8 = −0.3555 with 95% CI (−0.6582,−0.0391),
b9 = 0.5528 with 95% CI (0.2048, 0.9904),
b10,1 = 0.2847 with 95% CI (0.07123, 0.4936),
b10,2 = −0.1668 with 95% CI (−0.4127, 0.0796),
b10,3 = −0.1179 with 95% CI (−0.4086, 0.1873). (6.1.1)
Another option we have is to start the stepwise regression using all available covariates
and then removing or adding one by one in each cycle depending on their DIC values.
Table 6.8 (b) summarises this whole procedure which also took six cycles. Covariates
age (x1) and awareness (x7) are eliminated from the model during the first and second
cycle respectively. Duration of diabetes (x2), Hba (x5), and BMI (x3) are also not
very good predictors since they are eliminated by the stepwise procedure. In the end,
the best predictive model only contains covariates gender (x8), type of diabetes (x9),
retinopathy (x10), C-peptide (x4), and Ace (x6) with the posterior estimates of the
coefficients are as given in (6.1.1). This tells us that with the hierarchical model,
the two starting points we used result in the same predictive model. Note that from
Section 5.2, there is no significant covariate affecting consistency. Hence, the option











Table 6.7: Posterior estimates of missing values in hierarchical model.
Step (1) (2) (3) (4) (5) (6)
Previous model: γ − 0000000000 0000000010 0000000011 0000000111 0001000111
Action Initialise +x9 +x10 +x8 +x4 +x6
Current model DIC 112.20 104.11 101.51 98.44 97.72 96.66
γ 0000000000 0000000010 0000000011 0000000111 0001000111 0001010111
x1 113.29 106.13 102.98 101.05 99.23 98.73
x2 109.11 104.31 102.93 99.58 99.41 98.19
x3 111.22 105.40 101.56 98.63 98.35 98.15
x4 114.14 104.83 101.03 97.45 (∗)98.34 (∗)98.40
x5 113.93 105.68 103.30 101.02 99.38 98.64
x6 107.74 103.25 99.95 97.76 97.22 (∗)97.24
x7 113.98 105.43 102.22 100.57 100.39 98.22
x8 109.68 102.84 98.46 (∗)101.01 (∗)100.91 (∗)98.47
x9 104.01 (∗)112.16 (∗)106.83 (∗)103.25 (∗)105.45 (∗)102.99
x10 106.86 100.92 (∗)104.27 (∗)102.35 (∗)100.78 (∗)100.95
(a) Initial model: null model
Step (1) (2) (3) (4) (5) (6)
Previous model: γ − 1111111111 0111111111 0111110111 0011110111 0011010111
Action Initialise −x1 −x7 −x2 −x5 −x3
Current model DIC 105.62 103.03 101.89 99.60 97.49 96.66
γ 1111111111 0111111111 0111110111 0011110111 0011010111 0001010111
x1 (∗)103.69 105.63 103.38 102.18 99.22 98.73
x2 (∗)104.10 (∗)102.22 (∗)98.99 101.74 99.39 98.19
x3 (∗)104.78 (∗)103.15 (∗)100.03 (∗)98.63 (∗)96.82 98.15
x4 (∗)106.83 (∗)104.84 (∗)102.44 (∗)100.91 (∗)98.71 (∗)98.40
x5 (∗)104.51 (∗)101.74 (∗)99.24 (∗)98.10 99.65 98.64
x6 (∗)106.00 (∗)104.47 (∗)101.77 (∗)99.93 (∗)97.31 (∗)97.24
x7 (∗)104.00 (∗)100.69 103.90 101.82 99.17 98.22
x8 (∗)107.20 (∗)105.12 (∗)103.52 (∗)101.96 (∗)100.42 (∗)98.47
x9 (∗)108.34 (∗)106.43 (∗)104.98 (∗)103.23 (∗)101.60 (∗)102.99
x10 (∗)105.28 (∗)103.72 (∗)102.23 (∗)103.56 (∗)102.71 (∗)100.95
(b) Initial model: full model
Key: (+) = add a covariate to the current model, (−) = remove a covariate from a
current model, and (∗) = covariate present in the current model.
Table 6.8: Tabulated summary of stepwise procedure for hierarchical model with
grouped symptoms, using different starting points. Bold values refer to the lowest
DIC values in each step.
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6.2 Gibbs Variable Selection
This section discusses another method we use to select patient-specific covariates that
best describe the predictive model for consistency of symptom reporting for individual
patients. The method used here is Gibbs Variable selection, which was introduced by
Dellaportas et al. (2002). We consider three different sets of prior distributions for
comparison purposes. This section focuses only on predictive models arising from the
grouped symptoms model.
As before, covariates age (x1), duration of diabetes (x2), BMI (x3), C-peptide (x4),
haemoglobin A1c (Hba) (x5), serum angiotensin converting enzyme (Ace) (x6), aware-
ness of hypoglycaemia(x7), gender (x8), type of diabetes (x9) and retinopathy (x10)
are considered for inclusion in our predictive model. With p = 10 patient-specific
covariates in the model, we have a model space containing all potential models,
M = {M1, ...,M2p}. The 1024 possible models include the model with no covariates
or what we call a null model.
We introduce a p × 1 binary indicator vector, γ into the linear predictor where p is
the number of covariates under consideration. Thus we have,




The indicator variable, γ, will identify which covariate will be included in tth model,




where bt denotes the parameter vector in model Mt. f(D|bt,Mt) is the likelihood
function under model Mt, conditional on bt and π(bt|Mt) is the prior density of the
parameter vector bt (Kass and Raftery, 1995). The prior corresponding to modelMt
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To compare any two models we use posterior odds (Jeffreys, 1946) which can be
evaluated using ratios of the posterior probabilities from (6.2.1), to get the posterior













is the Bayes factor forM0 againstM1 and
π(M0)
π(M1)
is the prior odds
ratio. (6.2.2) can be written as, posterior odds = Bayes factor × prior odds. PO01 >
1 will implies that the data favour M0 and vice versa.
We can also monitor the variable inclusion probability, p(γj|D), which is the probabil-






Besides our main interest to estimate the maximum a posteriori (MAP) model, al-
ternatively we can trace a median probability (MP) model which refers to the model
which includes all variable with p(γj|D) > 0.5 (Ntzoufras, 2009).
Choosing prior distributions is crucial in Bayesian model selection as the posterior
model probabilities depend very much on the prior. This situation relates to the
Lindley Paradox, where a more parsimonious model is suggested with higher prior
variance. We use γ ∼ Bernoulli(0.5) to represent lack of information on which
covariates are important whereas the prior for bj is:
bj ∼ N(µj, σ2j ). (6.2.3)
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The independent prior, Zellner’s g-prior, and empirical prior are the three different
sets of parameters for prior distribution of bj explored in this study. Detailed discus-
sions are provided in next sections.
Independent priors
The first prior to consider is the independent prior originally used by Dellaportas et
al. (2002). Parameters µj and σ
2
j in Equation (6.2.3) are defined as follows:
µj = (1− γj)µ̄bj
σ2j = γjc
2 + (1− γj)σ̄2bj
where µ̄bj and σ̄
2
bj
are the posterior mean and variance of bj respectively, obtained
from a pilot run of the full model while c2 is a constant. Multiple values for constant
c2 are used for comparison and to study the effect of the Lindley-Bartlett paradox.
We use c2 = n, 1000 and 10,000. The sample size, n = 66, is the number of patients.
Table 6.9 (a) provides the mean and standard deviation (SD) of the posterior in-
clusion probabilities of the γj variables, corresponding to Xj covariates. These are
obtained with an MCMC run of 10,000 iterations after a 5000 burn-in period. With
c2 = n, gender (γ8) is the only covariate with high inclusion probability, 0.8098. As
c2 increases to 10,000 gender’s probability of inclusion decreases to just slightly over
0.5, that is 0.5048. The other nine covariates have probabilities less than 0.5. We
notice that the probability of inclusion of all covariates decreases as the prior variance
increases.
Tables 6.9 (b) - (d) present the ten predictive models with the highest estimated
posterior model probabilities and posterior odds compared to the top ranked model.
The model with the highest estimated posterior probability is called the maximum a
posteriori (MAP) model. When factor c2 = n, the MAP model is M129 and contains
covariate gender (γ8). We can also look at the median probability (MP) model, which
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is the model that includes all covariates with posterior inclusion probability at least
0.5. In this case, our MP model is also M129. Kass and Raftery (1995) state that
if the Bayes factor between models is less than 3, the differences between them can
be ignored. M145 which contain covariates Hba (γ5) and gender (γ8) has probability
0.1803 and posterior odd 1.31. Thus can we say that these two models are equally
good predictive models. M129 is also suggested as the MP and MAP model if we use
c2= 1000 and 10,000.
Zellner’s g - prior
The next prior we consider is the Zellner’s g-prior (Zellner, 1986). With this setting,
parameter b takes a multivariate normal prior distribution with mean µb and precision
S−1.
b ∼ NVM(µb,S−1)
where µb = µ0, ..., µp
with µj = (1− γj)µ̄bj for j = 1, ..., p.




[XᵀX]jk + (1− γjγk)I(j = k)S̄2bj
for j, k = 1, 2, ..., p. X is the n × (p + 1) standardised design matrix whereas c2 is a
constant. As described previously, µ̄bj and S̄
2
bj
take values of the estimated mean and
standard deviation of bj from a pilot run of the full model and γ0 = 1.
As previously, we use three different c2 values; c2 = n, 1000, and 10,000. The full
results of the posterior variable inclusion probabilities and the posterior model prob-
abilities are given in Table 6.10. The probability of inclusion of covariate gender (γ8)
is always greater than 0.5 even with a large prior variance. However, we can see the
probability of inclusion for every covariate decreases as the prior variance gets higher.
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This trend can be clearly seen in the probability of inclusion for retinopathy (γ10)
where it has declined from 0.9419 (with c2 = 66) to 0.3116 (with c2 = 10, 000).
Referring to Table 6.10 (b), the MAP model is M661 when c2 = 66. This model
includes covariates BMI (γ3), Hba (γ5), gender (γ8), and retinopathy (γ10) and has
probability of 0.0326. We can see that all ten models presented here have small pos-
terior odds suggesting high model uncertainty. The MP model is M721 (not shown
here), with the posterior odds when comparing it to the MAP model being 3.34. As
the prior variance gets higher, i.e. by using c2 = 1000 and 10,000, more parsimonious
models are suggested. M641, M645, and M145 are favoured in these cases. With
c2 = 1000, the MAP and MP models contain covariates gender and retinopathy, i.e.
M641, whereas with c2 = 10, 000 the MAP and MP selected models only have gender
as predictor, i.e. M129.
Empirical prior
The third prior we consider is the empirical prior (Ntzoufras, 2011). We substitute
the parameters in Equation (6.2.3) as follows:
µj = µ̄bj
σ2j = {γjn+ (1− γj)} σ̄2bj
where j = 1,2,...,p. µ̄bj is the posterior bj estimates obtained from a MCMC pilot run
of the full model with 10,000 iterations. σ̄2bj is the posterior variance of bj from the
same run. This prior setting is exactly the same with the independent prior when
covariate j is not in the model (i.e. when γj = 0), but is different when γj = 1.
Based on the variable inclusion probabilities in Table 6.11 (a), variables gender (γ8)
and retinopathy (γ10) have high probabilities, 0.9786 and 0.9419 respectively, making
these two covariates almost always included in all visited models. Other covariates
with probability of inclusion greater than 0.5 are type of diabetes (γ9) and Hba (γ5).
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The MAP model suggested by this prior isM915 (Table 6.11 (b)). Besides gender and
retinopathy, this model contains variables duration of diabetes (γ2), Hba (γ5), and
type of diabetes (γ9), and has posterior probability 0.0695. Since covariate duration
has probability of inclusion less than 0.5, it is not included in the MP model which is
M913. This model has probability 0.0134 and the posterior odd of M915 to M913 is
5.21 implying that with this prior setting, the MAP model is five times better than
the MP model. There are four other models that have posterior odd less than 3 if
compared to the MAP model. With posterior odd 1.40, we can say that M645 with
probability 0.0495 is almost as good as the MAP model. M661, M647, and M899
have probabilities less than the MAP models but their posterior odd are still below 3
indicating that these models are not significantly different from each other.
Note that gender is included in all selected models. Thus, we can say that this covari-
ate is prominent in predicting the consistency of individual patients. Together with
this, retinopathy and Hba also have high probability of inclusion and are selected
as important predictors by all three prior settings. Although different prior settings
come out with different ‘best’ models (MAP), they all have a small number of similar
models selected such as M661, M641, M645, and M145. Again, this is an indication
of model uncertainty.
6.2.1 Analysis with 59 patients
During the earlier phase of our work, we were only provided with data on 59 patients
before we received additional data on seven subjects. Therefore, we also have results
for Gibbs variable selection using only 59 patients. We present here the results when
using Zellner’s g-prior. Table 6.12 gives the inclusion probabilities for each covariate
and the posterior model probabilities.
Observing the inclusion probabilities of all covariates, we notice obvious differences
in inclusion probabilities of covariates Hba (γ5) and retinopathy (γ10). Hba does not
have very high inclusion probability if we include the seven additional patients (see
Table 6.10), except when using c2 = n where it has probability of inclusion above 0.5.
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On the other hand, when the seven patients are excluded (Table 6.12) the probability
is high at any level of c2. As a result, the ‘best’ models selected by this procedure
always include Hba. As for retinopathy, this covariate has high probability with the
seven patients in the analysis but decreases if we take them out. Therefore, the best
models do not contain this covariate, whereas in the previous analysis it is included
in almost each of the selected models.
When c2 = n the MAP model in Table 6.12 (b) is M209, which contains covariates
Hba (γ5), awareness of hypoglycaemia (γ7), and gender (γ8), and has posterior model
probability of 0.1102. This is similar to the outcome if we use c2 = 1000 where the
MAP model is also M209 but with higher probability, 0.3409.
Generally, models selected when using higher prior variance are much simpler than
models selected when c2 = 59. If c2 = 10,000, we obtain three models with posterior
odds ≤ 3 which are M145, M209, and M193. M145 is the MAP and MP model and
contain covariate Hba (γ5) and gender (γ8).
Based on this finding, results here are different from when these seven patients are
included in the analysis. Covariates Hba (γ5) and retinopathy (γ10) are highly affected
with the inclusion or exclusion of the seven patients. Hence, it seems like this method
is sensitive to changes in data. This ambiguous result may be due to small data size
(i.e. 59 and 66 patients) rather than to the variable having or not having appreciable
predictive value.
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(a) Inclusion probabilities for various prior variances.
c2 = n c2 = 1000 c2 = 10,000
Parameter p(γ|D) SD p(γ|D) SD p(γ|D) SD
γ1 0.0181 0.13 0.0039 0.06 0.0012 0.03
γ2 0.0467 0.21 0.0082 0.09 0.0011 0.03
γ3 0.1158 0.32 0.0446 0.21 0.0235 0.15
γ4 0.0363 0.19 0.0082 0.09 0.0021 0.05
γ5 0.3843 0.49 0.1865 0.39 0.0931 0.29
γ6 0.1192 0.32 0.0495 0.22 0.0213 0.14
γ7 0.1648 0.37 0.0316 0.17 0.0133 0.11
γ8 0.8098 0.39 0.7214 0.45 0.5048 0.50
γ9 0.1597 0.37 0.0285 0.17 0.0070 0.08
γ10 0.1709 0.38 0.0184 0.13 0.0013 0.04
(b) Posterior model probabilities - c2 = n
Rank Model No Model f(M|D) PO(M129/Mt)
1 M129 x8 0.2353 1.00
2 M145 x5 + x8 0.1803 1.31
3 M641 x8 + x10 0.0733 3.21
4 M133 x3 + x8 0.0373 6.31
5 M321 x7 + x9 0.0298 7.90
6 M17 x5 0.0256 9.19
7 M401 x5 + x8 + x9 0.0242 9.72
8 M177 x5 + x6 + x8 0.0207 11.37
9 M645 x3 + x8 + x10 0.0205 11.48
10 M161 x6 + x8 0.0196 12.01
(c) Posterior model probabilities - c2 = 1000
Rank Model No Model f(M|D) PO(M129/Mt)
1 M129 x8 0.5330 1.00
2 M1 constant 0.1415 3.77
3 M145 x5 + x8 0.0988 5.39
4 M17 x5 0.0587 9.08
5 M133 x3 + x8 0.0233 22.88
6 M33 x6 0.0181 29.45
7 M5 x3 0.0140 38.07
8 M161 x6 + x8 0.0123 43.33
9 M641 x8 + x10 0.0094 56.70
10 M193 x7 + x8 0.0088 60.57
(d) Posterior model probabilities - c2 = 10,000
Rank Model No Model f(M|D) PO(M129/Mt)
1 M129 x8 0.4615 1.00
2 M1 constant 0.3839 1.20
3 M17 x5 0.0613 7.53
4 M145 x5 + x8 0.0256 18.03
5 M5 x3 0.0150 30.77
6 M33 x6 0.0142 32.50
7 M65 x7 0.0082 56.28
8 M133 x3 + x8 0.0073 63.22
9 M49 x5 + x6 0.0026 177.50
10 M161 x6 + x8 0.0024 192.29
Table 6.9: Parameter inclusion probabilities and model probabilities with independent
normal prior.
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(a) Inclusion probabilities for various prior variances.
c2 = n c2 = 1000 c2 = 10,000
Parameter p(γ|D) SD p(γ|D) SD p(γ|D) SD
γ1 0.1659 0.37 0.0484 0.21 0.0165 0.13
γ2 0.2966 0.46 0.1951 0.40 0.0567 0.23
γ3 0.4672 0.50 0.2456 0.43 0.1206 0.33
γ4 0.2378 0.43 0.0770 0.27 0.0177 0.13
γ5 0.6120 0.49 0.3610 0.48 0.2986 0.46
γ6 0.4148 0.49 0.2592 0.44 0.1464 0.35
γ7 0.6198 0.49 0.4196 0.49 0.1826 0.39
γ8 0.8659 0.34 0.7498 0.43 0.7356 0.44
γ9 0.4124 0.49 0.2182 0.41 0.0672 0.25
γ10 0.9419 0.23 0.7459 0.44 0.3116 0.46
(b) Posterior model probabilities - c2 = n
Rank Model No Model f(M|D) PO(M661/Mt)
1 M661 x3 + x5 + x8 + x10 0.0326 1.00
2 M725 x3 + x5 + x7 + x8 + x10 0.0265 1.23
3 M709 x3 + x7 + x8 + x10 0.0237 1.37
4 M977 x5 + x7 + x8 + x9 + x10 0.0237 1.37
5 M753 x5 + x6 + x7 + x8 + x10 0.0196 1.66
6 M663 x2 + x3 + x5 + x8 + x10 0.0192 1.70
7 M737 x6 + x7 + x8 + x10 0.0185 1.76
8 M1009 x5 + x6 + x7 + x8 + x9 + x10 0.0180 1.81
9 M645 x3 + x8 + x10 0.0180 1.81
10 M647 x2 + x3 + x8 + x10 0.0161 2.02
(c) Posterior model probabilities - c2 = 1000
Rank Model No Model f(M|D) PO(M641/Mt)
1 M641 x8 + x10 0.0863 1.00
2 M645 x3 + x8 + x10 0.0608 1.42
3 M643 x2 + x8 + x10 0.0577 1.50
4 M705 x7 + x8 + x10 0.0408 2.12
5 M609 x6 + x7 + x10 0.0370 2.33
6 M657 x5 + x8 + x10 0.0321 2.69
7 M145 x5 + x8 0.0294 2.94
8 M661 x3 + x5 + x8 + x10 0.0232 3.72
9 M647 x2 + x3 + x8 + x10 0.0214 4.03
10 M737 x6 + x7 + x8 + x10 0.0198 4.36
(d) Posterior model probabilities - c2 = 10,000
Rank Model No Model f(M|D) PO(M641/Mt)
1 M129 x8 0.2055 0.63
2 M641 x8 + x10 0.1304 1.00
3 M145 x5 + x8 0.1265 1.03
4 M17 x5 0.0401 3.25
5 M645 x3 + x8 + x10 0.0335 3.89
6 M97 x6 + x7 0.0318 4.10
7 M133 x3 + x8 0.0278 4.69
8 M1 constant 0.0267 4.88
9 M643 x2 + x8 + x10 0.0240 5.43
10 M193 x7 + x8 0.0227 5.74















(b) Posterior model probabilities.
Rank Model No Model f(M|D) PO(M915/Mt)
1 M915 x2 + x5 + x8 + x9 + x10 0.0695 1.00
2 M645 x3 + x8 + x10 0.0495 1.40
3 M661 x3 + x5 + x8 + x10 0.0363 1.92
4 M647 x2 + x3 + x8 + x10 0.0332 2.09
5 M899 x2 + x8 + x9 + x10 0.0314 2.22
6 M903 x2 + x3 + x8 + x9 + x10 0.0219 3.17
7 M919 x2 + x3 + x5 + x8 + x9 + x10 0.0216 3.22
8 M663 x2 + x3 + x5 + x8 + x10 0.0201 3.47
9 M923 x2 + x4 + x5 + x8 + x9 + x10 0.0189 3.68
10 M977 x5 + x7 + x8 + x9 + x10 0.0181 3.85
Table 6.11: Parameter inclusion probabilities and model probabilities with empirical
prior.
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(a) Inclusion probabilities for various prior variances.
c2 = n c2 = 1000 c2 = 10,000
Parameter p(γ|D) SD p(γ|D) SD p(γ|D) SD
γ1 0.1347 0.34 0.0348 0.18 0.0105 0.10
γ2 0.2859 0.45 0.0695 0.25 0.0162 0.13
γ3 0.3029 0.46 0.0710 0.26 0.0212 0.14
γ4 0.1392 0.35 0.0422 0.20 0.0156 0.12
γ5 0.9201 0.27 0.8768 0.33 0.7836 0.41
γ6 0.1575 0.36 0.0443 0.21 0.0170 0.13
γ7 0.7501 0.43 0.5866 0.49 0.4269 0.49
γ8 0.9906 0.10 0.9798 0.14 0.9295 0.26
γ9 0.1497 0.36 0.0467 0.21 0.0144 0.12
γ10 0.6359 0.48 0.1211 0.33 0.0122 0.11
(b) Posterior model probabilities - c2 = n
Rank Model No Model f(M|D) PO(M209/Mt)
1 M209 x5 + x7 + x8 0.1102 1.00
2 M721 x5 + x7 + x8 + x10 0.0958 1.15
3 M725 x3 + x5 + x7 + x8 + x10 0.0612 1.80
4 M659 x2 + x5 + x8 + x10 0.0390 2.83
5 M723 x2 + x5 + x7 + x8 + x10 0.0368 2.99
6 M213 x3 + x5 + x7 + x8 0.0237 4.65
7 M663 x2 + x3 + x5 + x8 + x10 0.0226 4.89
8 M241 x5 + x6 + x7 + x8 0.0224 4.92
9 M753 x5 + x6 + x7 + x8 + x10 0.0212 5.20
10 M727 x2 + x3 + x5 + x7 + x8 + x10 0.0201 5.48
(c) Posterior model probabilities - c2 = 1000
Rank Model No Model f(M|D) PO(M209/Mt)
1 M209 x5 + x7 + x8 0.3409 1.00
2 M145 x5 + x8 0.2608 1.31
3 M193 x7 + x8 0.0557 6.12
4 M721 x5 + x7 + x8 + x10 0.0236 14.48
5 M149 x3 + x5 + x8 0.0225 15.15
6 M659 x2 + x5 + x8 + x10 0.0179 19.10
7 M213 x3 + x5 + x7 + x8 0.0174 19.65
8 M465 x5 + x7 + x8 + x9 0.0166 20.54
9 M241 x5 + x6 + x7 + x8 0.0160 21.37
10 M705 x7 + x8 + x10 0.0157 21.71
(d) Posterior model probabilities - c2 = 10,000
Rank Model No Model f(M|D) PO(M209/Mt)
1 M145 x5 + x8 0.4940 0.43
2 M209 x5 + x7 + x8 0.2102 1.00
3 M193 x7 + x8 0.1193 1.76
4 M65 x7 0.0475 4.43
5 M129 x8 0.0189 11.12
6 M149 x3 + x5 + x8 0.0128 16.49
7 M153 x4 + x5 + x8 0.0079 26.61
8 M81 x5 + x7 0.0075 28.21
9 M177 x5 + x6 + x8 0.0072 29.40
10 M401 x5 + x8 + x9 0.0066 31.85
Table 6.12: Parameter inclusion probabilities and model probabilities with Zellner’s
g-prior for 59 patients.
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6.3 Bayesian Model Averaging
Model uncertainty is a critical issue in model selection. Model selection often gives a
single ‘best’ model, thus giving us false impression of which model best explains the
data. Moreover, using different methods for model selection such as Gibbs variable
selection and stepwise regression will many times lead to different final models (Weis-
berg, 1985).
In the previous section, the Gibbs variable selection suggests a different ‘best’ model
when using different priors. Also, with each prior, the posterior model probability
does not strongly concentrate on only one model. We have at least two models with
posterior model probability odds between them ≤ 3, making it difficult to be con-
fident about which model makes the best predictive model and to leave out other
models. To deal with this model uncertainty problem we will use Bayesian model
averaging (Hoeting et al., 1999). Instead of using one single model for prediction,
this method averages a selected set of models. Madigan and Raftery (1994) measure
the performance of model averaging using logarithmic scoring rule and conclude that
averaging over all selected models gives better predictive ability than using a single
model. However, one needs to remember that this method does not tell us which
variables are important in the prediction model.
It will be time consuming to average all possible models in the model space,M. Thus
Bayesian model averaging sums over only non-negligible models, which are models
that have posterior odds ≤ 3, as compared to the ‘best’ model, since they are not
significantly different from each other. For each prior case, we select modelsMt with
posterior odds ≤ 3. Recall that from Section 2.5, individual patient consistency c̃i is
a function of w̃i =
1
σ2i
. Hence, this parameter is used to compute a model averaged
predicted consistency for patient i, by mixing the inference from selected modelsMt









i P (Mtk |D) (6.3.1)
= w̃
(1)
i P (Mt1|D) + w̃
(2)
i P (Mt2|D) + ...+ w̃
(K)
i P (Mtk |D) (6.3.2)
in which k =1,...,K is the sampled models and P (Mtk |D) is the posterior model
probability for model k.
As discussed previously, the Gibbs variable selection in Section 6.2 shows evidence
of model uncertainty. For instance, the outcome when using Zellner’s g-prior (with
c2 = n) in Table 6.10 tells us thatM661 is the ‘best’ model with posterior probability
0.0326. Nonetheless, this model only represents 3.26% of the total posterior model
probability indicating there is a fair amount of model uncertainty. To tackle this
uncertainty issue, we take an average of models, using Bayesian model averaging so
that instead of making conclusion only on model M661, other potential models are
taken into account too.
From the results in Tables 6.9- 6.11, we select models with posterior odds ≤ 3 and
summarise them in Table 6.13. This table lists the selected models together with
their corresponding covariates and posterior model probability, f(M|D). From the
table, it appears that covariate gender (x8) is a common variable for all the selected
models. Retinopathy (x10) also appears in all selected models except models selected
when using independent prior.
We elaborate here an example of how we conduct the model averaging. This example
mixes over potential best models obtained when using Zellner’s g-prior. There are 15
models with posterior odds ≤ 3, however we limit the averaging to only 10 models be-
cause remaining models have very small probability. These models account for about
22% of the total posterior probability. Therefore, we normalise these probabilities
over all selected models so that their sum equal to 1. The normalised probabilities,
f ∗(M|D) are given in the last column in Table 6.13. We then conduct MCMC simu-
lation of 20,000 iterations of each selected model Mk and monitor the value of w̃(k)i .
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Covariates
Selected model x2 x3 x5 x6 x7 x8 x9 x10 f(M|D) f∗(M|D)
Independent prior
M129 • 0.2353 0.5662
M145 • • 0.1803 0.4338
Zellner’s g-prior
M661 • • • • 0.0326 0.1510
M725 • • • • • 0.0265 0.1227
M709 • • • • 0.0237 0.1098
M977 • • • • • 0.0237 0.1098
M753 • • • • • 0.0196 0.0908
M663 • • • • • 0.0192 0.0889
M737 • • • • 0.0185 0.0857
M1009 • • • • • • 0.0180 0.0834
M645 • • • 0.0180 0.0834
M647 • • • • 0.0161 0.0746
Empirical prior
M915 • • • • • 0.0695 0.3161
M645 • • • 0.0495 0.2251
M661 • • • • 0.0363 0.1651
M647 • • • • 0.0332 0.1510
M899 • • • • 0.0314 0.1428
Table 6.13: Models selected based on results from Gibbs variable selection for Bayesian
model averaging. A bullet (•) indicates presence of a covariate in the model. The last
column shows normalised posterior model probability.




























The posterior densities of the consistency parameter w̃i from all ten models are given
in Figure 6.1, and the red plot is the estimate with the averaged model. Results for
subjects 1039, 3016, 5026, 6002, and 6064 are also shown in Figure 6.1.
Judging by the posterior odds, Gibbs variable selection with empirical prior (using
c2 = n) yields 5 believable models, as listed in Table 6.13. Model M915 is slightly
favoured than model M645, with it being 1.4 times better than M645 (Table 6.11).
These two models were averaged together with model M661, M647 and M899. The
posterior distributions of the weighted average w̃
(A)
i obtained for six selected patients
are given in Figure 6.2. For comparison purposes, posterior distributions of w̃
(k)
i for
the other five potential models are plotted on the same axes.
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Only the top two models indicated by Gibbs variable selection using independent prior
are selected for model averaging. The posterior distributions for w̃i for six subjects
based on the model averaging results are illustrated in Figure 6.3.
Some of the plots (see Figures 6.1 (b), 6.2 (c), and 6.3 (c)), show models that seem
equally good (because their posterior odds are ≤ 3) but have considerably different w̃i
distributions from one another which may lead to different conclusion or prediction.
This strongly shows the advantage of Bayesian model averaging where this method
allows for the incorporation of model uncertainty into making inference based on a
weighted average.
If we observe the results from Zellner’s g-prior, covariate awareness of hypoglycaemia
(x7) is not included in the ‘best’ selected model which is the model with highest poste-
rior probability. However, this covariate’s probability of inclusion is 0.6198 indicating
that this covariate may have predictive value and can be useful for prediction. By
averaging the subset of models, this covariate is utilised in making prediction.
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Figure 6.1: Posterior density plots of w̃i = σ
−2
i for different patients under selected
models from Gibbs variable selection using Zellner’s g-prior. The red plot represents
the averaged model.
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Figure 6.2: Posterior density plots of w̃i = σ
−2
i for different patients under selected































































































































Figure 6.3: Posterior density plots of w̃i = σ
−2
i for different patients under selected




In this chapter we discuss how we can select models that predicts patients’ consistency
well. We explore two methods which lead to different predictive models. We applied
these methods to three models; the grouped symptoms model, the grouped symptoms
model with interaction between covariates, and the hierarchical model with grouped
symptoms. With the stepwise selection procedure, we end up with different models
when starting the procedure from a different point (Tables 6.4 and 6.6). However,
there is a number of common covariates chosen between the models. This indicates
uncertainty that can lead to poor predictive ability.
Another method used to select the best predictive model is the Gibbs variable selec-
tion (GVS) where we consider three prior distribution settings for the coefficient b.
Based on the results discussed in Section 6.2, the best model when using an indepen-
dent prior isM129 which contains covariate gender, while with Zellners g-prior results
are dependent on the prior variance. With larger c2 the results are more consistent.
Although M641 (model with covariates gender and retinopathy) is the best model
when c2 = 1000, this model comes second when using c2 = 10,000 with posterior odds
0.63. On the other hand, with the empirical prior the best model is the model con-
taining covariates duration of diabetes, Hba, gender, type of diabetes and retinopathy
(M915). Even though we get different best models with different prior settings, we
can conclude that they are not inconsistent since models selected with posterior odds
≤ 3 in each prior setting are similar.
We then counter the uncertainty issue shown in the GVS method by using Bayesian
model averaging methodology. We select a subset of models obtained from GVS,
which consists of models with posterior odds ≤ 3, and average them for making pre-
dictions. However, if there are more than ten models with posterior odds ≤ 3 we limit




Conclusions and Further Research
7.1 Conclusions
The main contributions of this thesis are the development and assessment of statistical
logistic-type models for the consistency of symptoms experienced by individual pa-
tients during hypoglycaemia using MCMC methodology under a Bayesian approach.
We started by exploring different options for the symptom experiencing threshold
h(αij, βik) to fit to the core consistency estimation model. Model selection for the
best threshold was conducted by considering both the deviance information criterion
and likelihood comparisons for models with different thresholds. This comparison
suggested that the most suitable threshold for this model is h(αij, βik) = αijβik.
The sensitivity of our estimation to prior assumptions was also investigated, and we
demonstrated that our choice of priors did not have an important impact on the rank-
ing of the consistency estimates for the 66 patients considered. We then expanded
the consistency estimation model by incorporating between-group variability, when
symptoms of hypoglycaemia are classified into six different groups depending on the
cause of symptoms. The consistency of symptoms experienced by individual patients
with this calibrated model, is similar to that obtained with an earlier model (Zammitt
et al., 2011) suggesting that individuals show variation in consistency. Regarding the
grouped symptoms, autonomic and neuroglycopenic groups have the highest propen-
sity, implying that symptoms categorised in these groups are important in detecting
the onset of hypoglycaemia.
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Model assessment was performed to explore the adequacy of the grouped symptoms
models using the concept of stochastic latent residuals. This method was imple-
mented to the model with thresholds h(αij, βik) = αijβik and h(αij, βik) = αij + βik.
Preliminary checking showed that residuals for each patient come from a Uniform(0,1)
distribution, indicating a good fit. Furthermore, from the posterior distribution of p-
values, πγ, obtained with a Kolmogorov-Smirnov goodness-of-fit test, we concluded
that there is no strong evidence against the model tested. We used Pr(πγ <0.05)
as a measure of fit and it was found that the model with grouped symptoms using
threshold h(αij, βik) = αijβik fits the data better.
We verified the predictive ability of our model by comparing the observed data with
predicted values using an approach based on the posterior predictive distribution.
The model with grouped symptoms using threshold h(αij, βik) = αijβik, gave poste-
rior distribution of predicted number of reported symptoms containing the observed
number, implying that this model performs well in predicting consistency.
Earlier work was restricted to only using episodes not occurring within 24 hours, as
these episodes were thought to have the potential to reduce the intensity of following
episodes. In Chapter 4, we examined this claim by examining the correlation and
level of intensity between episodes occurring within 24 hours and episodes not within
24 hours. There is no considerable difference between the correlation of intensity
and the average intensity between the two cases. Due to these results, we concluded
that there is no evidence of episodes occurring within 24 hours having a considerable
effect on intensity. Following that, we also used permutation testing to examine if
episodes’ intensity shows association between cases where there are episodes within 24
hours and cases where those episodes are excluded. Again, results showed no evidence
against the hypothesis of no association. Therefore, subsequent analysis in the thesis
included data from all episodes regardless of their time of occurrence. Episodes with
missing date were also taken into account since it is not necessary to determine their
time of occurrence. Analysis with all episodes gave higher patients’ consistency as
compared to when excluding episodes within 24 hours. Also, more reliable estimates
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are obtained when all episodes are used. This was indicated by lower coefficient of
variation values when we used the additional episodes. Overall, the distribution of
the consistency estimates does not significantly change after the inclusion of the 24
hours episodes.
It is crucial for diabetic patients to understand and be aware of which factors may
cause variation in their symptoms of hypoglycaemia. Using generalised linear model
methodology and posterior precision estimates, σ̃−2i , under the model with grouped
symptoms, it was found that female patients are less consistent in reporting symptoms
of hypoglycaemia, which agrees with previous findings. Our results also suggested
that another significant factor affecting consistency is lack of retinopathy. We have
also examined the impact of interactions between covariates on consistency. Eleven
interactions were considered. According to the estimation results, modelling with in-
teractions between covariates agrees with our earlier findings where gender and ‘no
retinopathy’ appear to be significant. We also conclude that female patients experi-
ence reduction in consistency as their duration of diabetes and BMI measure increase.
When compared to male patients, female subjects with no retinopathy show lower
consistency, but those with proliferative retinopathy have higher consistency. For pa-
tients with no retinopathy, their consistency is higher if they have longer duration
of diagnosed diabetes. Besides that, the interaction between duration and C-peptide
level also significantly affects consistency, such that patients with long duration of
diabetes and high level of C-peptide have lower consistency estimates compared to
patients with shorter duration and lower C-peptide level.
We have also developed a hierarchical model that is able to estimate consistency and
determine factors affecting it in a single model. This is done by giving a hierarchi-
cal prior to the variance parameter, σ2i . Similar to the conclusion made with the
non-hierarchical model, this extended consistency model shows that consistency of
symptoms reporting among individual varies. However, when the hierarchical setting
is introduced the strong negative effect of gender disappears. In fact, no factor is
found significant.
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The thesis also includes work on variable selection to determine the most suitable
model to predict patients’ consistency using the model with grouped symptoms. We
used stepwise selection and Gibbs variable selection methodologies with different prior
settings for the model parameters. In stepwise selection, different initial points were
used resulting in two final ‘best models’. Starting the selection process with full
model, a model excluding age and duration was selected as the best predictive model.
However, with the null model and model containing covariate gender as the start-
ing model, a final model excluding age, duration, C-peptide and Ace was supported.
We repeated the same procedure including interactions between covariates. As can be
seen in Table 6.6, different starting points favour different predictor models. However,
the two resulting models have selected six common predictors. Applying the same
methodology to the hierarchical model gives a more consistent result, as regardless of
the starting points the selected predictive model is the same; this is the model with
covariates C-peptide, Ace, gender, type of diabetes, and retinopathy.
The second approach to variable selection was using Gibbs variable selection with an
independent prior, Zellner’s g-prior, and an empirical prior. The model with covariate
gender is found to be the best with the independent prior, but when using Zellner’s
g-prior a larger set of covariates is included in the predictive model. However, a more
parsimonious model is obtained as the prior variance increases. With the empirical
prior setting the best determined model is that containing covariates duration, Hba,
gender, type of diabetes, and retinopathy. Finally, we overcame the issue of uncer-
tainty in Gibbs variable selection with Bayesian model averaging.
Finally, we stress again here that as the sample of patients used in our analyses is
not necessarily representative of the population of diabetic patients suffering hypo-
glycaemic episodes, we do not consider our results to be directly generalised to this
entire population. However, our findings can be used to guide and inform studies in
patient groups with similar characteristics, and our methodology can be easily applied
to expanded data sets (where available) to provide more general conclusions.
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7.2 Further research
An interesting topic for future research would be exploring other distributions for
the threshold variable τijk. Among potential distributions are gamma, Weibull, and
Burr. Other positive-value distributions can also be considered. A different extension
to this thesis can be provided by modelling the correlation between episode inten-
sity through introducing correlation in the prior distributions of the parameters βik,
which represent to the intensity of the episodes of hypoglycaemia. It is possible to
consider using conditional autoregressive priors (Carlin and Banerjee, 2003) which
mainly model the dependence between neighbouring episodes. Such a model could be
useful for further determining the correlation between episodes’ intensity, especially
for cases which occur within 24 hours.
Finally, further research can be performed with new or follow-up data in future. The
models and methodology developed in this thesis can be adapted and extended to ap-
ply to richer data, in order for example, to investigate stronger association of symptom
consistency with patient-specific covariates. Also, more informative data might help
to improve the power of assessment and model diagnostics presented in this thesis,
and could also help distinguish better between competing models.
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Appendix A
Sample of Report Form
174
Figure A.1: Sample of report form (page 1).
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Figure A.2: Sample of report form (page 2).
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Appendix B
Covariates for All Patients
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Subject GEN AGE TYPE DUR RET BMI CPEP HBA ACE AWAR
1008 M 67 1 306 2 21.6 0.1 6.7 28 3
1009 M 41 1 60 1 27.9 0.18 7.6 43 3
1015 F 34 1 204 2 42.7 0.23 8.5 44 1
1021 M 39 1 36 1 24.9 0.13 9 24 3
1025 F 49 1 540 2 25.8 0.05 8.6 68 3
1028 M 51 1 324 1 29.7 0.05 NA 28 7
1036 M 31 1 12 1 21.2 0.62 10.1 33 2
1039 F 70 1 540 2 24.8 0.2 NA 5 2
1055 M 65 2 84 2 25.6 0.07 7 49 3
1057 F 43 2 120 1 37.5 0.69 6.5 38 1
1086 F 55 1 336 2 37.5 0.05 8.3 10 1
2009 F 57 1 540 3 33 0.22 7.2 30 5
2010 F 59 1 636 1 25.7 0.05 6.6 3 6
2012 M 34 1 48 1 27.4 0.45 6.8 63 2
2013 F 60 1 576 3 26.4 0.42 7 43 3
2015 F 58 1 432 2 22.1 0.14 7.8 33 6
2021 M 50 1 408 2 24.6 0.05 NA 4 2
2022 M 38 1 444 2 24.5 0.83 7.7 48 2
2027 M 26 1 57 1 22.5 0.62 7.9 28 6
3001 M 66 1 12 1 22 0.69 7.6 21 1
3015 F 60 1 180 1 22 0.05 7.2 98 3
3016 M 65 2 84 1 26 0.27 8.5 24 1
3022 M 58 1 300 2 32.4 0.05 7.1 7 1
3024 F 52 1 48 1 21 0.34 5.6 41 1
3029 M 60 1 36 1 23.8 0.33 6.5 18 1
3043 M 62 2 36 1 37 1.21 6.3 12 1
3046 M 51 2 24 2 23.7 2.22 7.1 20 1
3048 M 68 2 300 2 33 0.09 6.3 14 1
3050 M 49 1 36 1 25 0.06 NA 94 3
3052 M 57 2 108 1 25 0.24 8.4 8 2
3057 M 63 2 60 1 27 0.05 8.1 39 2
3065 F 68 2 408 NA 24.5 1.13 7.6 63 2
3067 M 61 2 372 3 33 2.51 7.8 4 1
4003 M 50 1 408 2 31.8 0.08 8.8 6 7
4008 M 62 1 528 3 23.9 0.05 8.3 50 5
4013 F 54 1 360 2 24.5 0.84 6.5 43 1
4023 M 46 1 57 1 23 0.59 NA 38 1
4028 M 69 2 168 1 25.1 0.97 7.5 46 1
4032 M 64 2 204 1 25.7 1.31 7.2 7 1
4034 M 33 1 30 1 23.8 NA 6.3 55 2
4043 M 61 1 288 2 21.9 0.85 6.5 9 3
4045 F 63 1 552 3 23.1 0.05 8.3 63 1
4049 F 22 1 6 1 19.5 0.34 7.3 50 1
4061 F 71 2 60 1 27.3 0.33 9.5 20 1
4063 M 70 1 18 2 27.7 0.64 7.2 76 3
4072 M 68 2 120 3 21.9 0.08 6.9 71 5
4076 M 58 2 156 1 28 0.52 7.5 6 1
5004 M 67 1 252 2 26.1 0.23 8 57 3
5009 M 72 2 108 3 30.5 1.69 8.9 41 1
5023 M 72 1 744 3 28.6 0.31 9 7 4
5026 M 69 1 540 3 22.7 0.05 6.6 24 1
5029 F 70 1 12 1 24.3 0.38 6.2 25 1
5044 F 22 1 36 1 26 0.14 6.8 22 2
5045 M 38 1 30 1 29.6 0.25 7.7 22 2
5088 F 68 1 18 1 24 0.82 7.2 50 3
6002 M 65 2 72 1 30.2 1.24 8.8 16 1
6010 M 42 1 36 1 23.3 0.28 6.9 34 1
6018 F 44 1 384 2 26 0.14 7.1 41 1
6019 F 36 1 24 1 20.5 0.87 NA 29 5
6023 F 51 1 444 1 23.5 0.07 6.1 41 6
6038 M 32 1 24 1 25.2 0.54 6.6 34 1
6056 M 74 2 12 1 26.8 0.45 8.1 7 1
6058 M 60 2 108 1 28.8 1.58 7.8 11 1
6062 M 61 2 18 1 27.7 1.12 6.7 23 1
6064 M 59 2 12 1 27.7 0.8 6.4 2 1
6065 F 34 1 36 1 24.3 0.61 7.7 32 1
Table B.1: List of covariates for all patients where RET 1 = no retinopathy; RET
2 = background retinopathy and RET 3 = proliferative retinopathy; hypoglycaemia
awareness (AWAR) score is from 1 to 7, with higher scores corresponding to weaker
awareness of hypoglycaemia. See Section 5.1 for full details.
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